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Ca2+ dyshomeostasis is considered to be an early pathogenic event in Alzheimer’s 
disease (AD). Abnormal levels and activity of Ca2+-regulated proteins are detected 
in post mortem AD brain, elevated neuronal Ca2+ is found in many cell and animal 
models of AD, and Ca2+-dependent signalling pathways are recognized to 
contribute to neurodegeneration in these models. The aims of this project were 
1) to further investigate changes in the levels or activity of Ca2+-activated proteins 
in association with tau and Aβ accumulation during the progression of AD, and 2) 
elucidate novel mechanisms underlying Ca2+ dysregulation in AD. Post-mortem 
brain tissue was obtained from controls and AD cases at different stages of disease 
development (Braak II-VI). Biochemical analysis of these tissues revealed that 
calpain-1 activity is increased in Braak stage II to VI brain in comparison to 
controls, suggesting that changes in Ca2+-sensitive signalling pathways occur very 
early during disease development. Elevated calpain-1 activity was associated with 
a transient upregulation of the endogenous calpain inhibitor, calpastatin, and 
preceded Aβ1-42 accumulation, activation of tau kinases, increased tau 
phosphorylation and synapse loss. These results corroborate findings from cell 
and animal models that Ca2+ dysregulation and calpain activation are upstream of 
tau phosphorylation and synapse loss in AD. In addition, end-stage (Braak stage 
VI) AD brains displayed elevated calpain-mediated cleavage of the sodium 
calcium exchanger 3 (NCX3), which normally extrudes excess cellular Ca2+, 
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suggesting that deficiencies in NCX3 function might contribute to the 
accumulation of excess intraneuronal Ca2+ in AD. In support of this, knockdown of 
NCX3 in primary neurons sensitized neurons to the toxic effects of Aβ1-42. In 
addition, treatment of neuronal cells with Aβ1-42 resulted in neurotoxicity which 
was associated with activation of poly(ADP-ribose) polymerase (PARP)-1, Ca2+ 
entry through transient receptor potential melastatin type 2 (TRPM2) channels, 
elevations in cytosolic Ca2+, activation of calpain, calpain-regulated tau kinases 
and tau phosphorylation at epitopes of relevance to AD and synapse loss. Overall, 
this work lends further support to the hypothesis that altered Ca2+ homeostasis 
plays an important role in early AD pathogenesis, and has identified novel 
mechanisms in this process including abnormal regulation of  PARP-1/TRPM2 
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1.1 The socioeconomic impact of AD 
 
The recognition of Alzheimer’s disease (AD) is attributed to the German 
psychiatrist Alois Alzheimer who, in 1906, first characterized the disorder in a 55 
year old female patient (Stelzmann et al., 1995). Today, AD is widely known as 
one of the most common neuropsychiatric disorders that affects more than 40 
million people worldwide - numbers estimated to double by 2030 (Alzheimer’s 
Disease International, 2015). The rise in AD incidence is explained by 
demographic ageing due to improved health care; as age is the single biggest risk 
factor for developing AD, an increase in the population life-span also increases the 
likelihood of developing the disease.  AD is the leading cause of dementia (60% of 
dementia cases) in people over 65, affecting approximately 6 % of that population 
age group and approximately 50 % of people over age 90. The World Health 
Organization (WHO) has identified AD as a public health priority due to its current 
catastrophic global cost of $605 billion (WHO, 2015).  In the UK, two-thirds of the 
overall cost of dementia (£26 billion) are incurred by mostly low-income 
households, who are often driven into poverty and unemployment by having to 
resort to unpaid or private social care to support those affected by the disease. 
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The contribution of the NHS towards nursing care and costly treatment accounts 
for a significant proportion of the government health budget, and the rising 
demand for these services places great strain on NHS resources (Alzheimer’s 
Society, 2015). In 2014, David Cameron addressed the UK’s dementia crisis by 
pledging more funding towards AD research, with priorities of experimental drug 
development, advances in clinical infrastructure and improvement of patient 
access to new drugs. The initiative came in light of the market failure of numerous 
potential disease-modifying drugs, which despite showing marked benefit in pre-
clinical studies, showed no efficacy in clinical trials (Schneider et al., 2014). This 
also led to some questions about our understanding of AD pathogenesis and 
conventional approaches to drug development (Mangialasche et al., 2010).  The 
pharmaceutical industry has since been refocused to include the exploration of 
new drug targets and on developing symptomatic treatments to improve patient 
quality of life. However, these therapies remain some way from clinical use; 
therefore, there is still no treatment that can halt or reverse disease progression, 
and so AD remains an incurable, ultimately fatal condition. The latest research has 
shown that delaying AD onset by only three years would have significant benefit 
for disease sufferers by easing the severity of symptoms and reducing the number 
of families afflicted by the disease, as well as saving the country up to £5bn per 
year (Alzheimer’s Research UK, 2015). Continued efforts from academic research 
institutions, the pharmaceutical industry and government bodies are therefore 
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required to enable the development of early diagnostic markers and new disease-
targeting therapies with the potential to treat, delay or prevent AD. 
 
1.2 AD clinical features and neurochemistry 
 
1.2.1 Clinical features 
AD is clinically characterized by progressive memory and cognitive deficits, 
neuropsychiatric changes and, in some cases, declining motor function 
(Alzheimer’s Society, 2015). Although the progression of AD varies between 
individuals, it can generally be divided into three stages: the preclinical stage with 
no overt clinical symptoms, the middle stage which manifests as mild cognitive 
impairment (MCI) and the final stage of AD dementia (National Institute of Health, 
2015). The first symptoms are typically observed during the MCI stage but are 
similar to the effects of normal ageing and, thus, do not always result in AD 
diagnosis. Individuals experience loss of short term memory, and may exhibit 
language impairment and poor judgment (Gagnon and Belleville, 2011; Parra et 
al., 2010). AD is typically diagnosed in patients exhibiting progressive memory 
loss (e.g. losing items and self-repetition), mild cognitive and intellectual 
impairment (e.g. problems handling money), difficulty performing normal daily 
tasks, as well as mood and personality changes (e.g. aggression, depression). In 
moderate AD, sensory processing and conscious thought are affected (Lyketsos et 
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al., 2011). Neuropsychiatric and behavioural symptoms include delusions, 
paranoia and hallucinations. Individuals lose the ability to distinguish familiar 
and unfamiliar faces, experience profound memory impairment and are unable to 
learn new things. In severe stages of AD, some individuals experience motor 
dysfunction (causing apraxia and incontinence), seizures, wasting from loss of 
appetite and they are prone to skin and other serious organ infections (Herrmann 
et al., 2007). This can be followed by longer periods of sleep in the terminal stages 
of disease, and finally death.  
 
1.2.2 Neurochemistry 
Most therapeutic agents currently used to treat AD act to counterbalance the 
neurochemical disturbances that have been long known to underlie AD symptoms 
(Keverne and Ray, 2008). Early post mortem examinations of AD patients 
revealed selective cholinergic denervation in the basal forebrain (Davies, 1976). 
This was later shown to be largely attributed to significant (up to 70%) reduction 
in choline acetyltransferase (ChAT) synthesis within the nucleus basalis of 
Meynert (nbM) and its cholinergic projections to the cortex, hippocampus and 
striatum (Perry et al., 1999). Reduced cholinergic activity in these areas is 
considered to be a major correlate of cognitive deficits in AD (Perry, Tomlinson et 
al. 1978). There are also observations of impaired choline transport, decreased 
acetylcholine (ACh) release, as well as reduced expression of muscarinic, nicotinic 
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and neuronal growth factor receptors within the nbM. The reason for transmitter 
system selectivity remains to be fully understood; however, there are reports of 
cholinergic denervation being linked to amyloid pathology (Kar et al., 2004; 
Teipel et al., 2014) (section 1.4.2). Currently used acetylcholinesterase (AChE) 
inhibitors, such as donepezil and galantamine, offer the most success in reducing 
behavioural and motor symptoms in AD by suppressing ACh metabolism, 
catalysed by AChE (Wilcock et al., 2003).  
Another prominent neurochemical feature of AD is loss of glutamatergic 
transmission within the cortex and cortical projections to the hippocampus, 
striatum, substantia nigra and brain stem (Hardy et al., 1987). As glutamate is vital 
for long-term potentiation (LTP), the process that underpins memory and 
learning, glutamatergic denervation is thought to account for early short-term 
memory loss and dementia in AD (Francis, 2008). There are, thus, indications that 
pharmacologically promoting glutamatergic transmission may be of benefit to 
memory and cognition in AD. On the other hand, memantine, a N-methyl-D-
aspartate receptor (NMDAR) antagonist, is one of the only agents shown to have 
a small effect in reducing the rate of cognitive decline in AD patients (Thomas and 
Grossberg, 2009), although this is usually transient. Memantine prevents excess 
stimulation of NMDARs by glutamate, thereby protecting neurons from 
excitotoxicity induced by intracellular Ca2+ overload (section 1.5) in response to 
NMDAR activation (Lipton, 2006).  This explains why current therapeutics act to 
replenish cholinergic and not glutamate activity, as levels of the latter require 
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physiological fine-tuning, rather than simply increasing their overall levels, in 
order to maintain neuronal homeostasis (Parsons et al., 2007). Surprisingly, 
memantine has also shown to be effective in reducing memory and learning 
deficits in AD caused by glutamatergic deficiency in patients. Of relevance to the 
discussion of AD drugs above, memantine had the opposite effect on cognitive 
function in animal studies (Creeley et al., 2006). 
 
1.3 AD genetics  
The majority of AD cases are diagnosed in the elderly and these are classed as 
sporadic late-onset AD (LOAD). These cases lack a clear genetic component, but 
could result from a complex pattern of inheritance that is most likely caused by a 
combination of polygenic, environmental and lifestyle factors. In a small 
proportion of cases (between 0.1 and 2 %), AD presents before the age of 65 and 
is caused by monogenic mutations in three genes that are inherited in a Mendelian 
fashion.  This type of disease is classed as familial early-onset AD (FAD), and is a 
more rapidly progressing dementia than LOAD. Genetic studies of both AD types 
have led to the establishment of the central hypothesis of AD pathogenesis, the 
amyloid cascade hypothesis (section 1.4), as well as identification of additional 




1.3.1 FAD  
In 1948, scientists described rare cases of Down’s Syndrome (DS) individuals 
who, in their 4th and 5th decades of life, exhibited cognitive and behavioural 
changes and brain lesions characteristic of senile dementia (Jervis, 1948). These 
brain lesions were later determined to be virtually identical to those seen in the 
AD population (Lott, 1982); however, they developed much earlier in DS 
compared to AD. The reason for this was discovered to be an extra copy of the 
amyloid precursor protein (APP) gene mapped to chromosome 21, which is 
triplicated in DS (Tanzi et al., 1987; Robakis et al., 1987; Goldgaber et al., 1987). 
The extra APP copy results in increased production of APP protein and 
overproduction of the protein’s cleavage product β-amyloid (Aβ), found in brain 
lesions in degenerating areas of both DS and AD brain (section 1.4.2). This was 
followed by the discovery that FAD is caused by autosomal dominant mutations 
in the APP gene (St George-Hyslop et al., 1987) that also affect APP processing to 
generate excess Aβ species. This signifies that APP biology is aberrant in both 
disorders and explains the early onset of dementia in DS.  
FAD can be genetically subdivided into three subtypes (Bird, 1993) on the basis 
of mutations in APP, presenilins (PS) 1 and 2. APP is a type I transmembrane 
protein that is subject to differential proteolytic processing by cellular secretases 
(Sisodia, 1992). PS1 and PS2 encode presenilin 1 and 2 - large multi-pass 
transmembrane proteins that are found in numerous cellular compartments and 
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serve a variety of biological functions (reviewed by Vetrivel et al., 2006). 
Presenilins form the catalytic core of the proteolytic enzyme γ-secretase, which 
cleaves numerous type I membrane proteins, including APP (Steiner, 2008). 
AD type 1 is caused by mutation of APP and accounts for up to 15 % of FAD cases; 
AD type 3 is caused by mutation of PS1 and occurs in the majority (30 to 70 %) of 
FAD cases, and AD type 4 is caused by mutation of PS2 and accounts for less than 
5 % of FAD cases (Bird, 1993). FAD individuals with no identifiable mutations in 
the aforementioned genes have also been reported, signifying that other genetic 
factors may be causative to FAD (Cruts et al., 1998; Janssen et al., 2003). As FAD 
subtypes are clinically indistinguishable, differentiating between them requires 
sequence analysis of PS1, PS2 and APP genes in carriers to identify the responsible 
mutations and confirm diagnosis. Over 170 PS1, 25 APP and 14 PS2 gene 
mutations have been identified in families with FAD in different parts of the world 
(Cruts et al., 2012). Most of these mutations are base pair substitutions, with 
several insertions and deletions identified, as well as a rare APP duplication in 
cases of FAD with cerebral amyloid angiopathy (Cruts et al., 2012).  
In FAD, PS1/2 mutations result in defective presenilins that interfere with γ-
secretase proteolytic activity, one of the enzymes that cleaves APP to generate Aβ. 
In general, PS1/2 mutations alter APP processing to result in increased 
production of pathogenic 42 amino acid Aβ peptides (Aβ42) and cause 
accelerated amyloid deposition (section 1.4.2; Duff et al., 1996). It was later found 
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that presenilins also function as Ca2+-conducting leak channels in lipid bilayers, 
and that PS1/2 mutations in FAD also cause deficient endoplasmic reticulum (ER) 
Ca2+ signaling (section 1.5.1; Tu et al., 2006).  
APP mutations cluster around the secretase cleavage sites on exons 16 and 17 of 
the APP gene, and they also act to alter APP proteolysis. The first identified APP 
mutation at codon 717 in exon 17 (London V717I mutation), located near the γ-
secretase cleavage site, was found to favour production of Aβ42 and alter APP 
subcellular localization (Goate et al., 1991). A double mutation at codons 670 and 
671 in exon 16 (Swedish KM670/671NL mutation; APPSWE), located near the β-
secretase cleavage site at N-terminal βAPP, was shown to increase production of 
all Aβ peptides (Mullan et al., 1992). This mutation is commonly used in 
transgenic mouse models of AD (such as the widely used J20, Tg2576 and 3xTg 
models) as these mice go on to accumulate high levels of Aβ and develop amyloid 
plaques (Webster et al., 2014). A recently established Chinese hamster ovary 
(CHO) cell line stably expressing mutant APP provides a physiologically source of 
Aβ that has been shown to recapitulate AD phenotype in vivo (Walsh et al., 2002a).  
Mutations in the MAPT gene encoding microtubule associated protein tau have 
not been linked to FAD, despite the well-documented importance of tau in AD 
pathogenesis (section 1.4.1). However, MAPT mutations are known to cause 
dementia in other neurodegenerative ‘tauopathies’, including frontotemporal 
dementia (FTD) and progressive supranuclear palsy (PSP) (Pickering-Brown et 
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al., 2004; Stanford et al., 2000). These mutations cause tau pathology and tau-
associated neurodegeneration by altering the alternative splicing pattern of 
MAPT to change the normal ratio of tau isoform expression, altering tau protein 
function or increasing the propensity of tau to aggregate  (section 1.4.2; Iovino et 
al., 2014; Spillantini and Goedert, 2013).  
 
1.3.2 LOAD 
Unlike in FAD, genetic inheritance is not observed in persons with LOAD. The 
single biggest risk factor for developing LOAD is age; however, genetic 
susceptibility is also thought to be a major contributing factor to LOAD prevalence 
and this appears to be more prominent in relatively early onset cases of sporadic 
AD (Mendez and Cummings, 2003). Other risk factors, including environmental 
and lifestyle factors, are thought to confer particular risk for the development of 
later onset LOAD cases (Alzheimer’s Society, 2015). Early studies in identical and 
non-identical twins have revealed that there is some genetic component in more 
than 60 % of LOAD cases (Bergem et al., 1997); therefore, genetic abnormalities 
are considered to be an important primary cause of LOAD. Functional 
investigation of the effects of genetic risk factors are the subject of substantial 




The development of relatively high throughput and inexpensive genetic screening 
technologies, such as genome-wide association studies (GWAS), involving large 
numbers of participants, has led to the identification of 20 new potential low risk 
loci for LOAD (Zou et al., 2014). The pathways in which the proteins encoded by 
these genes are active include calcium signaling, lipid and cholesterol metabolism, 
endocytosis, immunity, APP processing and synaptic function (Table 1). 
Moreover, recent GWAS of amyloid and tau transgenic animals shed insight into 
the genes responsible for the development of either pathology (section 1.4), as 
well as identifying genes that may influence early synaptic changes in AD and 
disease progression (Matarin et al., 2015).  The introduction of whole exome 
sequencing technology has led to the identification of polymorphisms in the 
triggering receptor expressed on myeloid cells 2 (TREM2) gene, which increases 
LOAD risk by 5-fold (Guerreiro et al., 2013). Abnormal TREM2 function resulting 
from these polymorphisms is shown to disrupt microglial Aβ clearance, which 
increases cortical Aβ burden and is associated with downregulation of 
neuroprotective cytokine signalling (Rivest, 2015; Ito and Hamerman, 2012).  
A recently identified variant of the CALHM1 gene on chromosome 10 has also been 
shown to influence LOAD risk (Dreses-Werringloer et al., 2008). CALHM1 encodes 
a multipass membrane glycoprotein that is thought to form a component of an 
uncharacterized Ca2+ channel in the brain. According to Dreses-Werringloer and 
colleagues (2008), the ‘channel’ regulates cellular levels of Ca2+ and Aβ 
production, and dysfunctional polymorphic variants of CALHM1 result in 
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aberrant increases in intracellular Aβ and Ca2+. CALHM1 also modulates Aβ levels 
in cerebrospinal fluid (CSF) in individuals at risk of AD (Koppel et al., 2011). These 
findings were the first genetic studies to suggest that changes in Ca2+ homeostasis 
are important for the development of AD, and are therefore of particular interest 
to this work.  
By far the strongest genetic risk factor for LOAD is the ε4 allele of apolipoprotein 
E (ApoE; Strittmatter et al., 1993). ApoE is a plasma protein involved in 
transportation and clearance of cholesterol and other cholesterol-like molecules, 
including Aβ (Mahley, 1988; Strittmatter et al., 1993). ApoE ε4 is one of 3 ApoE 
alleles located on chromosome 19, the other being ε2 and ε3. Most of the 
population carries the ε3 allele which does not influence AD risk, while the rarer 
ε2 allele has shown to reduce AD risk even in heterozygous individuals 
(Alzheimer’s Drug Discovery Foundation, 2015).  The ε4 allele is present in 
approximately 20 % of the population, and dose-dependently increases LOAD 
susceptibility (Liu et al., 2013). A study in 42 families with LOAD has shown that 
ε4 raises the risk of disease from 20% to 90%, and decreases the mean age of 
onset from 84 to 68 years (Corder et al., 1993). Moreover, homozygosity for ε4 
appears to be sufficient to cause AD by the age of 80. The presence of ApoE ε4 has 
shown to exert damage through both loss and gain of function effects such as 
reducing Aβ clearance from the CNS or promoting Aβ deposition, respectively. 
(Castellano et al., 2011). There is some evidence of a link between ApoE ε4 and tau 
pathology in AD (Glöckner et al., 2011), and ε4 carriers also expressing a MAPT 
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gene polymorphism are at a five-fold greater risk for developing LOAD (Raz and 
Miller, 2013).  Table 1 lists the 23 genes that are currently known to confer LOAD 
risk. 
Risk gene Chromosome Protein Implicated pathway Primary 
reference 
CLU 8 Clusterin 
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Table 1.1 A list of the genetic factors currently known to increase risk of sporadic late-
onset Alzheimer’s disease (LOAD). The encoded proteins, chromosome loci, implicated 
pathways and primary references for each gene are given. Polymorphisms in the genes 
in bold confer high risk of developing LOAD. Asterisks denote genes also implicated in 
early-onset familial AD.  
 
While 60 to 80 % of AD cases are heritable, the above loci identified by GWAS only 
account for a small proportion of heritability, even when combined with increased 
expression of the ApoE ε4 allele (Manolio et al., 2009). Further studies are 
therefore required to identify potential genetic risk factors that may account for 




1.4 AD neuropathology 
The neuropathological hallmark of neurodegenerative diseases such as AD is the 
aggregation of insoluble, fibrous protein into brain lesions. Such protein 
aggregation is not limited to disease but does not normally occur until very late in 
life. In AD, these protein aggregates comprise neurofibrillary tangles (NFTs) and 
amyloid plaques. The spatial and temporal distribution of these lesions follows a 
characteristic pattern during disease development, enabling accurate post 
mortem diagnosis and disease staging (Braak and Braak, 1997), and also 
correlates with AD clinical phenotypes (Brosch and Matthews, 2014; Storandt et 
al., 2009).  
 
1.4.1 NFTs 
Early studies of NFT ultrastructure (Fig. 1.1) revealed that these lesions are 
primarily composed of microtubule-associated protein tau aggregated into β-
sheet-rich paired helical filament (PHF) structures (Goedert et al., 1989; Iqbal et 
al., 1975; Wood et al., 1986; Yagishita et al., 1981). NFTs are intracellular protein 
accumulations, generally localized to somata of degenerating neurons and glia, 
but they can also occur in cell processes, where they are known as ‘neuropil 
threads’ (Braak et al., 1986). Following cell death, NFTs remain in the extracellular 
space as ‘ghost tangles’ which are associated with microglia or invading astrocytic 
processes (Ikeda, Haga, et al., 1992; Ikeda, Akiyama, et al., 1992).  
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NFTs have been found to correlate with neuronal loss and the severity of 
dementia in AD brain (Gómez-Isla et al., 1997; Bobinski et al., 1997; Arriagada et 
al., 1992; Lai et al., 2010), however, it is unclear whether NFTs themselves are 
cytotoxic or otherwise detrimental to their milieu. In fact, neuronal dysfunction 
and cognitive impairment correlate to ‘prefibrillar’ tau oligomers, suggesting that 
it is the pre-tangle tau modifications that mediate neurotoxic effects (Mufson et 
al., 2014; Patterson et al., 2011). Nevertheless, the importance of NFTs was 
highlighted by Eva and Heiko Braak in the late 1980s, who found that NFT spread 
follows a consistent hierarchical pattern throughout the brain as disease 
progresses and this permits neuropathological staging of AD and correlation of 
brain pathology to clinical phenotype (Braak and Braak, 1991).  Since then, 
immunohistochemical analysis of NFTs has been the accepted method of post 
mortem ‘Braak’ staging of AD in research and clinical diagnosis (Fig 1.1). The 
mechanisms of NFT intra- and intercellular spread remain to be established, but 
are currently the topic of intensive research (Gendreau and Hall, 2013). 
 
1.4.2 Tau 
The presence of tau as the main component of NFTs prompted the hypothesis that 
tau changes are causally related to neurodegeneration. This was confirmed in 
documented cases of FTD with parkinsonism linked to chromosome 17 (FTD-17) 
caused by a common MAPT mutation (P30IL), where tau dysfunction led to 
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neuronal death (Poorkaj et al., 1998; Hutton et al., 1998). Since then, extensive 
research has aimed to elucidate how tau structure, function and post-
translational modification can be disrupted to cause neuronal dysfunction and 
demise in these dementing diseases. Determining the significance of tau in AD 
aetiology has not been straight-forward due to the absence of a clear mutation-
disease link (section 1.3.1); nevertheless, the modifications observed to occur to 
tau proteins prior to its aggregation into NFTs in AD models served as evidence 
that abnormal tau likely plays a role in AD pathogenesis and has also provided 
valuable insight into tau function (Martin et al. 2011; Johnson & Stoothoff 2004; 
Morris et al., 2015).  
Tau is best known for its axonal expression in CNS neurons (Götz et al., 1995), 
although it is also recognised to localise to dendrites and cell soma (Hanger et al., 
2009). A major function of tau is to stabilize microtubules for axonal transport, 
which it mediates by C-terminal binding to microtubule protein tubulin which 
promotes tubulin polymerisation and stabilisation. However, tau is also found 
localized to cell membranes and various intracellular domains, indicating that it 
has additional cellular functions (Brandt et al., 1995; Pooler and Hanger, 2010). 
Alternative splicing of tau around the N-terminus and microtubule-binding 
domain (MBD) generates six isoforms in adult human brain, which differ in their 
inclusion or exclusion of N-terminal inserts and microtubule binding repeat 
sequences (‘R’) - the latter of which differentially affects tau binding to 
42 
 
microtubules, microtubule stability and axonal dynamics (Goedert et al., 1989; 
















Fig. 1.1 AD brain is characterized by intraneuronal neurofibrillary tangles (NFTs) 
containing tau protein. NFT tau is abnormally modified which causes it to aggregate 
into (A) paired helical filaments (PHF), visualised here by electron microscopy, that 
are components of (B) NFTs, as shown here following silver staining of AD brain. (C) 
NFT load and distribution pattern are used in neuropathological staging (Braak I-VI) 
of AD. In early stages of AD (I-II), NFTs are localized to the transentorhinal region 
(CA1, subiculum and entorhinal cortex). They spread to the limbic system 
(hippocampus, amygdala) in later stages of disease (III-IV), as indicated by white 
arrows in panel C, and ultimately to the cortex and throughout most of the rest of the 
brain at end stage disease (V-VI). NFTs correlate with cognitive impairment in 
patients (adapted from Jucker and Walker, 2013).  
A B 
C 
I-II III-IV V-VI 
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The normal expression of 3R and 4R tau isoforms gives an approximately 1:1 
ratio; however altered 3R to 4R tau ratios are seen in FTD-17 and other tauopathy 
brains, such as Pick’s disease, and this is speculated to induce neurotoxic cascades 
in tau mutant animals (Fig. 1.2; Goode et al., 2000; Stoothoff et al., 2009; Bronner 
et al., 2005). AD brains show approximately equal expression of 3R and 4R tau; 
however, 4R tau has been implicated in NFT formation in models of AD (Goedert 
et al., 1989).  
Tau processing is normally tightly regulated as it undergoes a number of post-
translational modifications in both physiological and pathological conditions, 
including phosphorylation by protein and tyrosine kinases, as well as truncation, 
cross-linking, isomerization, glycation, nitration and ubiquitination (Morris et al. 
2011; Morris et al., 2015). Tau docking to microtubules is regulated by 
phosphorylation of tau at numerous epitopes around the MBD, which alters MBD 
conformation and detaches tau from microtubules (Lindwall and Cole, 1984; Jho 
et al., 2010). Physiologically, this is important in enabling microtubule 
disassembly during developmental or post-injury neurite outgrowth; however, 
detached tau can accumulate in neurons and neurites, forming insoluble filaments 
and ultimately NFTs (Chuckowree and Vickers, 2003; Lee et al., 2001). 
Conversely, in the dephosphorylated state, tau is able to attach to and stabilize 
microtubules, enabling bidirectional axonal transport of proteins vital for 
neuronal function (Fig. 1.3) (Drubin and Kirschner, 1986; Hollenbeck and Saxton, 
2005).   
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Tau was found to be hyperphosphorylated in NFTs in seminal studies of AD brain 
(Grundke-Iqbal et al., 1986), in primary neurons treated with fibrillar Aβ 
(Busciglio et al., 1995) and in tissue aggregates from tauopathy brain and tau 
mutant animals (Lee et al., 2001). While the link between tau phosphorylation and 
the propensity of tau to aggregate is unclear (Lippens et al., 2007), preventing tau 
phosphorylation at AD-relevant epitopes is shown to diminish tau aggregation 
and be neuroprotective (Perez et al., 2003; Hong et al., 1997; Noble et al., 2005). 
Tau inclusions in AD brain exhibit 45 phosphorylation sites (Fig. 1.2), in 
comparison to only 10 in control brain, indicating that abnormal tau 
phosphorylation is key to AD pathogenesis and that targeting tau kinases to 
reduce tau phosphorylation may be of therapeutic benefit (Hanger et al., 2009). 
Recent studies in transgenic animal models of AD have raised some doubts as to 
the pathogenic role of hyperphosphorylated tau (Morris et al., 2015), however, 
this may simply be an artefact of the model system used for study.  
Considerable research has highlighted several prominent protein kinases that 
phosphorylate tau at serine/threonine residues and can affect its microtubule 
binding capacity in AD (Avila, 2006). These include the proline directed kinases 
glycogen synthase kinase-3 (GSK3), cyclin-dependent kinase 5 (cdk5), p38 and c-
















epitopes and has been linked to a variety of pathogenic cascades, including Aβ 
production, long term potentiation (LTP) impairment, inflammation and neuritic 
damage (DaRocha-Souto et al., 2012; Hooper et al., 2008). Cdk5 activity is also key 
to tau pathology as its overexpression in tau mutant mice is associated with 
A 
B 
Fig. 1.2 AD brain contains six isoforms of CNS tau abnormally phosphorylated at 
multiple epitopes. (A) Alternative splicing, inclusion or absence of exons (E) 2, 3 and 
10 give rise to the different tau isoforms, with varying numbers of N-terminal inserts 
(N) and microtubule binding repeats (R). Alzheimer’s brain shows equal ratios of 
each isoform; however, other neurodegenerative diseases, such as FTD-17 and Pick’s 
disease are associated with altered tau ratios. (B) Approximately 45 epitopes are 
shown to be abnormally phosphorylated in AD tau inclusions. These sites cluster in 
the proline rich domain (PRD) and in the C-terminal region, with a few sites contained 
within the microtubule-binding domain (MBD) of tau. Of these sites, 6 have been 
identified by phospho-specific antibody labelling (indicated in orange) while the 
remaining sites have been identified by mass spectrometry and/or Edman 
degradation (adapted from Hanger et al., 2009). 
46 
 
significant aggregation of tau and cortical NFTs (Noble et al., 2003), memory 
decline and neurodegeneration (Cruz et al., 2003). Inhibition of these tau kinases 
is neuroprotective in transgenic animals and brain slice cultures (Hinners et al., 
2008; Selenica et al., 2007; Noble et al., 2005). However, growing evidence 
indicates  reciprocal regulation between GSK3 and cdk5, which adds a level of 
complexity to targeting specific tau kinase inhibitors to treat AD (Engmann and 
Giese, 2009; Chow et al., 2014; Plattner et al., 2006). Moreover, it is unclear which 
phospho-epitopes are involved in the physiological regulation of microtubule 
stability, which are abnormally phosphorylated in pathological states and 










Fig. 1.3. Illustration of the mechanism by which tau aggregates and forms NFTs in AD. 
Tau is abnormally phosphorylated and aggregates into paired helical filaments (PHF) 
that eventually form neurofibrillary tangles (NFTs). Tau mutations, 
hyperphosphorylation of tau or instability of microtubules all cause tau to detach from 
microtubules. Both phosphorylated and dephosphorylated unbound tau monomers 
are prone to dimerization which leads to further aggregation into PHF (adapted from 
Mukrasch et al., 2005) 
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1.4.3 Amyloid plaques  
Amyloid plaques were first observed in abundance in AD brain by Dr. Alzheimer, 
and have since been used to diagnose disease posthumously, together with NFTs 
(Wong et al., 1985). Also known as senile and neuritic plaques, amyloid plaques 
are extracellular deposits of primarily fibrillar and oligomeric Aβ, but are also 
found to sequester metal ions, proteoglycans and other cell components 
(reviewed by Atwood et al., 2002). Plaque-associated Aβ is generated by 
intraneuronal APP processing and the release of Aβ into the extracellular space as 
soluble peptides, which then aggregate into diffuse amorphous plaques (Ghiso 
and Frangione, 2002). Aβ is continuously deposited in the extracellular matrix 
throughout AD progression, and with increasing involvement of neurites, over 
time results in the formation of dense core neuritic plaques that are also tau-
positive (Fig. 1.4). Unlike diffuse plaques, mature plaques stain with Congo red 
and Thioflavin S and have high β-sheet content, indicating the presence of 
misfolded fibrillar Aβ (Irvine et al., 2008).  
Plaque formation is closely associated with the activation of microglia and 
astrocytes, which are seen to cluster around plaques in APP mutant mice and in 
post mortem AD brain (Rozemuller et al., 1986; Frautschy et al., 1998; Mrak et al., 
1996). It is hypothesized by some that plaque-adjacent astrocytes exert a 
neuroprotective effect by forming a barrier that prevents pathological Aβ from 
damaging surrounding cells; however, activated astrocytes can also suppress 
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microglial phagocytosis of plaque material in vitro, thereby preventing efficient 
clearance of Aβ and allowing plaques to persist (DeWitt et al., 1998). Moreover, 
local secretion of soluble Aβ peptide induces astrocytic stress and Ca2+ 
dyshomeostasis, which are widely shown to differentially contribute to 
downstream neurodegenerative processes in AD (Verkhratsky et al., 2010, 2014; 
Alberdi et al., 2010; Kulijewicz-Nawrot et al., 2013; Garwood et al., 2011). Taken 
together, these findings point to a duality of the neuroinflammatory response in 
the early stages of AD, where glia mediate neuroprotective plaque homeostasis 
and Aβ clearance, while also perturbing neuronal function. In turn, the production 
of harmful oxidative and inflammatory molecules by activated glia argues that 
plaque formation may be a vital early neuroprotective response to AD 
mechanisms that is lost in the later stages of disease (Atwood et al., 2002).  
Although the presence of plaques can predict onset of cognitive symptoms 
(Serrano-Pozo et al., 2011), it is widely debated whether or not plaques 
themselves underlie cognitive decline in AD. Clinicopathological studies have 
shown a weak direct correlation between plaque density and severity of cognitive 
impairment, and suggest that plaque pathogenesis is mediated by NFTs in late 
stage AD (Serrano-Pozo et al., 2011). Moreover, early synaptic changes relevant 
to cognitive deficits are shown to occur prior to plaque deposition in hippocampi 
of APP/PS1 mice (Cummings et al., 2015). However, the major genetic factors in 
AD (ApoE4, SORL1, APP and PS mutations; section 1.3.2) are all seen to directly 
potentiate plaque formation and strongly increase risk of dementia (Mayeux and 
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Hyslop, 2008). Similar to the situation with tau, recent research has focused on 
pre-fibrillar intermediates of Aβ which are likely to mediate synaptic dysfunction 
in AD (Castellani et al., 2008). This is paralleled by an emerging paradigm shift 
from brain lesions as neurodegenerative triggers to them being considered as 
neuroprotective ‘host’ responses to upstream pathogenic processes (Streit and 

















A B C 
D I-II III-IV V-VI 
Fig. 1.4 AD brain is characterized by extracellular amyloid plaques containing β-
amyloid (Aβ) protein. A-C show immunolabelled Aβ plaques from AD brain. Plaque 
morphology changes with continued deposition of Aβ from (A) diffuse, amorphous 
plaques to (B) dense core plaques with high fibrillar Aβ content and (C) tau-positive 
neuritic plaques. Amyloid deposition occurs in close proximity to neurofibrillary 
tangles (NFTs). (D) Plaques show the reverse distribution pattern to that of NFTs, with 
widespread cortical involvement early in disease and penetration to the 
transentorhinal region and subcortical brain areas (white arrow) in later disease 
stages. Plaque burden generally increases throughout disease progression. Unlike 
NFTs, amyloid plaques do not correlate with severity of cognitive phenotype and are 




1.4.4 APP processing 
The primary constituent of amyloid plaques, Aβ, is a peptide of varying length (38-
43 aa) that is constitutively generated from proteolytic processing of APP 
(O’Brien and Wong, 2011; Zhang et al., 2011). APP is a large type 1 
transmembrane protein comprising a long extracellular N-terminal domain, a 
single transmembrane region and a short cytoplasmic C-terminal tail.  Alternative 
splicing of APP generates 8 isoforms that range from 365 to 770 amino acids (aa), 
the most common of which are 695, 751 and 770 aa in length, with 695 aa APP 
being highly expressed in the mammalian CNS (Reinhard et al., 2005). Although 
the function of APP remains poorly understood, its expression appears to be 
concentrated in areas of high synaptic activity, with studies suggesting roles for 
APP in synaptogenesis, synaptic plasticity, neurite growth and cell adhesion 
(Gralle and Ferreira, 2007). Nascent APP is intracellularly trafficked via the 
endoplasmic reticulum (ER) and trans-Golgi network, during which it undergoes 
several post-translational modifications, including O- and N-glycosylation and 
phosphorylation. APP then undergoes fast axonal transport in post-Golgi vesicles 
to dendritic and axonal surface membranes where it is expressed as mature 
protein and exerts its physiological functions (Haass et al., 2012).  
APP is differentially metabolized by proteolytic secretases via two opposing 
pathways - the non-amyloidogenic and amyloidogenic secretory pathways (Zhang 
et al., 2011; Fig. 1.5). The non-amyloidogenic pathway precludes Aβ formation as 
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a result of cleavage of APP by α-secretase through the extracellular portion of the 
Aβ sequence, which generates a truncated C-terminal fragment (C83) lacking the 
N-terminal region of peptide. Subsequent cleavage of intramembranous APP by 
γ-secretase releases a truncated Aβ fragment (p3) and the APP intracellular 
domain (AICD). During amyloidogenesis, APP is extracellularly cleaved by β-
secretase to yield a C-terminal fragment (C99), the direct precursor of Aβ, and a 
large ectodomain of APP (APPsβ). C99 is then cleaved by γ-secretase to release Aβ 
peptides of varying lengths.  Amyloidogenic APP processing occurs on the plasma 
membrane and at the subcellular level, generating extracellular and intracellular 
pools of Aβ, both of which exert pathogenic effects in vitro (Vetrivel and 
Thinakaran, 2006; LaFerla et al., 2007).  
The two major Aβ species produced from APP are the 40 and 42 aa peptides (Aβ-
40 and Aβ-42).  Aβ1-42 is able to rapidly aggregate in vitro as a result of secondary 
structural changes (higher β-sheet content and greater hydrophobicity) that 
enable oligomerization and protofibril formation (Ahmed et al., 2010). In AD 
patients, Aβ1-42 predominantly accumulates in neurons or is sequestered into 
neuritic plaques, while Aβ1-40 is found in high amounts in CSF (Portelius, 
Andreasson, et al., 2010; Gouras et al., 2000). Application of soluble Aβ1-42 
oligomers to primary neurons causes neurotoxicity (Hartley et al., 1999; Atherton 
et al., 2014) and accumulation of Aβ1-42 in animals leads to synaptic loss and 
cognitive dysfunction (Stéphan et al., 2001; Walsh et al., 2002a). Moreover, Aβ1-
42 has been extensively linked to tau phosphorylation and truncation, Ca2+ 
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abnormalities and oxidative stress, and is therefore considered an important 
upstream pathogenic trigger in AD (Zempel et al., 2010; De Felice et al., 2007; 
Ittner et al., 2010; Liang et al., 2010). Numerous studies, including this work, 
therefore use soluble oligomeric Aβ1-42 to model AD mechanisms in vitro.  
In FAD, missense mutations in APP and PS1/2 shift homeostatic APP processing 
towards Aβ production, resulting in either 1) overproduction of all peptides, 2) 
increased Aβ1-42:40 ratio or 3) increased fibrillisation of Aβ (section 1.3.1; 
Morris et al., 2014; Weggen and Beher, 2012). While LOAD aetiology lacks 
mutations in APP or PS1/PS2 genes, the majority of AD patients still show 
increased levels of brain and CSF Aβ, likely as a result of the presence of 
susceptibility genes and/or environmental factors (Lacor et al., 2004; Atherton et 
al., 2014). For example, high dietary cholesterol, associated with increased ApoE 
ε4 and LOAD risk (section 1.3.2), is known to affect Aβ production (Sing and 
Davignon, 1985). Cholesterol depletion promotes non-amyloidogenic APP 
processing in human embryonic kidney (HEK) cells overexpressing the α-
secretase ADAM10 (Kojro et al., 2001), and reduces Aβ production in APP-
transfected hippocampal neurons (Simons et al., 1998). Moreover, deficiency of 
proteases involved in physiological APP processing are thought to potentiate 









1.4.5 The amyloid cascade hypothesis of AD 
 
The amyloid cascade hypothesis of AD proposes that brain Aβ protein, whether in 
soluble or fibrillar form, or contained within plaques, acts as the pathogenic 
trigger of cascades leading to formation of NFTs, perturbation of synaptic function 
Fig 1.5 Amyloid precursor protein (APP) is proteolytically processed via two 
pathways: non-amyloidogenic (black arrows) and amyloidogenic (green arrows). 
Non-amyloidogenic APP processing precludes formation of pathogenic β-amyloid 
(Aβ) by α- and γ-secretase-mediated truncation of the Aβ sequence. Amyloidogenic 
APP processing results in Aβ formation through β- and γ-secretase-mediated cleavage 
around the Aβ sequence. Familial mutations favour amyloidogenesis, which may be 
also influenced by levels of apolipoprotein ε (ApoE) protein and physiological APP 
proteases (adapted from Sisodia and St George-Hyslop, 2002) 
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and ultimately neuronal demise (Reitz, 2012; Hardy and Higgins, 1992; Suzuki, 
1997). Evidence from recent studies has shifted the focus from amyloid plaques, 
which are now argued by some to protect the brain from harmful chemicals 
generated during AD progression (Castellani et al., 2008; Atwood et al., 2002), to 
soluble Aβ oligomers, which are shown to directly perturb synaptic function and 
cause neurotoxicity in cell and animal models of AD (McLean et al., 1999; Haass 
and Selkoe, 2007; Sivanesan et al., 2013; Lue et al., 1999). However, decades of 
scientific research following the introduction of the amyloid hypothesis in the 
mid-1980s have led to evidence both for and against a primary role for Aβ in AD 
pathogenesis (reviewed by Morris et al., 2014).  
The discovery that DS individuals with early dementia harbour a triple copy of 
APP, display increased Aβ production and AD-like brain lesions first linked AD 
phenotype to aberrant APP physiology and Aβ production (section 1.3.1). 
However, it is important to note that not all DS individuals develop AD (Zigman et 
al., 2008), suggesting that Aβ may not be the sole risk factor in DS and AD. While 
FAD cases are attributed to mutations in APP and PS genes, known to increase 
Aβ/Aβ1-42 production, these individuals comprise less than 1 % of all AD cases, 
while the rest suffer from LOAD that lacks mutations in the above genes (section 
1.3). On the other hand, increased dosage of ApoE ε4 and polymorphisms in 
TREM2 - the only known high risk LOAD loci to date - are both shown to modulate 
Aβ production and clearance (section 1.3.2). The notion that other pathogenic 
events, aside from increased Aβ production, cause AD is also supported by animal 
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models. APP and PS1 mutant rodents are shown to recapitulate several of the 
features of human AD, such as Ca2+ dyshomeostasis and synaptic dysfunction 
(Kuchibhotla et al., 2008; Webster et al., 2014; Cummings et al., 2015; Matarin et 
al., 2015); however, the recently established 3xTg-AD (triple transgenic AD) 
mouse expressing APPSWE, PS1M146V and MAPTPS01L mutations was the first model 
to demonstrate a clear age-dependent onset of AD pathology (Oddo et al., 2003) 
that was consistent with human disease (Mastrangelo and Bowers, 2008; Volicer 
et al., 2001). In this model, early accumulation of soluble Aβ is followed by plaque 
deposition at 4 months and NFT formation at 6 months, and animals also exhibit 
synaptic deficits and circadian rhythm abnormalities (Oddo et al., 2003). These 
findings suggest that toxic Aβ oligomers may lie upstream of a pathogenic chain 
of events, including abnormal tau phosphorylation and synaptic dysfunction, 
which are shown to be critical to Aβ neurotoxicity (Zempel et al., 2010; Liang et 
al., 2010; Hung et al., 2005; Jin, Yin, Yu, et al., 2015).  
Notably, perturbation of synaptic function is shown to be a central event in AD 
that underpins the progressive memory deficits and impaired learning abilities 
seen in patients (Selkoe, 2002). Early cortical biopsies revealed up to 35 % 
reduction in synaptic density within a few years of onset of clinical AD (Davies et 
al., 1987), with synapse loss correlating more robustly with early cognitive 
symptoms than plaques and tangles, gliosis or neuronal loss (Terry et al., 1991). 
The observations of increased levels of soluble Aβ in MCI patients (Lue et al., 
1999) and, recently, decreased synaptic density in APP mutant mouse 
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hippocampus (Price et al., 2014) suggest a causal link between Aβ and synaptic 
dysfunction in AD.  Indeed, APP transgenic mice display depletion of presynaptic 
terminals coupled with an increase in soluble Aβ at an early age, prior to plaques 
(Elder et al., 2010), and Aβ diminishes LTP, synapses and spine counts in neurons 
(Zempel et al., 2010). Furthermore, altered synaptic gene expression and function 
is seen to occur prior to plaque deposition in APP/PS1 mice (Cummings et al., 
2015). Therefore, it is likely that the increasing soluble pool of Aβ is responsible 
for the synaptic and cognitive changes in AD. The mechanisms through which Aβ 
disrupts synaptic function are shown to include caspase-2 activation, (Pozueta et 
al., 2013; Bredesen et al., 2010), tau missorting (Hoover et al., 2010), oxidative 
stress (section 1.5.3; Forero et al., 2006) and Ca2+ dyshomeostasis (section 1.5.2 
Sun et al., 2014). 
Despite the above evidence that Aβ is, at least in part, responsible for the 
neuropathological features of AD, anti-Aβ therapies have so far failed to halt 
disease progression or alter cognitive phenotype in clinical trials (Conway et al., 
2003). These therapies either directly targeted Aβ by active and passive 
immunization or prevented Aβ production through inhibition of γ- and β-
secretases and PS (Morris et al., 2014). Recently, focus has been shifted to anti-
tau therapies, which aim to prevent abnormal tau phosphorylation and 
aggregation by 1) inhibition of specific tau kinases, 2) directly immunizing against 
tau, and 3) disaggregating existing tau inclusions in the brain (Hanger et al., 2009). 
This group has previously shown that inhibition of GSK3 by lithium reduced tau 
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phosphorylation and rescued neurodegeneration and cognitive deficits in vivo 
(Noble et al., 2005), and other tau therapies have shown promise in multiple 
animal models of AD (reviewed by Brunden et al., 2009). Therefore, it is likely that 
combined therapies targeting multiple disease pathways, including Aβ and tau, 
may be required to effectively halt AD progression.  
 
1.5 The Ca2+ hypothesis of AD 
In the brain, Ca2+ functions as a ubiquitous intracellular messenger that 
orchestrates a host of glial and neuronal functions, including glial information 
exchange, neuronal excitability, synaptic transmission, plasticity and metabolism 
(Cheng et al., 2006; Deitmer et al., 1998). The functionality and viability of the 
different CNS cell types requires tight regulation of intracellular Ca2+ levels and 
signalling, as deviations from physiological concentrations can be cytotoxic and 
trigger pro-apoptotic and necrotic mechanisms of cell death (Berridge et al., 
2000). The ways through which intracellular Ca2+ is fine-tuned include 1) 
regulated Ca2+ entry and exit via plasma membrane Ca2+-permeable channels, 
receptors and protein pumps, 2) intracellular Ca2+ buffering,  3) sequestration of 
Ca2+ into intracellular stores and 4) extrusion of excess cellular Ca2+ (Fig. 1.6).  
In AD, numerous components of the neuronal and glial Ca2+ toolkit are perturbed 
to result in intracellular Ca2+ overload and subsequent aberrant induction of Ca2+ 
signalling cascades (Grolla et al., 2013; Lim et al., 2014; Abramov et al., 2004; 
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Thibault et al., 2007). According to substantial evidence, including this work, 
these Ca2+ perturbations contribute to the early synaptic and cognitive changes 
seen in prodromal AD (Chakroborty and Stutzmann, 2011; Chakroborty et al., 
2012; Rubio-Moscardo et al., 2013; Chakroborty et al., 2012; Supnet and 
Bezprozvanny, 2010), and mediate the subsequent neurodegenerative processes 
in later stages of AD (Buxbaum et al., 1994; Pierrot et al., 2006; Aarts and 












Fig 1.6 The fine-tuning of homeostatic intracellular Ca2+concentrations is crucial for 
neuronal function. This is mediated by 1) regulated entry of Ca2+ through plasma 
membrane proteins, including voltage-gated calcium channels (VGCCs), N-Methyl-D-
aspartate receptors (NMDA-R), non-NMDA glutamate receptors (AMPA-R), nicotinic 
acetylcholine receptors (nAChR), and transient receptor potential channels (TRPC), 2) 
intracellular Ca2+ buffering by Ca2+-binding proteins, 3) sequestration of Ca2+ into 
endoplasmic reticulum (ER) and mitochondria  via sarcoendoplasmic reticulum Ca2+ 
ATP-ase (SERCA) and sodium calcium exchanger (NCX) pumps, respectively, and 4) the 
extrusion of excess Ca2+ via protein pumps, including NCX and the plasma membrane 
Ca2+ ATP-ase (PMCA). In sporadic AD models, these mechanisms of Ca2+ regulation are 
differentially perturbed directly by Aβ or through Aβ-induced signalling cascades 
(Grienberger and Konnerth, 2012) 
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1.5.1 Ca2+ dysregulation in FAD 
Disruptions of intracellular Ca2+ are thought to underlie the development of FAD 
(Etcheberrigaray et al., 1998) and this is replicated in several animal models of 
FAD (Honarnejad and Herms, 2012; Smith et al., 2005). In particular, PS1/2 
mutations cause perturbations in ER Ca2+ homeostasis by altering the ER Ca2+ leak 
function of PS (Tu et al., 2006). In mouse embryonic fibroblasts, (MEF) ablation of 
PS1 and PS2 genes resulted in increased PS-mediated Ca2+ leak, which accounts 
for 80% of the total passive release from the ER (Tu et al., 2006). Expression of PS 
with FAD mutations in transgenic mice and cell lines also enhances Ca2+ release 
from ER via inositol 1,4,5-trisphosphate receptors (IP3Rs), which contributes to 
cytosolic Ca2+ filling (Stutzmann et al., 2004, 2007). This is amplified by 
stimulation of ER Ca2+-sensitive ryanodine receptors (RyR) by IP3R-liberated Ca2+, 
which mediates further RyR-mediated Ca2+ release from ER - a mechanism termed 
Ca2+-induced Ca2+ release (CICR; Verkhratsky and Shmigol, 1996). In addition, 
increased activity of the sarcoendoplasmic reticulum calcium transport ATPase 
(SERCA) in PS1 mutant mice increases Ca2+ sequestration into the ER, which in 
turn leads to ER Ca2+ overload (Supnet and Bezprozvanny, 2010). Together, these 
fluctuations in intra-ER Ca2+ alter the activity of ER proteins to result in ER stress, 
which leads to impaired synaptic plasticity, excitotoxicity and apoptosis 
(Verkhratsky and Toescu, 2003; Rose and Konnerth, 2001; Sokka et al., 2007). 
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Post mortem cerebellar tissue from FAD patients carrying the PS1-E280A 
mutation display abnormal mitochondrial morphology, reduction of Ca2+-
dependent mitochondrial transport proteins adaptor protein mitochondrial Rho 
GTPase and protein kinesin heavy chain isoform 5C, and diminished cerebellar 
activity prior to plaque formation (Sepulveda-Falla et al., 2014). Moreover, 
respiratory stress associated with mitochondrial dysfunction occurs downstream 
of perturbed ER Ca2+ homeostasis and prior to brain lesions in AD brain (Celsi et 
al., 2009). It is therefore hypothesized that early disruption of intracellular Ca2+ 
stores and accelerated Aβ deposition, both induced by FAD mutations, act in 
concert to trigger downstream neurodegenerative processes, such as plaque 
formation, during the progression of AD.  
 
1.5.2 Ca2+ dysregulation in LOAD 
The initial finding that Aβ neurotoxicity is abolished in Ca2+ free solutions, or in 
the presence of L-type voltage gated Ca2+ channel (L-VGCC) antagonists, 
implicated the influx of extracellular Ca2+ in Aβ-mediated neurotoxicity (Brorson 
et al., 1995). Indeed, in  cell culture, Aβ was found to upregulate the activity of 
Ca2+-permeable membrane proteins, including VGCCs, NMDARs and Na+/K+-
ATPases either by oxidative modification or direct binding to receptors (Mark et 
al., 1995; Kasparová et al., 2001; Ueda et al., 1997; Molnár et al., 2004), resulting 
in cytotoxic intracellular Ca2+ elevations. Notably, NMDAR expression was shown 
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to determine neuronal vulnerability to Aβ (Danysz and Parsons, 2012), and Aβ-
induced excitotoxic Ca2+ elevations require excess stimulation of NMDAR 
receptors (Harkany et al., 2000a). Aβ was also shown to spontaneously insert 
voltage-sensitive Ca2+-permeable pores in the lipid bilayer of plasma and 
mitochondrial membranes, which further promotes overload of cytosolic and 
mitochondrial Ca2+, intramitochondrial accumulation of Aβ and mitochondrial 
dysfunction (Demuro et al., 2011; Chen and Yan, 2010). In individuals with high 
susceptibility to LOAD (section 1.3.2), single nucleotide polymorphisms of the 
CALHM1 channel increases neuronal Ca2+ permeability and Aβ production, and 
the ε4 ApoE allele dose-dependently increases cytosolic Ca2+ through activation 
of P- and Q-VGCCs (Dreses-Werringloer et al., 2008; Muller et al., 1998). Studies 
in primary cortical neurons have also revealed that Aβ-induced Ca2+ overload and 
neuronal death is mediated by depletion of ER Ca2+ stores (Suen et al., 2003; 
Ferreiro et al., 2006), which suggests that disrupted ER Ca2+ homeostasis is a 
shared feature of FAD and LOAD.  
The excess accumulation of cytosolic Ca2+ in neural cells leads to the activation of 
Ca2+-sensitive proteases, including calpains and caspases, which are known to 
contribute to a wide variety of neurodegenerative processes in AD (Chan and 
Mattson, 1999). Calpains are overactive in AD brain (Huh et al., 2001; Atherton et 
al., 2014; Nixon et al., 1994; Saito et al., 1993), and cause dysregulated proteolysis 
of key structural and signalling proteins, including cytoskeletal α-spectrin and tau 
(Atherton et al., 2014; Warren et al., 2007). Tau is pathologically truncated by 
62 
 
calpains to result in generation of toxic species that promote tau phosphorylation 
and aggregation, and are also directly toxic to neurons in cell models of AD 
(Flores-Rodríguez et al., 2015; Park and Ferreira, 2005; Liu et al., 2011), although 
the physiological significance of these fragments has been the subject of debate 
(Garg et al., 2011). Importantly, calpain-mediated N-terminal truncation and 
activation of key tau kinases, GSK3 and cdk5, causally links calpain activity to tau 
phosphorylation in multiple studies, including this work (Taniguchi et al., 2001; 
Jin, Yin, Yu, et al., 2015; Rao et al., 2014). The activation of caspases by calpains 
promotes further caspase-mediated tau cleavage and triggers caspase-dependent 
synaptic dysfunction and apoptotic signalling (Juin et al., 1998; Nakagawa and 
Yuan, 2000; Chan and Mattson, 1999), although the relevance of this for 
neurodegeneration in AD is also unclear (de Calignon et al., 2010). Early Ca2+ 
changes are also thought to alter APP function and metabolism through altered 
calpain activity, to promote further Aβ production, for instance through increased 
β-secretase activation (Kyratzi & Efthimiopoulos 2014; Buxbaum et al. 1994; 
Liang et al. 2010; Koppel et al. 2011; Pierrot et al. 2006; Mathews et al., 2002). In 
turn, accumulation of tau and Aβ in dendritic spines is shown to perturb the spine-
specific Ca2+ transients that mediate memory formation, instead causing 
progressive global Ca2+ elevations that precede neuronal death (Michael Berridge, 
personal communicaton; Ittner et al., 2010; Zempel et al., 2010).  
Recently, experiments in this laboratory, including this work, have shown that Aβ-
induced calpain overactivation may also affect the extrusion of cytosolic Ca2+ in 
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AD  (Chapter 3; Atherton et al., 2014). Primary neurons exposed to Aβ display 
increased calpain activity and generation of inactive and calpain-cleaved species 
of the sodium calcium exchanger (NCX) 3 (Atherton et al., 2014) - also observed 
here in end-stage AD brain. NCXs play a vital role in Ca2+ homeostasis as they 
provide the major route of Ca2+ efflux in conditions of excess intracellular Ca2+ 
(Verkhratsky et al., 2013). As shown in this work, perturbation of NCX3 function 
confers neuronal vulnerability to subtoxic doses of Aβ, which suggests that 
impaired Ca2+ extrusion may also contribute to excitotoxicity and neuronal death 
in AD (Atherton et al., 2014). 
 
1.5.3 Oxidative stress and Ca2+ regulation in AD 
Oxidative stress, the build-up of reactive oxygen species (ROS) to an extent that 
exceeds the antioxidant capacity of a cell, increases neuronal vulnerability to 
excitotoxicity by inducing aberrant Ca2+ signalling (Naziroǧlu, 2011). Multiple 
studies have shown that Aβ induces oxidative stress in neurons, which leads to 
DNA damage and activation of DNA-dependent nuclear poly(ADP-ribose) 
polymerase-1 (PARP-1; De Felice et al., 2007; Canevari et al., 2004; Fonfria et al., 
2005; Abeti et al., 2011). Depending on the ‘repairability’ of the DNA damage, 
PARP-1 determines cell fate either by initiating DNA repair or signalling apoptosis 
(Andrabi et al., 2006; Fonfria et al., 2005). Active PARP-1 catalyzes the synthesis 
of ADP-ribose (ADPR) polymers (PAR), which are attached to nuclear acceptor 
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proteins for genomic stability, or translocate to the cytoplasm for signal 
transduction to different cellular compartments (Scovassi and Poirier, 1999). 
PARP signalling and ‘PARylation’ are in turn regulated by nuclear poly(ADP-
ribose) glycohydrolase (PARG), which hydrolyses PAR into free ADPR. In the 
cytoplasm, ADPR acts as a potent activator of transient receptor potential 
melastatin type 2 (TRPM2) - a non-selective Ca2+-conducting channel that is 
highly expressed in the brain (Xie et al., 2010). ADPR binds and activates TRPM2, 
leading to channel pore opening and entry of Ca2+ down an electrochemical 
gradient.  
PARP activity and PAR formation are increased in AD brain (Love et al., 1999), 
suggesting that downstream aberrant TRPM2 stimulation and disrupted Ca2+ 
homeostasis could contribute to neuronal death in AD. Indeed, PARP-induced 
activation of TRPM2 channels was required for Aβ neurotoxicity in primary 
striatal neurons, as inhibition of TRPM2 activity either by pharmacological 
blockade, co-expression of the endogenous short isoform TRPM2-S which lacks 
functional activity, or small interference RNA targeting TRPM2 rescued 
excitotoxicity and neurodegeneration caused by H2O2 or Aβ (Fonfria et al., 2005). 
However, it is uncertain at which stage TRPM2 is activated during the time course 
of neuronal Ca2+ changes induced by Aβ. For example, PARP-1 is activated rapidly 
following stereotactic injection of NMDA into mouse striatum, and is required for 
NMDAR-dependent excitotoxicity in these animals (Mandir et al., 2000). On the 
other hand, TRPM2 channels were found to modulate NMDAR subunit expression, 
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thereby conferring neuronal vulnerability to ischaemic neuronal death (Alim et 
al., 2013). Moreover, it remains to be determined whether changes in TRPM2 
expression and function underlie neurodegenerative or neuroprotective 
processes in AD. Figure 1.7 illustrates the differential effects of Aβ on neuronal 









Fig 1.7 In cell models of AD, Aβ proteolytically cleaved from APP disrupts intracellular 
Ca2+ homeostasis. This occurs through 1) stimulation of excess influx of extracellular 
Ca2+ through plasma membrane VGCCs, NMDARs and TRPM2 channels, 2) increased 
release of Ca2+ from the ER and 3) impaired extrusion of excess cytosolic Ca2+  through 
NCX3.  Aβ directly modifies VGCC and NMDAR activity and indirectly activates TRPM2 
channels through increased PARP activity and ADPR synthesis. The Aβ-induced 
increases in Ca2+ cause aberrant activation of calpains, which proteolytically cleave 
NCX3, and increased Ca2+ influx into mitochondria, followed by mitochondrial stress 
(adapted from Park et al., 2014)  
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1.6 Aims and objectives of this thesis  
The aim of this study was to further investigate the mechanisms underlying Ca2+ 
dyshomeostasis in AD, as well as to gain insights into the role of Ca2+ in 
downstream neurodegenerative processes that occur during the progression of 
disease.  
The specific objectives of this work were to investigate:  
1. Changes in Ca2+-activated proteins in post mortem brain from different 
stages of AD, with comparison to brains from other neurodegenerative 
diseases and control tissue 
2. The mechanisms through which Aβ induces neural Ca2+ dyshomeostasis 
3. The contribution of Ca2+-activated proteins to Aβ-induced pathogenic 















All reagents used for the experiments described in this thesis were obtained from 
Sigma-Aldrich Company, Ltd., Dorset, UK, detailed below, unless otherwise stated. 
All plasticware used for tissue culture was purchased from Fischer Scientific Ltd., 
UK. Ultrapure water was used in preparation of all solutions and was dispensed 
from an Elgar® Maxima water purification system (Veolia Water Ltd., UK). All 
reagents and materials used for tissue culture were sterilised by autoclaving at 
15lb/inch2 for 90 min.  
 
2.1.1 General molecular biology reagents 
 
Oligonucleotides 
Table 2.1 lists the synthetic phosphorothioated sense and antisense 



















Table 2.1. Phosphorothioated sense and antisense oligonucleotides used for molecular 
experiments. The oligonucleotide name, sequence, manufacturer and primary references 
are given.  
 
Transfection Reagents 
Lipofectamine 2000® (Invitrogen Ltd., UK) 
OptiMEM I (Invitrogen Ltd., UK) 
 
 
2.1.2 Cell culture materials 
Primary cortical cultures 




Complete Neurobasal™ medium Neurobasal™ medium without 
phenol red (Life technologies 
Ltd., UK) 
       1 % (v/v) B27 supplement 
2 M L-glutamine (PAA 
Laboratories) 
60 units/ml penicillin (PAA 
Laboratories) 
100 units/ml streptomycin 
(PAA Laboratories) 
 
Trypsin/ Trypsin(EDTA)  1x in Hank’s  
ethylenediaminetetraacetic acid (EDTA) Balanced Salt Solution (HBSS; 
Life Technologies Ltd., UK), 
without Ca2+ and Mg2+ 
 
DNase I Components supplied with 




Corporation, New Jersey, USA)       
                        2000 U/ml deoxyribonuclease  
 in Earl’s Balanced Salt Solution 
(EBSS; Life Technologies, Ltd., 
UK) 
 
Albumin-ovomucoid protease solution Components supplied with 
Papain dissociation system 
(Worthington Biochemical 
Corporation, New Jersey, USA)           
          10 mg/ml ovomucoid  
          10 mg/ml albumin     
          in EBSS 
 
HBSS Without Ca2+ and Mg2+ (Life 




Trypan blue 0.4 % trypan blue solution 
(Thermo Fischer Scientific Inc., 
MA, USA)  
 
SH-SY5Y cultures 
Supplemented DMEM: F-12 Dulbecco’s modified eagle 
medium (DMEM; Lonza Ltd., 
UK)  
with Ham’s F-12 (1:1) 




                                  with phenol red       
              10 % (v/v) foetal bovine serum 
(FBS) (Sera Laboratories 
International)   




60 units/ml penicillin (PAA 
Laboratories) 
100 units/ml streptomycin 
(PAA Laboratories) 
    
 
 
2.1.3 General cell biology solutions 
 
Chemical and biological agents for cell culture 
Chemical and biological agents used to treat primary neuronal cultures are 


















(Tsujinaka et al., 1988) 
Merck Chemicals 
Ltd., UK 
(+)-MK 801 Maleate 
Irreversible N-methyl-D-
aspartate receptor 









Lithium Chloride (LiCl) 




Sodium Chloride (NaCl) 









Hydrogen peroxide (H2O2) 
Reactive oxygen species, 





β-amyloid (Aβ) 1-42, 
human 
Synthetic Aβ1-42 peptide, 
models amyloid cascade in 
vitro 
California Peptide 
Research Inc., CA, 
USA 
β-amyloid (Aβ) 1-42, 
human 
Secreted from 7PA2 
Chinese Hamster Ovary 
(CHO) cells stably 
expressing mutant (V717F) 
human amyloid precursor 
protein (APP)  
Professor D. Walsh 
(Harvard Medical 
School) 
Table 2.2. Chemical and biological agents used to treat primary neuronal cultures. Agent 
name, primary target and manufacturer are given.  
  
Protein buffering and tissue lysis solutions 
Phosphate-buffered saline (PBS) 1 PBS tablet dissolved in 200ml 
ultra-pure H2O to give a final 
concentration of: 
       10 mM phosphate 
       137 mM NaCl 
       2.7 mM KCl, pH 7.4 
       In ultra-pure H2O 
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PBS-T PBS containing 
       50 mM Tween-20 
       In ultra-pure H2O 
 
Tris-buffered saline (TBS)    50 mM Tris, pH 7.6 
       150 mM NaCl 
       In ultra-pure H2O 
 
TBS homogenization buffer    50 M TBS, pH 7.4 
2 mM ethylene glycol 
tetraacetic acid (EGTA) 
Mini protease inhibitor cocktail 
tablet, 1 tablet in 10 ml (Roche 
Diagnostics Ltd., UK) 
In ultra-pure H2O 
 
Extra strong lysis buffer (ESLB)   10 mM Tris-HCl, pH 7.5 
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       75 mM NaCl   
0.5 % (w/v) sodium dodecyl 
sulfate (SDS) 
       20 mM sodium deoxycholate  
       1 % (v/v) Triton X-100 
       2 mM Na3VO4 
       1.25 mM NaF 
       10 mM EDTA 
Mini protease inhibitor cocktail 
tablet, 1 tablet in 10 ml (Roche 
Diagnostics Ltd., UK) 
In ultra-pure H2O 
    
 
2 x protein loading buffer    0.5 M Tris-HCl, pH 6.8 
(National Diagnostics Ltd., UK)   4.4 % (w/v) SDS  
       20 % (v/v) glycerol 
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2 % (v/v) 2-mercaptoethanol 
(β-ME) 




2.1.4 Enzyme-linked immuno-sorbent assay (ELISA) 
 
Standard diluent buffer    ESLB  
       TBS  
Mini protease inhibitor cocktail 
tablet, 1 tablet in 10ml (Roche 
Diagnostics Ltd., UK) 
 
Sample diluent buffer    TBS  
Mini protease inhibitor cocktail 
tablet, 1 tablet in 10ml (Roche 
Diagnostics Ltd., UK) 
Standard Reconstitution Buffer    55 mM NaHCO3, pH 9.0 
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       in ultrapure H2O 
 
Remaining components and solutions were provided with:  
Human Aβ1-40 ELISA kit, Invitrogen Ltd., UK 
Human Aβ1-42 ELISA kit, Invitrogen Ltd., UK 
 
 
2.1.5 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Acrylamide gels for SDS-PAGE were prepared by diluting stocking solutions from 
National Diagnostics Ltd. (UK) in ultra-pure H2O.  
Final gel compositions were: 
7.5 % resolving gel, pH 8.8    7.5 % (v/v) acrylamide 
       25 % (v/v) resolving buffer 




0.1 % (v/v) N, N, N’, N’ 
tetramethylethylenediemine 
(TEMED) 
In ultra-pure H2O 
 
10 % resolving gel, pH 8.8    10 % (v/v) acrylamide 
       25 % (v/v) resolving buffer 
0.01 % (w/v) APS 
0.1 % (v/v) TEMED 
      In ultra-pure H2O 
 
12 % resolving gel, pH 8.8    12 % (v/v) acrylamide 
       25 % (v/v) resolving buffer 
 0.01 % (w/v) APS 
 0.1 % (v/v) TEMED  




16 % resolving gel, pH 8.8    16 % (v/v) acrylamide 
       25 % (v/v) resolving buffer 
0.01 % (w/v) APS 
0.1 % (v/v) TEMED 
In ultra-pure H2O 
 
4 % stacking gel, pH 8.8    4 % (w/v) acrylamide 
       25 % (v/v) stacking buffer 
       0.075 % (w/v) APS 
       0.1 % (v/v) TEMED 
       In ultra-pure H2O 
 
Gel running buffers 10x Tris-Glycine-SDS-PAGE 
Buffer (Scientific Laboratory 
Supplies, Ltd., UK) 
       Diluted to 1x in ultrapure H2O 
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10x Tris-Tricine-SDS-PAGE 
Buffer (Scientific Laboratory 
Supplies, Ltd., UK) 
       Diluted to 1x in ultrapure H2O 
 
Western blotting 
Immunoblotting transfer buffer   10x Tris-Glycine-Buffer 
(Scientific Laboratory Supplies, Ltd., UK)   20 % (v/v) methanol 
       in ultrapure H2O 
        
 
Ponceau S red solution    7 % (v/v) glacial acetic acid 
       0.2 % (w/v) Ponceau S red 




5 % milk blocking solution 5 % (w/v) non-fat skimmed 
milk powder in PBS 
 
Odyssey blocking solution Odyssey blocking solution 
(LiCor Biosciences, NE, USA) 
diluted 1:1 with PBS 
5% BSA blocking solution  5 % bovine serum albumin 
(BSA) (w/v) in PBS 
  
Protein molecular weight markers 
Precision Plus® Protein All Blue Standard (Bio-Rad Laboratories Inc., CA, USA) 
with 10 pre-stained bands ranging from 250kDa to 10kDa 
 
2.1.6 Live microscopy  
 
Extracellular (EC) buffer (pH 7.4)    121 mM NaCl 
       6 mM NaHCO3 
       5.4 mM KCl 
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       5.5 mM D-Glucose 
       0.8 mM MgCl2 
25 mM HEPES 
       1.8 mM CaCl2 
       in ultrapure H2O 
 
Ca2+-free EC buffer (pH 7.4)    121 mM NaCl 
       6 mM NaHCO3 
       5.4 mM KCl 
       5.5 mM D-Glucose 
       0.8 mM MgCl2 
       25 mM HEPES 
       in ultrapure H2O 
 
High K+ EC buffer (pH 7.4)    5 mM NaCl 
       129 mM KCl 
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       30 mM D-Glucose 
       1 mM MgCl2 
       25 mM HEPES 
       2 mM CaCl2 
       in ultrapure H2O 
 
Fluo-4-AM 1 mM fluo-4-AM (Life 
Technologies, UK) 
       in anhydrous DMSO 
 
Pluronic® F-127     20% (Life Technologies, UK)  
       in anhydrous DMSO 
 
2.1.7 Immunocytochemistry (ICC) 
 
4 % paraformaldehyde (PFA) 4 % (w/v) PFA in PBS, or 
diluted in PBS from 16 % liquid 
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PFA stock solution (Alfa Aesar, 
Johnson Matthey Co., MA, USA) 
Permeabilisation solution    5 % (w/v) BSA  
       0.05 % (v/v) Triton X-100 
       In PBS 
 
Blocking solution     5 % (w/v) BSA  
       0.05 % (v/v) Triton X-100 
       In PBS 
Hoechst 33342 10 mg/ml bisbenzimide 
H33342 trihydrochloride 
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5 % milk 
blocking 
solution 
Table 2.3. Primary antibodies used for western blotting (WB). Information on epitope 
and antigen, species, working dilution, manufacturer and blocking solution are given. 
 
Table 2.4 lists the primary antibodies used for immunocytochemistry (ICC).  
 
 



























1:500 Dako Ltd., UK 
6E10 
Amino acids 1-17 
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Table 2.4. Primary antibodies used for immunocytochemistry (ICC). Information on 
epitope and antigen, species, working dilution and manufacturer are given. All antibodies 
were diluted in 5 % bovine serum albumin solution with 0.01% Tween in PBS. 
 
Table 2.5 lists the secondary antibodies used for WB.  
 
 
Antibody Dilution Source 




Invitrogen Ltd., UK 





Invitrogen Ltd., UK 
Goat anti-rabbit IgG HRP-linked 1:2000 





Goat anti-mouse IgG HRP-linked 
 
1:2000 
GE Healthcare Life 
Sciences, 
Buckinghamshire, UK. 
Table 2.5. Secondary antibodies used for western blotting (WB). Information on species, 
working dilution and manufacturer are given. All antibodies were diluted in 5 % milk 
blocking solution in PBS 
 
Table 2.6 lists the secondary antibodies used for ICC. 
 
 
Antibody Dilution Source 




Invitrogen Ltd., UK 




Invitrogen Ltd., UK 




Invitrogen Ltd., UK 
98 
 
Alexa Fluor® 488 goat 
anti-rabbit IgG 
1:250 Molecular Probes, 
Invitrogen Ltd., UK 
Table 2.6. Secondary antibodies used for immunocytochemistry (ICC). Information on 
species, working dilution and manufacturer are given. All antibodies were diluted in 5 % 
bovine serum albumin solution with 0.01 % Tween in PBS  
 
2.1.9 Cell death assays 
 
LIVE/DEAD® Cell Viability Assay LIVE/DEAD® Fixable far red 
Dead Cell Stain Kit (Invitrogen 
Ltd., UK)  




2.1.0 Post mortem human brain 
 
Post-mortem human frontotemporal cortex was obtained from the Medical 
Research Council Neurodegenerative Disease Brain Bank. Case details are 






Case No. Sex 
Age 
(years) 
PMD (h) Case notes 
CTRL* A047/02 F 87 22 
Normal adult 
brain 




CTRL A040/07 F 82 13 
Argyrophilic 
grains low to 
moderate 
density 
CTRL A124/04 M 59 50 
Normal adult 
brain 
CTRL A150/01 M 40 40 
Normal adult 
brain 





II A153/06 F 92 17 
Some tau 
deposition 
II* A063/10 F 90 50 
Mild 
Alzheimer’s-type 
changes and mild 
amyloid 
angiopathy 



















BNE stage III 
III* A045/12 M 86 52 Ageing changes 




















IV* A175/12 F 89 56 
Alzheimer’s 
disease HP tau 
























VI A168/05 F 84 36 Braak VI 
VI* A094/04 M 88 46 Definite Braak VI 
VI A059/07 F 92 42 Braak VI 
VI A191/07 F 69 16 Braak VI 
Table 2.7. Post mortem cases from which control and AD frontotemporal cortex were 
obtained. Information is given on sex, age, post mortem delay (PMD) and case diagnostic 











2.2.1 Cell Culture 
SH-SY5Y cells 
SH-SY5Y cells were maintained in supplemented DMEM: F-12 medium (section 
2.1.2) in 175 cm3 culture flasks at 37 ˚C in a humidified atmosphere of 5 % CO2. 
Cells were passaged every 5 days, upon reaching approximately 80 % confluency 
in culture. To passage cells, DMEM: F-12 was aspirated from flasks and cells were 
washed twice with sterile PBS. Cells were then incubated with 1 ml of 0.05 % 
Trypsin/0.02 % EDTA for 5 min at 37 ˚C. Flasks were shaken to aid cell 
detachment, which was checked under a light microscope. To stop the Trypsin 
reaction, 4 ml supplemented DMEM: F-12 medium was added to flasks. Cells were 
mechanically dissociated using a 10 ml Stripette® serological pipette (Sigma-
Aldrich Co., Ltd., UK) and the presence of single cells was confirmed under a light 
microscope. The cell suspension was then diluted 5-fold in supplemented DMEM: 
F-12 and re-seeded in fresh 175 cm3 culture flasks.  
 
Primary cortical cultures 
Sterile culture plastic was coated with 10 μg/ml PDL overnight at 37 ˚C and 
washed once with sterile ultrapure H2O prior to cell plating. Cortical neurons 
105 
 
were isolated from embryonic day 18 (E18) Sprague-Dawley rats (Charles River) 
as previously described (Ackerley et al., 2000). Briefly, pregnant rats were 
sacrificed by Schedule 1 methods, according to the (Scientific Procedures) Act 
1986. Embryos and embryonic brains were removed under aseptic conditions. 
Cortices were dissected from embryonic brains in ice cold HBSS (section 2.1.2).  
Cortices were dissociated under sterile conditions using reagents from the Papain 
Dissociation kit (Worthington Biochemical Corp., NJ, USA). Cortical tissue was 
minced in a petri dish containing HBSS and the cell solution transferred into a 50 
ml falcon tube. Excess HBSS was removed and 2.5 % trypsin solution was added 
to cortices. The cell suspension was then incubated at 37 ˚C for 30 minutes with 
occasional agitation to enable dissociation. DNase was then added to cortices to 
minimize ‘sticky’ DNA fragments and tissue clumping, and the falcon tube was 
inverted twice. The solution was then removed and replaced with supplemented 
phenol red-free Neurobasal™ media without allowing cortices to dry.  The cortices 
were then placed into 1 ml trituration solution and mechanically dissociated by 
vigorous trituration with a sterile 5 ml pipette until all cortices were fully 
dissociated. The tissue solution was next strained through a sterile 70 μM nylon 
strainer (BD Biosciences Corp., MA, USA) into a 50 ml falcon tube to yield a 
homogenous single cell suspension. Cells were then centrifuged for 5 minutes at 
1000 x g (av) using a Sorvall® Legend T Plus bench-top centrifuge (DJB Labcare 
Ltd., UK). The supernatant was discarded and the cell pellet re-suspended into 
1ml Neurobasal™ per embryonic brain. A sample of the cell suspension was 
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stained with trypan blue and cell density was calculated using a haemocytometer. 
Cells were then plated at the required density on PDL-coated plates. Cultures 
were maintained in supplemented Neurobasal™ medium at 37 ˚C in a humidified 
atmosphere of 5 % CO2 for 4-14 days in vitro (DIV).  
 
Treatment of primary cortical cultures with oligonucleotides 
Rat E18 cortical cultures were plated on 18 mm coverslips (Marienfeld Superior, 
Germany) at a density of 250,000 cells per well. Cultures were treated at 4 DIV 
with antisense and sense phosphorothioated oligodeoxynucleotides, specific for 
rat NCX3 (Iwamoto & Kita, 2006). The 5’-3’ sequence of NCX3 antisense: 
GCCATACACAAGAG; the 5’-3’ sequence of NCX3 sense: CTCTTGTGTATGGC 
(section 2.1.1). Cultures were incubated with 5μM oligodeoxynucleotides and 
Lipofectamine 2000® (Life Technologies, UK), a lipid-based transfection reagent 
for eukaryotic cells, according to the manufacturer’s protocol. For each well, 16μl 
oligodeoxynucleotides were mixed with 1μl Lipofectamine 2000® and 70μl Opti-
MEM® I (Life Technologies, UK) and incubated for 20 min at room temperature 
to allow formation of liposome-DNA complexes. During this time, the conditioned 
media was removed from cultures and replaced with 1 ml per well of Opti-MEM® 
pre-warmed to 37 ˚C. Conditioned media was kept for later use. Transfection mix 
was topped up with Opti-MEM® and mixed gently. Opti-MEM® was removed 
from cultures and 1 ml of transfection mix was added drop-wise to cells, following 
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which cells were incubated for 4 hours at 37 ˚C. Afterwards, the transfection mix 
was removed and replaced with conditioned media. After 24 hours of incubation 
with oligodeoxynucleotides to allow adequate suppression of endogenous protein 
transcription, cultures were treated with vehicle or a subtoxic (1μM) 
concentration of oligomeric Aβ1-42 for a further 16 hours.  
 
Pharmacological treatment of primary cortical cultures and SH-SYFY cells 
For treatment with chemical agents, primary cortical cultures were plated in six 
well plates at a density of 1 million cells per well, while SH-SY5Y cells were plated 
in 12 well plates on 18 mm glass coverslips at a density of 100,000 cells per 
coverslip. The agents used, as well as the vehicle used to prepare stock solutions 
and the final concentrations used are detailed in Table 2.8. Control cultures were 













100 mM 1 μM 
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Calpeptin Ultrapure H2O 20 mM 10 μM 
MK-801 Ultrapure H2O 10 mM 1 μM 
Caspase inhibitor IV DMSO 5 mM 100 μM 
LiCl Ultrapure H2O 1 M 5 – 20 mM 
NaCl Ultrapure H2O 1 M 5 – 20 mM 
KCl Ultrapure H2O 129 mM 50 mM 
H2O2 Ultrapure H2O 30 % 1 mM 
Aβ 1-42, human 
(synthetic) 
Ultrapure H2O 500 μM 1 μM, 10 μM 
Aβ 1-42, human 
(secreted) 
DMEM >500 pg/ml >500 pg/ml 
Table 2.8. Details of agents used to treat cell cultures. The diluent, stock and 
working concentrations for each agent are shown.  
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Preparation of soluble oligomeric Aβ 
Human Aβ1-42 purchased from California Peptide Inc. (CA, USA) was dissolved in 
sterile ultrapure H2O to a stock concentration of 500 μM, as described by Town et 
al., (2002). This preparation yields predominantly soluble Aβ oligomers. Aβ 
oligomers were added either directly to cultures, to the centre of each well, or 
were diluted in culture medium before adding to cultures to give a final 
concentration of 1-10 μM. Cultures were gently agitated to ensure uniform 
distribution of Aβ to cells. Control cultures were treated with an equal volume of 
ultrapure H2O.  
 
2.2.2 Protein extraction  
Preparation of tissue homogenates from human brain 
Frozen post-mortem human frontotemporal cortex was prepared in two different 
ways, depending on the protein of interest. Tissue was dissected and 
homogenized at 50 mg/ml in TBS homogenization buffer using an electric 
homogeniser (Ultra Turrax® T8, Werke GmbH & Co., Germany) for analysis of α-
spectrin, calpain I, caspase-3, NCX3, TRPM2 and PARP. Tissue was homogenized 
at 100 mg/ml in extra strong lysis buffer and then sonicated for  10 seconds at 
output setting 4 with a VibraCells™ sonicator (Sonics & Materials INC, USA) for 
analysis of total and cleaved tau and tau phosphorylation epitopes (DAKO, tau1, 
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PHF1 and CP13). During this, tissue and homogenates were constantly kept on ice 
to minimize protein degradation. Samples were then centrifuged at 25,000 x g 
(av) for 20 minutes at 4 ˚C on a 5415R desktop centrifuge (Eppendorf Ltd., UK). 
Supernatants were collected, mixed with 2 x protein loading buffer at a 1:1 ratio 
and stored at -80 ˚C until required.  
 
Preparation of cell lysates from cell cultures 
Rat E18 cortical cultures were prepared as described in section 2.2.1. Culture 
medium was aspirated and cultures were washed twice in PBS pre-warmed to 
37˚C. Cells were scraped into 250 µl PBS and centrifuged for 10 seconds at 13,000 
g. Supernatants were then discarded and pellets were re-suspended in 75-100 µl 
ESLB with 1 protease inhibitor cocktail tablet per 10ml buffer (section 2.1.3). 
Cortical lysates were sonicated for 10 s and then centrifuged at 4˚C for 20 min. 
Supernatants were discarded and pellets were resuspended with 75 µl ESLB. 
Lysates were then mixed with equal volumes (75 µl) of 2 x sample buffer (section 






2.2.3 Quantitative Aβ ELISA 
Aβ1-40 and Aβ1-42 ELISA 
Human Aβ1-40 and Aβ1-42 ELISA kits were purchased from Invitrogen Ltd., and 
ELISA experiments performed according to the manufacturer’s instructions. All 
reagents provided in the kits were equilibrated at room temperature for 10 min 
prior to experiments. Human post-mortem brain homogenates previously 
homogenized in extra-strong lysis buffer (ESLB; section 2.1.3) were used. 4 µl of 
each sample was added to 296 µl TBS buffer containing Mini protease inhibitor 
cocktail tablet (1 tablet in 10 ml, Roche Diagnostics Ltd., UK) to provide a 1:75 
dilution of all samples.  ELISA Aβ standards of known concentrations (10,000, 
500, 250, 125, 62.5, 31.35, 15.63, 7.81 and 0 pg/ml for Aβ1-40 and 100,000, 
10,000, 1000, 500, 250, 125, 62.5, 31.25, 15.63 and 0 pg/ml for Aβ1-42) were 
prepared from recombinant human Aβ1-40 and Aβ1-42 peptides provided in the 
kits. Standards were reconstituted in filtered sodium bicarbonate buffer (section 
2.1.4) as instructed, and were then serially diluted in TBS buffer containing 
protease inhibitor cocktail (section 2.1.3) to achieve an equivalent 1:75 dilution 
of all standards. 50 µl of each standard and sample were added in duplicate to the 
96 well plate provided in the kit. 50 µl of primary detection antibody was then 
added to all wells and the plates incubated at room temperature for 3 hours with 
agitation. All material was discarded from wells to remove any unbound protein 
and plates were washed with diluted wash buffer (section 2.1.4) four times. 100 
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µl goat anti-rabbit-HRP linked detection antibody was then added to each well 
and plates were incubated at room temperature for a further 30 min with 
agitation. All material was discarded from wells and plates were washed a further 
four times with wash buffer. Following this, 100 µl of stop solution (stabilised 
chromogen) was added to each well. Plates were incubated at 37 ˚  C for 1 h 30 min 
in the dark until a colour change (indicative of HRP reaction) was observed in 
wells. Absorbances were read at 450 nm using a Wallac 1420 Victor3TM plate 
reader (Perkin Elmer Ltd., UK). A standard curve was generated using absorbance 
values of protein standards using Excel (Microsoft Corp., USA) and this was used 
to calculate Aβ concentrations in pg/mg tissue.  
 




Prior to SDS-PAGE, samples were prepared in two different ways, depending on 
the protein of interest. For analysis of C-terminal APP fragments (including Aβ) 
protein samples were diluted 1:1 in 2 x Novex® Tricine SDS Sample Buffer (Life 
Technologies, UK) and boiled at 85 ˚C for 2 minutes to denature and reduce 
proteins. For analysis of all other proteins, samples were diluted 1:1 in 2 x protein 
loading buffer (National Diagnostics Ltd., UK) and boiled at 100 ˚C for 5 minutes. 
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All samples were then centrifuged at 10, 000 x g (av) for 30 seconds on a 5414R 
desktop centrifuge (Eppendorf Ltd., UK) to remove cell debris and insoluble 
material.  
Polyacrylamide gels were cast in 1.0 mm plastic cassettes purchased from Life 
Technologies (UK). Resolving gel solutions ranged from 7.5-16 % polyacrylamide 
and were prepared as described in section 2.1.5. Liquid gel solutions were poured 
into cassettes and left to fully polymerize for at least 15 minutes. Isopropanol was 
added to the top of the resolving gel immediately after pouring to eliminate 
bubbles and ensure a uniform interface between the resolving and stacking gels. 
After polymerization of the resolving gel, isopropanol was thoroughly washed off 
using ultrapure H2O. Stacking gels of 4 % polyacrylamide were prepared as 
described in section 2.1.5 and poured immediately after preparation, with 1mm 
plastic combs (Life Technologies, UK) inserted to form wells prior to gel 
polymerisation. Alternatively, pre-cast 1.0mm, 15 well Novex® 16 % Tricine 
Protein Gels were purchased from Life Technologies (UK).  
Gels were inserted into the XCell SureLock™ Mini-Cell electrophoresis system 
(Life Technologies, UK), which were then filled with 1 x running buffer (glycine- 
or tricine-based, depending on the preparation and gel type used) until the wells 
were fully submerged. Proteins were separated by electrophoresis at 150 V for 90 
minutes. PrA mixture of protein molecular weight markers (section 2.1.5) was 




Following SDS-PAGE, proteins were transferred onto Protran® nitrocellulose 
membranes (BA85, 0.45 μm pore size, Whatman Ltd., UK) in XCell II™ Blot 
Modules (Life Technologies, UK) using XCell SureLock™ Mini-Cell Electrophoresis 
Systems (Life Technologies, UK) filled with 1 x transfer buffer (section 2.1.5). 
Prior to transfer, membranes were soaked in transfer buffer for at least 2 min to 
ensure buffer permeation into membrane pores. Protein was transferred at 30 V 
for 2 h on ice. For some proteins, successful transfer was determined by brief 
incubation of membranes in Ponceau S red stain (section 2.1.5) at room 
temperature, followed thorough PBS washing to remove the solution. The 
negatively-charged Ponceau S red stain reversibly binds to positively charged 
protein amino groups and non-covalently to non-polar groups, which allows all 
protein to be detected without interfering with subsequent immuno-labelling.  
Membranes were incubated in 5 % milk blocking solution, 5 % BSA blocking 
solution or Odyssey® Blocking Buffer (Li-cor Biosciences Ltd., UK), depending on 
primary antibody, to prevent non-specific binding. Membranes were gently 
rocked for 1 hour at room temperature in blocking solution on a Stuart® SSL4 
see-saw rocker (Bibby Scientific Ltd., UK). Primary antibodies were prepared in 
appropriate blocking solution and were added to membranes, which were then 
incubated overnight at 4 ˚C with gentle agitation on a MaxQ™ 4000 benchtop 
refrigerated digital shaker, Thermo Fisher Scientific Inc. (USA). The next day, 
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primary antibodies were removed and membranes were washed 3 times in PBS 
for 5 minutes. The appropriate secondary antibodies were diluted in 5 % milk 
blocking solution and then added to membranes to incubate in for 1 hour at room 
temperature, with gentle agitation on a Stuart® SSL4 see-saw rocker (Bibby 
Scientific Ltd., UK). The secondary antibodies were then removed and membranes 
were washed a further 3 times in PBS.  
Proteins were detected by two methods, depending on compatibility with 
primary antibody. Membranes incubated in fluorophore-tagged secondary 
antibodies (section 2.1.8) were scanned for infra-red fluorescence emission at 
700 nm (red) and 800 nm (green) wavelength on an Odyssey® infrared scanning 
system (Li-cor Biosciences Ltd., UK) which allows simultaneous detection of two 
target antigens, and thus two proteins. Scanning intensity of membranes was 
optimized according to the strength of the background and antigen signals in 
order to allow for quantification of integrated signal intensity within a linear 
range. Only protein bands showing the expected molecular weight were 
quantified using Odyssey® analysis software V3.0 (Li-cor Biosciences Ltd., UK), 
and background signal was subtracted automatically. Measured signal intensities 
were exported to Excel (Microsoft Corp., USA), and calculations were performed 
to standardise amounts of protein of interest against those of housekeeping 
proteins (β-actin for rat protein and NSE for human protein) within the same 
sample. Data was then exported to Graphpad Prism (Ver 6, Graphpad software 
Inc., CA, USA) for statistical analysis.  
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For proteins that could not be detected using the Odyssey® system, signals were 
visualized using an enhanced version of the chemiluminescence reaction (ECL). 
Membranes were incubated in secondary antibodies conjugated to horse radish 
peroxidase (HRP) (section 2.1.8) for 1 hour at room temperature with rocking, 
followed by 3 PBS washes of 10 minutes each. Membranes were then incubated 
in Pierce® ECL Western Blotting Substrate (Thermo Scientific, IL, USA) at room 
temperature for 2 minutes. The blotting substrate was mixed to comprise equal 
volumes of enhanced luminol reagent and oxidizing reagent (1 ml each per 
membrane). During incubation of membranes in substrate, HRP catalyzes the 
oxidation of luminol into a light-emitting reagent that allows visualization of the 
protein of interest complexed with the HRP-tagged antibody. The amount of light 
emitted from the oxidation reaction directly correlated with the amount of 
protein and its location on the membrane. Compared to conventional 
chemiluminescence, ECL enhances light emission more than 1000-fold, which 
allows for detection of protein at 1 to 10 pg. Membranes were then placed 
between two sheets of acetate film in an 18 x 24 cm CAWO X-ray screen (Scientific 
Laboratory Supplies Ltd., UK), and the sheets smoothed out to eliminate air 
pockets between membrane and acetate. Images were developed in a dark room, 
by placing high performance chemiluminescence film (Amersham, UK) on top of 
the membrane. Films were exposed for varying times to optimize detection (30 
seconds to 1 hour, depending on the primary antibody affinity) and developed 
using a SRX-101A Medical Film Processor (Konica Minolta Medical Imaging, USA). 
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Films were then digitalized and protein amounts were quantified using open-
source ImageJ software (v 1.41o, National Institute of Health, USA).  
To ensure equal protein content in post mortem samples prior to analysis, 
preliminary western blots to determine housekeeping protein amounts (e.g NSE) 
were run for all samples and these were quantified as previously above. Samples 
were then normalised to the lowest protein concentration by dilution in 
appropriate buffer.  
 
2.2.5 Cell Death Assays 
LIVE/DEAD® Fixable Dead Cell Assay 
The viability of rat primary cortical cultures before and after treatment was 
assessed using a LIVE/DEAD® Fixable Far Red Dead Cell Stain Kit (L10120, Life 
Technologies, UK) according to the manufacturer’s protocol. The amine-reactive 
stain provided reacts with amines on the cell plasma membrane and with free 
amines in the cytosol of cells with compromised membranes to yield a fluorescent 
signal, allowing quantification of the proportion of dead cells in a cell population. 
One vial of stain was dissolved in 50 μl anhydrous DMSO prior to use. Conditioned 
media was removed from culture wells and the cells were briefly washed once in 
PBS pre-warmed to 37 ˚C. The stain was diluted 500-fold in pre-warmed PBS to 
give a final working concentration and mixed thoroughly to ensure a uniform 
118 
 
distribution. The stain was then added to cultures and left to incubate for 30 
minutes at 37 ˚ C with 5 % atmospheric CO2 in a dark humidified incubator to allow 
time for binding and permeation into cells. The stain was then removed and the 
cells briefly washed twice with pre-warmed PBS. The fluorescent signal was 
detected at a fluorescence emission wavelength of 700 nm using the Odyssey® 
infrared scanning system (Li-cor Biosciences Ltd., UK). To determine the effects 
of treatment on cell death, the difference in fluorescent intensities in treated cells 
was then calculated as a proportion of fluorescent intensities in control cells.  
 
2.2.6 Immunocytochemistry 
Cultures grown on glass coverslips were washed once with PBS pre-warmed to 
37 ˚C to remove media and then fixed in 4 % (v/v) paraformaldehyde (PFA) in 
PBS for 5 minutes at 37 ˚C with 5 % atmospheric CO2 in a humidified incubator. 
Cells were then washed 3 times with PBS, 5 minutes for each wash, to remove all 
traces of PFA, and permeabilised in permeabilisation solution (section 2.1.7) for 
2 minutes at room temperature. Cells were then washed a further 3 times in PBS-
T and, to prevent non-specific binding of primary antibodies, BSA blocking 
solution was added for 1 hour at room temperature on a Stuart® SSL4 see-saw 
rocker (Bibby Scientific Ltd., UK). Primary antibodies diluted in BSA blocking 
solution were then added to cells immediately after blocking and incubated for a 
further hour at room temperature. Primary antibodies were then removed and 
119 
 
the cells washed 3 times in PBS-T. The appropriate species of fluorophore-
conjugated secondary antibodies diluted in BSA blocking solution were then 
added to cells to incubate for 1 hour at room temperature. This was followed by a 
further 3 PBS-T washes. The nuclear stain Hoescht 33342 was diluted at 1:1000 
and added to cultures to incubate for 2 minutes at room temperature. Cultures 
were then thoroughly washed 3 times with PBS-T to remove all traces of the stain. 
Cells were mounted on glass microscope slides using fluorescence mounting 
media (Dako Ltd., UK) and kept at 4 ˚C, in darkness until used for imaging.  
Cells were imaged using a Leica Microsystems (LLC., Germany) DM5000B 
fluorescence microscope using the appropriate filter sets (Leica Microsystems 
LLC., Germany) and images were captured on a CTR5000 camera using Leica 
Microsystems (LLC., Germany) AIF lite software. All settings (exposure, gain and 
intensity) were kept constant between treatments and images. Images of 3 
random regions per coverslip, and 3 coverslips per treatment condition, were 
captured. Quantification of immuno-positive cells, relative fluorescence 
intensities and co-localization analysis, when required, were performed using 






2.2.7 Live microscopy  
Fluo-4 Ca2+ imaging 
Ca2+ imaging experiments were conducted in primary cortical neurons and SH-
SY5Y cells plated onto 18mm glass coverslips (Marienfeld, Germany). Neurons 
were imaged at 7 to 10 DIV. SH-SY5Y cells were imaged at passage 18 to 20 and 
were allowed to reach approximately 80% confluency before plating on 
coverslips. On the day of experimentation, 1 mM stock of fluo-4 AM Ca2+ indicator 
(cell permeable) was diluted in 10 ml extracellular solution (section 2.1.6) to give 
a final working concentration of 2.5 µM. The solution was supplemented with 
Pluronic® F-127 (section 2.1.6) diluted from 20% stock to achieve a 1:1 
concentration with fluo-4 AM. This facilitated solubilisation and cellular dispersal 
of acetoxymethyl ester, important for effective binding of cytosolic Ca2+. Following 
removal of Neurobasal™ or DMEM/F-12 medium (section 2.1.2) from neurons or 
SH-SY5Y cells, respectively, coverslips were incubated in fluo-4 AM solution (0.5 
ml per coverslip) for 30 min at 37 ºC in a humidified incubator. The fluorescent 
indicator solution was then aspirated and coverslips were incubated in 
extracellular solution for a further 30 min at 37 ºC in a humidified incubator. This 
allowed de-esterification of the indicator and binding of it to Ca2+.  
Coverslips were placed in an open Ludin imaging chamber (Life Imaging Services, 
Switzerland) and sealed using high-vacuum silicone grease (Sigma-Aldrich Co, 
Ltd., UK.). 0.5ml of extracellular solution was added to the chamber, which was 
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then positioned on the stage of a Zeiss Axiovert 200M inverted live imaging 
microscope (Carl Zeiss Ltd., UK) and maintained in a 5 % CO2 environment and 37 
ºC (respectively controlled by ‘The Brick’ gas mixer and ‘The Box’ temperature 
control system, Life Imaging Services, Switzerland) throughout experimentation. 
Recordings were conducted using a Lambda LS illuminator (Sutter Instrument 
Co., CA, USA) to provide excitation at 485 nm, with fluorescence emission detected 
at 520 nm with a Lambda 10-3 filter wheel (Sutter Instrument Col, CA, USA). Cells 
were visualized under brightfield through a 40X oil lens (Leica Microsystems LLC., 
Germany) and fluorescent images were captured using a Cascade II: 512 camera 
(Photometrics LLC., AZ, USA) and MetaMorph® imaging software (Molecular 
Devices LLC., CA, USA). For each experiment, images were captured using 100 ms 
exposure and 1 s interval (1 image acquired per second) for a duration of 10 min. 
Excitation intensities and exposure times were kept to the minimum required for 
signal detection in order to reduce photobleaching and phototoxicity. Cells that 
were not successfully loaded with Fluo-4 or did not depolarize with 50 mM KCl 
were excluded from analysis.  
Where appropriate, cells were pre-treated with compounds (section 2.2.1) for 3 
hours prior to imaging.  These compounds were added simultaneously to fluo-4 
incubations, washes and Aβ mixtures. Before Aβ treatments, extracellular 
solution was removed from the closed chamber and replaced with a pre-prepared 
mixture of compound in extracellular solution, immediately before recording. 
Images were analysed using ImageJ software (v.1.41o, NIH, USA) and a ‘Ca2+ 
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analyser’ plugin (designed by K. J de Vos, University of Sheffield, Sheffield, UK). 
Signal values were acquired and measured by defining ‘regions of interest’ in 
selected cells using the ‘Ca2+ analyser plugin’. Excel (Microscoft Corp., USA) for 
analysis. Changes in Ca2+ fluorescence were calculated as change in 
fluorescence/resting Ca2+ fluorescence (Δf/f).  
 
2.2.8 Statistical Analyses 
The normality of data was assessed using the D’Agostino-Pearson omnibus test 
using GraphPad Prism v6.0 (La Jolla, CA, USA) software. Unpaired t-tests were 
used to compare and determine the statistical difference between two sample 
sets. Comparison of two or more groups of data was made using one way analysis 
of variance (ANOVA) with Tukey’s post-hoc analysis. Two-tailed Spearman’s rank 
correlation tests with linear regression were used for correlation analyses. 










Elevated calpain activity causes cleavage of NCX3 and 
precedes tau phosphorylation and loss of synaptic 
proteins in Alzheimer’s disease brain 
 
3.1 Introduction 
Characteristic deposition of Aβ in extracellular senile plaques and aggregation of 
hyperphosphorylated tau in intraneuronal neurofibrillary tangles (NFTs) are 
associated with synaptic and neuronal dysfunction in Alzheimer’s disease (AD; 
Noble et al., 2013). Substantial research points to neuronal Ca2+ dyshomeostasis 
as a key mediator of neurodegeneration in AD (Berridge, 2014; Lim et al., 2014). 
Increased production of Aβ has been shown to elevate cytosolic Ca2+  (Kuchibhotla 
et al., 2008) by increasing its influx through native ion channels, receptors 
(Supnet and Bezprozvanny, 2010; Wang and Mattson, 2014) and the formation of 
Ca2+-permeable amyloid pores (Demuro et al., 2011), enhanced release of Ca2+  
from intracellular stores  (Nelson et al., 2010; Supnet and Bezprozvanny, 2010) 
and inactivation of Ca2+-extruding protein pumps (Atherton et al., 2014). 
Prolonged elevation of intracellular Ca2+  initiates excitotoxic cascades that 
involve activation of Ca2+-sensitive proteins such as calcium/calmodulin-
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dependent protein kinase (CAMKK2; Mairet-Coello et al., 2013), calcineurin (Wu 
et al., 2010; Mohmmad Abdul et al., 2011) and calpain (Town et al., 2002; Atherton 
et al., 2014).  
Calpains are a family of Ca2+-activated cysteine proteases that are strongly 
implicated in AD because of their roles in altering key disease proteins, including 
APP to regulate Aβ levels (Morales-Corraliza et al., 2012), tau (Ferreira and Bigio, 
2011), dynamin-1 to affect memory, and synaptic proteins such as the NMDAR 
subunit NR2B to impair synaptic health (Simpkins et al., 2003; Kelly et al., 2005). 
Calpain is also involved in the activation of key tau kinases, such as glycogen 
synthase kinase 3 (GSK3; Goñi-Oliver et al., 2007) and cyclin-dependent kinase 5 
(cdk5; Lee et al., 2000) that phosphorylate tau and enable tau-mediated 
neurodegenerative processes in vivo (Noble et al., 2003; Cruz et al., 2003; Gómez-
Sintes et al., 2007).  
Multiple studies have demonstrated elevated calpain activity in late stage AD 
brain (Saito et al., 1993), particularly in neurons containing NFTs (Grynspan et al., 
1997). Elevated calpain activity in AD brain is associated with increased cleavage 
of numerous calpain substrates in these tissues (Jin et al., 2015; Liu et al., 2005; 
Wu et al., 2007; Atherton et al., 2014). Recently, a strong link between calpain 
activation, calpain-mediated cleavage of GSK3, GSK3 activation and tau 
phosphorylation at key disease epitopes has been demonstrated in late stage AD 
(Jin et al., 2015). Calpain has also shown to cleave the sodium calcium exchanger 
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3 (NCX3; Bano et al., 2005). NCX3 is one member of a family of three ion 
exchangers that extrude Ca2+ in exchange for Na+ in conditions of high cytosolic 
Ca2+ (Lytton, 2007). In a cell-based model of ischaemia, inactivation of NCX3 upon 
its cleavage by calpain led to retention of intracellular Ca2+, further calpain 
activation and resultant glutamate-induced neurotoxicity (Bano et al., 2005) - 
results confirmed in additional models (Brustovetsky et al., 2010a). Calpain 
activity is known to be increased in AD brain (Saito et al., 1993), thereby 
suggesting that NCX3 activity and function may also be altered by calpain in AD, 
where it may contribute to the excitotoxic elevations of Ca2+ that are believed to 
occur early during the development of AD.  
To investigate these events in more detail, the aims of this chapter were to 1) 
determine whether or not calpain activation is increased and is associated with 
NCX3 cleavage in AD brain relative to brain from controls and other 
neurodegenerative tauopathies, and 2) to investigate the stage of AD 
development at which calpain activity is first increased and 3) to determine any 
temporal associations between elevated calpain activity, alterations in tau 
kinases, tau and synaptic markers during the progression of AD. To achieve this, 
postmortem brain from Braak stage II to VI AD tissue was compared with that 






It was first important to determine if calpain activity is altered in association with 
NCX3 cleavage in AD brain relative to control brain. In addition, to determine if 
these changes are specific to AD or are a feature of other neurodegenerative 
diseases, brain from patients diagnosed with frontotemporal dementia with tau 
mutations (FTD-Tau), progressive supranuclear palsy (PSP), and corticobasal 
degeneration (CBD) was also analyzed. FTD-tau, PSP and CBD are characterized 
by accumulation of tau pathology in the absence of increased Aβ production. 
Comparison of biochemical changes in these “pure” tauopathies with those in AD 
brain therefore allows comment on events particularly relevant for tau-
associated neurodegeneration. Lysates from postmortem brain were prepared as 
described in section 2.1.10 and were assessed by western blotting using 
antibodies directed towards key proteins of interest. 
 
3.2.1 Calpain-1 activity is increased in AD brain and brains from 
other tauopathies 
Calpain-1 is a Ca2+-activated cysteine protease that exists as an 80 kDa pro-
enzyme and undergoes autolytic activation to yield 76 and 58 kDa active 
fragments (Baki et al., 1996; Veeranna et al., 2004). To determine if calpain 
activity is altered in neurodegenerative tauopathy brain, lysates from post 
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mortem control and end stage tauopathy brains were immunoblotted with an 
antibody specifically against active (76 kDa) calpain-1. These blots revealed a 
single prominent band of 76kDa (Fig. 3.1), as previously described (Atherton et 
al., 2014).  To control for gliosis and/or neuronal protein loss resulting from 
neurodegeneration or post mortem delay, blots were also probed with an 
antibody against neuronal specific enolase (NSE) as a loading control. 
Standardization of bands to NSE allowed normalization of protein amounts in 
each sample. Quantitation of normalized band intensities revealed that active 
calpain-1 is significantly increased in AD tissue (p < 0.001), as well as in PSP, CBD 
and FTD tissue (p < 0.05) compared to controls (Fig. 3.1B). These findings are in 
accordance with previous reports of elevated calpain-1 activity in AD brain (Saito 
et al., 1993), and in addition this study reveals that increased calpain-1 autolysis 
to its active subunit occurs in other neurodegenerative tauopathies that are not 
characterized by Aβ accumulation.  
 
3.2.2 CAST activity is reduced in AD and tauopathy brain 
The endogenous calpain inhibitor, calpastatin (CAST), is a key intracellular 
regulator of calpain-1 activity that helps to prevents calpain over-activation 
induced by prolonged elevations of intracellular Ca2+ (Murachi, 1990). Reduced 
amounts or activity of CAST has previously been linked with the increased calpain 
activity observed in AD brain (Saito et al., 1993; Rao et al., 2008). Here, CAST 
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activity was examined in AD and tauopathy cortical lysates by immunoblotting 
with an antibody detecting CAST holoprotein (110-120 kDa), active calpain-
cleaved CAST species (37-75 kDa) - that together with CAST holoprotein have 
inhibitory activity - and inactive CAST fragments (< 25 kDa; Fig. 3.1). Amounts of 
active CAST were quantified as a proportion of total CAST and revealed a 
significant reduction in CAST activity in AD (p < 0.001), CBD (p < 0.01), PSP and 
FTD brains (p < 0.05), compared to control (Fig. 3.1C). Corresponding increased 
amounts of inactive CAST were found in these diseased brain lysates compared to 
controls (Fig. 3.1D). This data supports previous evidence demonstrating 
decreased CAST activity in AD brain (Saito et al., 1993; Rao et al., 2008), and also 
shows similar changes in other tauopathy brains.   
 
3.2.3 Calpain cleavage of NCX3 is increased in AD brain 
The NCX3 belongs to a family of 3 plasmalemmal pumps that extrude excess Ca2+ 
to maintain homeostatic intracellular levels (Lytton, 2007). NCXs are subject to 
cleavage by proteases, including calpain, which inactivates the exchanger by 
preventing its binding to Ca2+ (Bano et al., 2005, 2007).  
Amounts of full-length and cleaved NCX3 were measured by immunoblotting 
lysates prepared from post mortem brain with an antibody previously shown to 
detect NCX3 holoprotein (110 kDa), calpain-cleaved (~60kDa) and caspase-
cleaved (~66 kDa) NCX3 species,  in primary neurons (Bano et al., 2005). Bands 
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of these expected sizes were apparent in the postmortem brain lysates assessed 
here (Fig. 3.1A). The density of protein bands were quantified and following 
normalization to NSE amounts in each sample, it was found that there was 
significantly less full-length NCX3 in AD tissue compared to controls (p < 0.01; Fig. 
3.1E) in line with previous findings (Sokolow et al., 2011). This was paralleled by 
a significant increase in the amounts of calpain-cleaved NCX3, quantified as a 
proportion of total NCX3 (p < 0.01; Fig. 3.1F). This latter finding is consistent with 
observations of elevated calpain-1 activity in these samples. Amounts of full-
length and calpain-cleaved NCX3 were not altered in any other disease group (Fig. 
3.1 E, F), suggesting that calpain cleavage of NCX3 is specific to AD. In addition, 
there were no changes in the amounts of caspase-cleaved NCX3 in any 
neurodegenerative disease brain when compared to control (Fig. 3.1G), 
supporting previous findings that there are no increases in caspase-3 activity in 
cortical tissues from these diseased brains (Atherton et al., 2014). Since 
exchanger activity is disrupted upon calpain cleavage of NCX3 (Bano et al., 2007), 
these findings indicate that normal NCX3 function is lost in AD, which might 
suggest that impaired NCX3 function could contribute to dysregulation of 






















Fig. 3.1 Calpain-1 activity and calpain-mediated NCX3 cleavage are elevated in AD 
brain. (A) Representative immunoblots of post mortem cortical lysates. Blots were 
probed with antibodies against active calpain-1 at 76 kDa, NCX3 holoprotein at 110 
kDa, caspase-3 cleaved NCX3 at 66 kDa and calpain-cleaved NCX3 at approximately 
60 kDa. An antibody against calpastatin (CAST) detects 110 kDa holoprotein , active 
CAST fragments of > 25 kDa and inactive fragments of < 25 kDa. Blots were also 
probed with an antibody against neuron-specific enolase (NSE), a 46 kDa protein. Box 
plots show protein amounts of (B) active calpain-1 relative to NSE, (C) active CAST 
and (D) inactive CAST, both as a proportion of total CAST, (E) NCX3 holoprotein, (F) 
calpain-cleaved NCX3 and (G) caspase-cleaved NCX3, all as a proportion of total NCX3. 
CTRL: control (n = 20), AD: Alzheimer’s disease (n = 20), PSP: progressive 
supranuclear palsy (n = 5), CBD: corticobasal degeneration (n = 5), FTD: 




3.2.4 NCX3 expression sensitizes neurons to Aβ-induced 
neurotoxicity 
Elevated calpain-mediated NCX3 cleavage was only detected in AD brain, and not 
in neurodegenerative diseases characterized by only tau pathology, suggesting 
that the inactivation of NCX3 by calpain might be related to increased Aβ 
concentrations, and therefore could mediate Aβ-induced neurotoxicity. This 
group, and many others, have previously shown that treatment of primary cortical 
neurons with Aβ leads to calpain-1 activation, and subsequent neurotoxicity  
(Town et al., 2002; Atherton et al. 2014; ), and this group showed that these events 
were associated with calpain-mediated NCX3 cleavage (Atherton et al., 2014).  
To further investigate the connection between Aβ-induced neuronal death and 
NCX3, primary cortical neurons were transfected for 24 h with 
phosphorothioated sense or antisense oligonucleotides specific for rat NCX3, as 
previously described (Iwamoto and Kita, 2006). Western blotting of neuronal 
lysates confirmed knockdown of NCX3 protein by antisense NCX3 
oligonucleotides (Fig. 3.2A). Quantification of protein bands, following 
normalisation to β-actin amounts, showed that there was a significant (p < 0.05) 
reduction (38.5 ± 12.6 %) in full-length NCX3 protein amounts when compared to 
control treated cells, in line with previously published data (Ranciat-McComb et 
al., 2000). There were no changes in the amounts of cleaved NCX3 species 
following treatment of cells with antisense oligonucleotides, possibly reflecting a 
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slower turnover rate of these fragments than that of full-length NCX3 (Fig. 3.2A). 
As expected, sense oligonucleotides to NCX3 did not alter NCX3 protein levels (Fig. 
3.2B).  
Following oligonucleotide treatment, cultures were also treated with a subtoxic 
dose of oligomeric Aβ (1μM) for a further 16 h. This treatment alone did not 
significantly alter cell death in cultures (Fig. 3.2C). In contrast, application of 1μM 
Aβ to cultures pre-treated with antisense NCX3 oligonucleotides caused a 
significant increase in cell death when compared to vehicle-treated or sense NCX3 
oligonucleotide transfected cells (p < 0.01; Fig. 3.2C). These findings highlight a 
close association between NCX3 amounts and Aβ neurotoxicity. It is likely that 
cellular mechanisms exist to compensate for the loss of NCX3 function, and these 
may explain the relatively modest effect of NCX3 suppression on Aβ-induced 
neuronal loss observed in these experiments.  Indeed, compensation by other NCX 
family members was previously shown to compensate for NCX3 suppression in 
cultured rat cerebellar granule cells treated with glutamate (Bano et al., 2007). 
Nonetheless, these findings suggest that reduced expression of functional NCX3 















3.2.5 Characterization of biochemical changes in AD-relevant 
proteins in post mortem brains of different AD stages 
Alterations in Ca2+ homeostasis are proposed to occur during the very earliest 
stages of AD development (Chakroborty 2012; Chakroborty et al. 2012).  Since 
Fig. 3.2 Knockdown of NCX3 expression sensitizes cortical neurons to Aβ. Rat primary 
cortical cultures were transfected with antisense (as) or sense (s) oligonucleotides 
against NCX3 for 24 h followed by treatment with a subtoxic dose (1μM) of oligomeric 
Aβ for a further 16 h. (A) Representative immunoblots of cortical lysates probed with 
antibodies detecting NCX3 holoprotein at 110 kDa and cleaved fragments at, 60-66 
kDa. Blots were also probed with an anti-β-actin antibody (42 kDa) as a loading 
control. Bar graphs show (B) total NCX3 protein amounts standardized to β-actin and 
(C) proportion of neuron death as measured by live/dead assay following treatment 
with 1μM Aβ, Aβ and antisense NCX3 oligonucleotides, 1μM Aβ and sense NCX3 
oligonucleotides, or oligonucleotides alone, all expressed  as a percentage of neuron 
death in control cultures. Data are mean ± SEM (n = 3). *p < 0.05, **p < 0.01 
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calpain is a Ca2+-activated protease, assessment of calpain activity in early stage 
AD brain was used as an indicator of changes in Ca2+, and how these relate to 
changes in other important disease proteins. Therefore, postmortem human 
frontotemporal cortex was obtained from Braak stage II-VI AD brain and 
compared to age- and post mortem delay (PMD)-matched controls that showed 
no clinical or histopathological evidence of neurodegenerative diseases. It was 
important to first confirm the Braak staging of these tissues. The microtubule-
associated protein tau accumulates in a hyperphosphorylated form in NFTs in 
affected regions of AD brain (Hanger et al., 2009). The accumulation of 
phosphorylated tau is associated with synaptic and neuronal dysfunction in AD 
(Crimins et al., 2013), and therefore tau is a promising target for new dementia 
therapies (Noble et al., 2011).  
Post mortem brain homogenates were probed with antibodies against total tau 
(DAKO), detecting bands ranging from 37 to 75 kDa in size, and tau 
phosphorylated at the PHF1 epitope (Ser396/404), which yields bands ranging 
from 50-68 kDa in size, corresponding to full-length tau in the adult human CNS 
(Fig. 3.3A). The intensity of tau bands were normalized to those for NSE in the 
same sample. Quantification of band densities showed that, compared to control 
brain, there is an increase in total tau protein amounts in early AD stages that is 
sustained throughout AD progression. The increase in total tau was significant in 
Braak stage II, IV and VI brains compared to control (p < 0.05), with Braak stage 
III and VI elevated, but not significantly, which likely reflects the small sample 
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number and/or variation within groups (Fig. 3.3B). Immunoblotting of 
postmortem brain lysates with the PHF1 antibody revealed bands only in late 
stage AD brain, suggesting that the amounts of tau phosphorylated at these sites 
in early to mid-AD are quite low, certainly below the level of detection of 
immunoblotting. Quantitative analysis of tau phosphorylated at PHF1 sites 
following normalization to total tau amounts in the same sample showed that tau 
is significantly more phosphorylated at Ser396/404 in late stage AD (Braak stage 
VI) when compared to earlier stages of AD and control brain ( p < 0.001; Fig. 3.3C). 
This trend was also observed when samples were immunoblotted with an 
antibody against tau phosphorylated at Ser202 (CP13; data not shown). These 
findings are in support of previous reports of increased total tau protein in 
degenerating AD cortical regions (Khatoon et al., 1994), and may represent 
accumulation of degradation-resistant aggregated tau in tissue homogenates. The 
results are unlikely to reflect increases in tau expression since previous reports 
have failed to identify any changes in total tau mRNA in AD brain when compared 
to control brain (Boutajangout et al., 2004; Hyman et al., 2005). To further confirm 
Braak staging of post mortem brain samples, immunohistochemistry was 
performed on fixed tissue using an antibody against phosphorylated tau (AT8) 
which recognises NFTs in AD brain. These studies revealed the expected and well-
characterized progressive appearance of tangle-like structures in Braak IV-VI 





















Fig. 3.3 Tau accumulates throughout AD development and is hyperphosphorylated in 
end-stage disease.  (A) Representative immunoblots of post mortem cortical lysates 
from control and Braak II-VI AD brain. Blots were probed with antibodies against total 
tau (DAKO) at 40 to 75 kDa and tau phosphorylated at Ser396/404 (PHF1) which 
detected defined bands of 50 to 62 kDa. Blots were also probed with an antibody 
against 46 kDa neuron-specific enolase (NSE) as a loading control. Bar graphs show 
amounts of (B) Total tau (DAKO) and (C) tau phosphorylated at PHF1 sites, both 
standardized to NSE amounts in each sample. (D) Post mortem cortical sections 
immunostained with an antibody against phosphorylated tau (AT8) that labels 
neurofibrillary tangles (NFTs). CTRL: control (n = 7), Braak II: early AD (n = 4), Braak 
III: early AD (n = 3), Braak IV: moderate AD (n = 4), Braak V: advanced AD (n = 3), 




3.2.6 APP processing is altered in early AD brain 
Amyloid precursor protein (APP) is a large type 1 transmembrane protein that is 
proteolytically cleaved to yield toxic Aβ peptides in AD (Dawkins and Small, 
2014). To assess changes in APP cleavage in post mortem AD brain, samples were 
immunoblotted with an antibody specific for C-terminal APP (6E10), which 
recognizes 3 bands at 106, 113, and 130 kDa, characteristic of the 3 major 
isoforms of human APP holoprotein (Fig. 3.4A; Nordstedt et al., 1991; Delvaux et 
al., 2013). When standardized to NSE, quantification of western blot band 
intensities showed that there are significantly increased amounts of total APP 
holoprotein in Braak stages II and III AD brain lysates ( p < 0.01) when compared 
to those from control brain, with late stage AD brain showing  approximately 
equivalent levels to that observed in control tissue (Fig. 3.4B). This findings are in 
line with and extend previous studies which have reported no differences in the 
amounts of total APP holoprotein between control, non-demented and end-stage 
AD brains (Nordstedt et al., 1991).  
The major Aβ isoforms produced from pathological APP cleavage in AD are the 40 
and 42 residue variants, the latter possessing a higher propensity to aggregate 
and induction of neurotoxicity in vitro (Gouras et al., 2000; Butterfield, 2002). To 
assess changes in amount of secreted Aβ1-40 and Aβ1-42 in post mortem control 
and AD tissue, specific amounts of each peptide were measured in these samples 
using Invitrogen Aβ ELISAs, as previously described (Vagnoni et al., 2011, 2012). 
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These experiments revealed no significant difference in the amounts of Aβ1-40 in 
lysates from AD of any stage and control tissues (Fig. 3.4C). In contrast, there was 
a significant increase in Aβ1-42 tissue burden in Braak stage IV (p < 0.05), Braak 
V (p < 0.01, Braak V) and Braak VI (p < 0.05, Braak VI) AD brain when compared 
to that measured in control lysates (Fig. 3.4D). Similar findings were previously 
reported following analysis of cortical lysates from sporadic AD individuals 
(Shinohara et al., 2014).  
Immunohistochemical analysis of fixed post mortem cortical sections with an 
antibody against Aβ (6E10) confirmed the expected presence of diffuse amyloid 
plaques in Braak II and III tissue, and dense core and neuritic plaques in Braak IV 
and VI tissue, none of which were observed in control sections (Fig. 3.4E).  
The above findings reveal transient elevations in APP holoprotein amounts in 
early stage AD brain, which may signify an, as yet unestablished, compensatory 
mechanism in response to early pathological changes in AD brain. Moreover, the 
changes in APP processing identified here were found to precede increases in 
Aβ1-42 production and the senile plaque deposition detected in moderate to end 
stage AD brain. Interestingly, the presence of diffuse plaques in immunostained 
cortical tissue was observed prior to accumulation of Aβ as measured by ELISA, 






















Fig. 3.4 Transient elevations of total APP amounts occur in the early stages of AD, 
and persistent accumulations of Aβ1-42 are observed in end-stage disease. (A) 
Representative immunoblots of post mortem cortical lysates from control and 
Braak II-VI AD brain. Blots were probed with an antibody against the major forms 
of full-length APP (110-130 kDa) and NSE was used as a loading control (46 kDa). 
Bar graphs show amounts of (B) APP standardized to NSE and (C) Aβ1-40 and 
Aβ1-42 as measured by quantitative ELISA. (D) Immunostaining of post mortem 
cortex sections with an antibody against Aβ (6E10) that labels diffuse and senile 
plaques. CTRL: control (n = 7), Braak II: early AD (n = 4), Braak III: early AD (n = 
3), Braak IV: moderate AD (n = 4), Braak V: advanced AD (n = 3), Braak VI: severe 




3.2.7 Calpain-1 activity is increased in early AD brain and 
sustained throughout disease 
Calpain-1 is activated by prolonged intracellular Ca2+ elevations, which are 
postulated to occur in the early, asymptomatic stages of AD (Chakroborty and 
Stutzmann, 2011; Chakroborty et al., 2012). To investigate temporal changes in 
Ca2+ throughout AD course, post mortem frontotemporal lysates were probed 
with an antibody against the active subunit of calpain-1, yielding a single 
prominent band at 76 kDa (Fig. 3.5A). Quantitative analysis of western blot band 
intensities, following normalization to NSE, showed significantly elevated calpain-
1 activity in lysates from Braak stage III AD brain (p < 0.05) relative to controls, 
that was sustained in Braak IV (p < 0.05), Braak V (p < 0.01) and Braak VI (p < 
0.001) lysates (Fig. 3.5B). These findings indicate that calpain overactivation is 
prolonged throughout AD development.  
 
3.2.8 CAST activity is upregulated in early, but not late AD brain 
CAST activity is decreased in end stage AD brain (Fig. 3.1). Here, this work was 
extended by examining changes in CAST activity in different AD stages by 
immunoblotting post mortem cortical lysates with an antibody that detects active 
CAST (holoprotein at 110 kDa and fragments at 37-75 kDa) and inactive CAST (< 
25 kDa; Fig. 3.5A). When standardized to NSE, quantification of band intensities 
for full length and active CAST as a proportion of total CAST revealed that levels 
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of active CAST are significantly increased in Braak III AD brain (p < 0.05) 
compared to control (Fig. 3.5C). Although CAST levels also appeared to be 
increased in Braak stage IV and V tissue lysates, these were found to be not 
significantly different from controls. No significant differences in inactive CAST 
amounts were observed between any AD brain lysates and controls (Fig. 3.5D).  
 
3.2.9 Caspase-3 activity is unaltered throughout AD progression 
Multiple studies point to a crosstalk between calpains and caspases (Nakagawa 
and Yuan, 2000), and activation of neuronal caspase-3 by apoptotic and non-
apoptotic stimuli has been linked to neurodegenerative processes in the brain 
(Porter and Jänicke, 1999; de Calignon et al., 2010). Caspase-3 is a 32 kDa 
proenzyme that is activated upon caspase-8- and caspase-9-mediated cleavage 
into 17 and 19 kDa active fragments, respectively.  
To assess caspase-3 activity, post mortem lysates were immunoblotted with an 
antibody against caspase-3 that labels pro-caspase-3 and its active fragments. 
This antibody detected a 17 kDa active caspase-3 band, as previously found in 
post mortem brain (Atherton et al., 2014; Fig. 3.5A). Following normalization to 
NSE, the densities of caspase-3 bands were quantified. The results showed that 
there were no significant differences in caspase-3 activity in lysates from any AD 
stage brain when compared to control tissue (Fig. 3.5E). This finding supports 
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previous results from this group (Atherton et al., 2014) and others (Jellinger and 
C. Stadelmann, 2000).  
 
3.2.10 Proteolytic processing of α-spectrin increases with 
advancing AD stages 
A common substrate of both calpain-1 and caspase-3 is the cytoskeletal protein 
α-spectrin. To determine if cleavage of α-spectrin corresponds with increased 
activity of calpain in AD brain, immunoblots of post mortem brain lysates were 
probed with an anti-α-spectrin antibody that detects holoprotein at 240 kDa, 
calpain- and caspase-cleaved fragments (145 to 150 kDa) and caspase-3-cleaved 
fragments (110 to 125 kDa; Fig. 3.5A). Calpain- and caspase-cleaved species were 
separately quantified and normalized to NSE. The results of this analysis showed 
a trend of increasing calpain- and caspase-cleaved α-spectrin fragments (145-
150kDa) with advancing disease stage. The increases in calpain/caspase-cleaved 
α-spectrin cleavage were significant in lysates from Braak stage III (p < 0.05) and 
VI (p < 0.01) brain tissues (Fig. 3.5F). No significant differences in the amounts of 
caspase-3-cleaved α-spectrin species were found between any AD group and 
control (Fig. 3.5G). These findings are in support of earlier analyses of calpain-1 
and caspase-3 activities (Fig. 3.5B-E), and suggest that, unlike caspases, there is 
















Fig. 3.5 Calpain-1 activity is elevated in early AD brain and is sustained in late stage 
disease. (A) Representative blots of post mortem cortical lysates from control and Braak 
II-VI AD individuals. Blots were probed with antibodies that detect active calpain-1 at 
76 kDa and active caspase-3 at 17 kDa. An anti-calpastatin (CAST) antibody detects full-
length CAST at 110 kDa, active CAST at > 25 kDa and inactive CAST at < 25 kDa. An 
antibody against α-spectrin detects holoprotein at 240 kDa, calpain- and caspase-
cleaved fragments at 140 to 150 kDa and caspase-cleaved fragments at 110 to 125 kDa. 
Blots were also probed with an antibody against neuron-specific enolase (NSE) antibody 
(46 kDa), as a loading control. Bar graphs show amounts of (B) active calpain-1 following 
normalisation to NSE (C) active CAST and (D) inactive CAST as a proportion of total 
CAST, (E) active caspase-3 following normalisation to NSE, (F) calpain-cleaved α-
spectrin and (G) caspase-cleaved α-spectrin standardized to NSE. CTRL: control (n = 7), 
Braak II: early AD (n = 4), Braak III: early AD (n = 3), Braak IV: moderate AD (n = 4), 
Braak V: advanced AD (n = 3), Braak VI: severe AD (n = 4). Data is mean ± SEM. *p < 0.05, 




3.2.11 Cdk5 activity is elevated in early AD brain and its activity 
is sustained throughout disease progression 
Cdk5 is a proline-directed serine/threonine kinase that phosphorylates several 
serine and threonine residues on tau in AD brain (Hanger et al., 2009). However, 
the specific contribution of cdk5 to AD pathogenesis is somewhat controversial 
(Patrick et al., 1999; Taniguchi et al., 2001; Giese, 2014). Cdk5 activation requires 
complex formation with one of its neuronal activators, p35 or p25. P35 is subject 
to cleavage by calpain into a smaller fragment, p25, which is a more stable and 
potent cytoplasmic activator of cdk5. Prolonged activation of cdk5 as a result of 
p25 over-expression leads to increased tau phosphorylation, aggregation and 
NFT formation, Altered APP processing and enhanced Aβ production, synaptic 
and neuronal demise in transgenic mice (Noble et al. 2003; Cruz et al. 2003; Cruz 
et al., 2005).  
To examine the activation of cdk5 in these brain samples, blots were probed with 
an antibody against cdk5 holoprotein, detecting a 33 kDa band, and an antibody 
against p35 which detects both p35 and p25 at 35 and 25 kDa, respectively (Fig. 
3.6A). Quantitative analysis of band densities in these blots revealed no significant 
changes in the amounts of cdk5 or p35 in any AD group compared to control 
(Fig.3.6B). In contrast, when measuring p25 as a proportion of p35, there was a 
significant increase in p25/p35 ratio in Braak stage III that was sustained in all 
later Braak stages (p < 0.01; Fig. 3.6D). These results are indicative of increased 
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calpain-mediated degradation of p35 to p25 and, therefore, indicate increased 
cdk5 activity from an early stage in AD that is sustained throughout mid- and late- 
stage disease.  
 
3.2.12  GSK3 expression and activity are increased in late stage 
AD brain 
GSK3 is a proline-directed serine/threonine kinase that is widely recognized to 
play a a pivotal role in AD pathogenesis (Hooper et al. 2008; Hanger et al., 2009). 
GSK3 exists as two species, GSK3α and GSK3β, which are respectively 
phosphorylated at Ser21 and Ser9 to inhibit kinase activity. GSK-3 is 
constitutively active, with the addition of phosphate to Ser21/9 acting to inhibit 
kinase activity (Hanger et al., 2009). Activation of GSK3 can be induced upon 
calpain cleavage of GSK3 at its N-terminus, which acts to removes inhibitory 
phosphorylation at Ser21/9 residues (Goñi-Oliver et al., 2007).  
To examine the activity of GSK-3 in AD brain, post mortem blots were probed with 
an antibody against total GSK3, detecting two bands at 51 and 47 kDa which 
represent GSK3α and GSK3β, respectively (Fig. 3.6A). Blots were also probed with 
an antibody against GSK3 phosphorylated at Ser21/9 (pGSK3), which yielded a 
single prominent band in these samples (Fig. 3.6A). This band is likely to 
represent GSK3β phosphorylated at Ser9, since our group has previously 
146 
 
observed that this antibody has higher affinity for GSK3β. For this reason, 
quantitative analysis of pGSK3 did not differentiate between GSK3α and GSK3β. 
When normalized to NSE, analysis of GSK3 protein bands revealed significantly 
increased amounts of total GSK3α (p < 0.01) and GSK3β (p < 0.001) in end stage 
AD (Braak VI) brain when compared to control brain (Fig. 3.6E, F). Quantification 
of pGSK3 showed significantly reduced phosphorylation of GSK3 in Braak stage V 
and VI AD brain lysates when compared to those from control tissue, indicating 
that GSK3 activity is significantly increased in the later stages of AD.  
 
3.2.13 Synaptic proteins are upregulated in early Braak stages 
and lost in end-stage AD brain 
AD is characterized by widespread synaptic dysfunction and loss that is believed 
to be mediated by alterations in Ca2+, calpain activity and tau phosphorylation 
(Wu and Lynch, 2006; Crimins et al., 2013). To begin to understand changes in 
synaptic activity in the brain samples used in this study, lysates of post mortem 
brain were immunoblotted were with antibodies against major pre- and 
postsynaptic markers. Synapsin I was selected as a pre-synaptic marker. Synapsin 
I is a neuronal phosphoprotein localized to small presynaptic vesicles that plays a 
vital role in neurotransmitter release (Bähler et al., 1990). The antibody against 
synapsin I yielded an approximately 80 kDa doublet, likely reflecting differential 

















postsynaptic markers, antibodies specific to postsynaptic density-95 protein 
(PSD95) and the NR2B subunit of NMDARs were used. These yielded bands at the 
Fig. 3.6 Cdk5 and GSK3 activities are increased in AD brain. (A) Representative blots of 
post mortem cortical lysates from control and Braak II-VI AD brain. Blots were probed 
with antibodies against cyclin dependent kinase 5 (cdk5) holoprotein at 33 kDa, p35 at 
35 kDa and the calpain-cleaved fragment, p25 (25 kDa). Blots were also probed with 
antibodies detecting glycogen synthase kinase 3 (totGSK3) -α and -β at 52 and 47 kDa, 
respectively, and GSK3 phosphorylated at Ser9 (pGSK3) at 52 kDa. Anti-neuron-specific 
enolase (NSE) antibody was used as a loading control (46 kDa). Bar graphs show amounts 
of (B) cdk5 following normalisation to NSE, (C) p35 as a proportion of cdk5, (D) p25/p35 
ratio, (E) totGSK3α and (F) totGSK3β following normalisation to NSE, and (G) pGSK3 
standardised as a proportion of total GSK3. CTRL: control (n = 7), Braak II: early AD (n = 
4), Braak III: early AD (n = 3), Braak IV: moderate AD (n = 4), Braak V: advanced AD (n = 




expected sizes of approximately 95 and 170 kDa, respectively (Fig. 3.7A). PSD95 
is commonly used as a marker for synaptic loss as it comprises an integral portion 
of the postsynapse (Dorostkar et al., 2014).  NR2B is an extrasynaptic Ca2+-
permeant ionotropic glutamate receptor that mediates excitotoxicity and is 
subject to calpain cleavage in AD (Ittner et al., 2010).  
The density of protein bands were measured and normalized to NSE content in 
the same sample. Quantitative analysis of these findings showed that there was a 
common pattern of expression for all synaptic markers, where protein amounts 
increased in early AD stages, followed by recovery to control levels and/or protein 
loss in late stage AD. The amounts of both synapsin I and NR2B were significantly 
increased in early AD (p < 0.05; Braak III and II respectively), followed a reduction 
to levels close to control in Braak IV to VI tissue (Fig. 3.7B, C). Levels of PSD95 
protein were also significantly elevated in Braak III tissue (p < 0.05), and returned 
to levels below control in Braak VI lysates (Fig. 3.7D). The reduction in PSD-95 in 
Braak stage VI tissues was clearly apparent, but was not statistically significant, 
which may result from variation within small sample sets. Nevertheless, these 
findings suggest that there is an increase in synaptic activity or synapse number 
in the early stages of AD, which is eventually followed by synapse loss as the brain 
atrophies in end-stage disease. Furthermore, it is possible that increased NR2B 
expression in the early Braak stages could have contributed to glutamate 




3.2.14 Calpain-1 activity correlates with Aβ1-42 load, tau kinase 
activity and tau accumulation 
Considerable research links alterations in neuronal Ca2+ to Aβ overproduction, 
tau phosphorylation and synaptic changes in AD (LaFerla and Oddo, 2005; Zempel 
et al., 2010). Therefore, it was important to determine if there is any correlation 
between active calpain-1 amounts and disease-relevant changes in the 
postmortem brain lysates examined here (Fig. 3.8). 
Fig. 3.7 Pre- and post-synaptic markers are elevated in early Braak stages. (A) 
Representative blots of post mortem cortical lysates from control and Braak II-VI AD 
brain. Blots were probed with antibodies that detect synapsin I at 80-85 kDa, the NR2B 
subunit of NMDARs (NR2B) at 170 kDa, and post-synaptic density 95 protein (PSD95) 
at 95 kDa. An antibody against anti-neuron-specific enolase (NSE) provided a loading 
control (46 kDa). Bar graphs show amounts of (B) synapsin I, (C) NR2B and (D) PSD95 
all standardized to NSE. CTRL: control (n = 7), Braak II: early AD (n = 4), Braak III: early 
AD (n = 3), Braak IV: moderate AD (n = 4), Braak V: advanced AD (n = 3), Braak VI: 
severe AD (n = 4). Data is mean ± SEM. *p < 0.05  
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These analyses revealed a significant positive correlation between active calpain 
1 and Aβ1-42 (p < 0.001; Fig. 3.8A), confirming findings previously reported by 
this group (Atherton et al., 2014) in sporadic AD brain, and also reports from 
others in experimental models of AD (Mathews et al., 2002; Town et al., 2002). 
These findings support evidence showing that calpain may be induced by and/or 
regulate Aβ production. Active calpain-1 amounts were also significantly 
correlated with amounts of calpain- and caspase-cleaved α-spectrin fragments (p 
< 0.001; Fig. 3.8B) and p25 amounts (p < 0.05; Fig. 3.8C), as would be expected for 
calpain substrates, with this data acting as further confirmation that there is 
increased calpain-1 activity in AD brain. Notably, amounts of active calpain-1 
showed a significant negative correlation with levels of GSK3 phosphorylated at 
the inhibitory residues Ser21/9 (pGSK3) (p < 0.001; Fig. 3.8D). These findings are 
likely to be indicative of N-terminal cleavage of GSK3 by calpain (Goñi-Oliver et 
al., 2007), which cleaves these N-terminal phosphorylation sites to activate GSK-
3.  These findings are in keeping with recent reports of calpain-mediated GSK3 
regulation in end-stage AD brain (Jin, Yin, Yu, et al., 2015). Interestingly, active 
calpain-1 levels also showed a significant positive correlation with amounts of 
total tau (p < 0.05; Fig. 3.8E) in AD brain. Tau is subject to N-terminal truncation 
by calpain-1 to yield neurotoxic fragments (Garg et al., 2011a; Liu et al., 2011), for 
which reason the correlation between calpain-1 and accumulation of tau could 
signify increased calpain-mediated generation of these tau fragments. Finally, 
correlation analyses between tissue Aβ burden and synaptic markers showed a 
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significant negative correlation between Aβ1-42 and NR2B amounts (p < 0.01; Fig. 
3.8G), but no correlation between Aβ1-42 and synapsin-1 or PSD95 (Fig. 3.8F, H). 
These findings indicate that in conditions where Aβ1-42 is elevated, there is loss 
of NR2B, likely reflecting previously reported synaptotoxic effects of Aβ at NMDA 

















Fig. 3.8 Calpain-1 activity correlates with Aβ burden, kinase activities and tau amounts 
in AD brain. Scatter plots show the correlation between levels of active calpain-1 and (A) 
Aβ1-42, (B) calpain- and caspase-cleaved α-spectrin fragments, (C) p25/p35 and (D) 
phosphorylated (inactive) GSK3 (pGSK3) in lysates from control and AD brain. Aβ tissue 
burden as measured by ELISA was also correlated with (F) synapsin, (G) NR2B and (H) 
PSD95 protein amounts. Parametric correlation analysis was used to generate correlation 




3.3 Summary and Discussion 
The main findings of this chapter are: 
• Elevated calpain-1 activity in the cortex of end-stage AD and other 
neurodegenerative brain relative to controls.  
• Increased calpain-mediated cleavage of NCX3 in end-stage AD brain, but 
not that from other tauopathies, compared to controls. 
• Reducing NCX3 expression sensitizes rat primary neurons to subtoxic 
concentrations of Aβ, suggesting a functional link between NCX3 function 
and Aβ-induced neurotoxicity. 
• Progressive accumulation of tau from early- to late-stage AD brain, and 
increased tau phosphorylation in end-stage disease. 
• Increased APP holoprotein amounts in early Braak stage AD brain, prior to 
increased production of Aβ1-42 in late-stage disease.  
• Calpain-1 activity is elevated in early stages of AD tissue and this is 
sustained throughout disease progression. 
• Elevations in amounts of active calpain-1 preceded increased activities of 
the key tau kinases ckd5 and GSK3. 
• Increased expression of synaptic proteins in early AD brain, followed by a 
return to control levels or loss in end-stage disease. 
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• Positive correlations between active calpain-1 amounts, Aβ1-42, activities 
of cdk5 and GSK3, and tau accumulation. 
 
3.3.1 Calpain-1 activity is elevated in neurodegenerative disease 
brain 
Altered neuronal Ca2+ homeostasis causes the induction of intracellular signaling 
cascades that have the capacity to mediate the neurodegenerative changes seen 
in AD (LaFerla, 2002). The data presented in this chapter demonstrates that there 
are marked increases in the activity of the Ca2+-activated cysteine protease 
calpain-1 in late-stage AD brain, confirming findings previously reported by many 
other groups (Saito et al., 1993; Tsuji et al., 1998). This increase in calpain activity 
was also observed in brain tissue from patients with PSP, CBD and FTD. This is 
consistent with previous reports of calpain activation in  end-stage PSP and CBD 
brain (Ferreira and Bigio, 2011). 
 The increase in calpain-1 activity observed in these tissues was associated with 
reduction of active CAST, the endogenous calpain inhibitor that is itself a 
substrate of calpain and which has previously been shown to be depleted in AD 
brain (Rao et al., 2008). When taken together, these results suggest that elevated 
calpain-1 activity is a common neurodegenerative disease feature, suggesting that 
there is accumulation of intracellular Ca2+ in affected brain regions in all of these 
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diseases. Moreover, calpain-mediated suppression of CAST inhibitory activity 
implies that calpain activity is exacerbated in end-stage AD in a positive-feedback 
manner, thereby accelerating degradation of cytoskeletal substrates and disease-
relevant proteins such as α-spectrin and tau (Ferreira and Bigio, 2011; Huh et al., 
2001).    
 
3.3.2 NCX3 is cleaved by calpain in AD brain and confers 
neuronal vulnerability to Aβ in primary culture 
NCX3 belongs to a family of plasmalemmal exchangers that provide a route of Ca2+ 
efflux during conditions of high intracellular Ca2+, thereby serving a vital 
homeostatic function. Reduction of NCX3 holoprotein amounts was observed here 
in late-stage AD brain relative to control, and this was accompanied by increases 
in the amounts of calpain-cleaved, inactive, NCX3 fragments. While depletion of 
functional NCX3 in AD brain was previously reported (Sokolow et al., 2011), 
demonstration of increased calpain-cleaved NCX3 in this AD tissue here is a novel 
finding. Moreover, generation of these cleaved NCX3 species correlates with Aβ1-
42 burden (Atherton et al., 2014) and is absent in tissue from other 
neurodegenerative conditions. This suggests that calpain-mediated NCX3 
cleavage is induced by Aβ1-42 in a mechanism specific to AD, and therefore that 
analysis of NCX3 processing could have potential as a biomarker for AD. This is 
particularly relevant since NCX3 can be detected in plasma (Atherton et al., 2014).  
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Of interest, proteolytic inactivation of NCX3 was not associated with 
compensatory upregulation of NCX1, as shown by this group (Atherton et al., 
2014) and others (Sokolow et al., 2011); however, changes in the expression of 
other Ca2+ transport proteins such as plasma membrane Ca2+-ATPases were not 
assessed in these studies. Calpain-mediated cleavage and inactivation of NCX3 has 
been previously shown in an in vitro model of ischaemia. In these studies, 
inactivation of NCX3 upon calpain proteolysis resulted in glutamate-induced 
excitotoxicity associated with impaired extrusion of excess cellular Ca2+ (Bano et 
al., 2005).  Moreover, NCX3 knockout mice exhibit delayed clearance of excess 
resting Ca2+ and diminished LTP, implying a crucial role for NCX3 in learning and 
memory. These findings have led to the current hypothesis that altered NCX3 
function contributes to AD. In support of this idea, knockdown of NCX3 with 
antisense oligonucleotides was shown here to sensitize primary neurons to a 
normally subtoxic dose of oligomeric Aβ. These data suggests that NCX3 could 
mediate neuronal dysfunction and loss in AD, with calpain-mediated inactivation 
of NCX3 in response to Aβ preventing neuronal Ca2+ clearance, thereby promoting 






3.3.3 Calpain-1 activation precedes Aβ overproduction, tau 
phosphorylation and synaptic loss in AD 
The temporal associations between key neurodegenerative processes during the 
course of AD are as yet unclear, and to begin to understand these, changes in 
proteins were studied here using post mortem cortical tissue exhibiting 
pathological changes consistent with early, mid and late disease stages. It is 
demonstrated here that calpain-1 activity is elevated in the early stages of AD 
development (Braak stage III) and this is sustained in later stages of disease. The 
increase in calpain-1 activity was found to precede activation of the tau kinases 
cdk5 and GSK3, hyperphosphorylation of tau at disease-relevant sites, elevated 
Aβ production and loss of synaptic proteins (Fig. 3.9). These findings in post 
mortem brain complement multiple studies carried out in cell and animal models 
of sporadic AD, all of which suggest that aberrant Ca2+ signalling induced by Aβ 
mediates the neurodegenerative changes seen in disease (Khachaturian, 1989; 
LaFerla, 2002; Stutzmann et al., 2007; Thibault et al., 2007; Bezprozvanny and 
Mattson, 2008; Stutzmann and Mattson, 2011; Berridge, 2014).  
In parallel to increased calpain-1 activity, this study demonstrates upregulation 
of the major synaptic proteins synapsin I, PSD95 and the NR2B subunit of 
NMDARs in the early stages of AD. These results may represent an initial 
compensatory response of neurons to the synaptic dysfunction that is proposed 
to occur as disease starts (Forero et al., 2006), as well as elevated Ca2+ and calpain 
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activities. Following these early increases, protein amounts of synapsin I and 
NR2B are reduced to approximately control levels in moderate to late Braak 
stages, whereas PSD95 amounts are decreased somewhat below control levels in 











The synapsin I protein expression pattern here is inconsistent with previous 
observations of significantly reduced synapsin I amounts in Braak V-VI AD 
posterior cingulate cortex compared to non-cognitively impaired controls (Scheff 
et al., 2015). However, this inconsistency is likely accounted by connectivity 
differences between the frontotemporal and posterior cingulate cortex (Pearson 
Fig. 3.9 The temporal association between calpain activity, APP processing and Aβ 
production, tau kinase activity, tau phosphorylation (p-tau) and pre- and postsynaptic 
markers. Diagram depicting protein amounts in different Braak stages using a scale of 
light grey (low protein amounts) to dark grey (high protein amounts). Calpain-1 
activity is elevated in parallel to increases in amounts of APP holoprotein and synaptic 
markers. The increase in active calpain-1 is sustained throughout AD progression, and 
is followed by activation of tau kinases cdk5 and GSK3, tau phosphorylation and 




et al., 2011). The depletion of PSD95 in end-stage AD tissue was expected since 
terminal stages of AD are characterized by widespread synaptic degeneration and 
neural atrophy (Arendt, 2009). Furthermore, PSD95 is subject to calpain cleavage 
in adult rat brain (Lu et al., 2000), and its reduction in late-stage AD post mortem 
tissue could be explained by calpain hyperactivity. The relatively small loss of 
synaptic protein amounts detected here in end-stage disease brain could also 
have been a reflection of the relative insensitivity of western blotting to detecting 
small changes in protein abundance. 
NR2B is cleaved by calpain in primary neurons after excitotoxic glutamatergic 
activation and in vivo during ischaemia, giving rise to the presence of active 
NMDAR forms on the cell membrane (Simpkins et al., 2003). Calpain-cleaved 
NR2B products were not observed in any post mortem tissue here, which may be 
due to the effects of post mortem protein degradation or these species being 
below detectable levels. However, the early increases in NR2B holoprotein 
amounts could also be indicative of a neuroprotective response to calpain 
cleavage of this protein in early AD stages. Similarly, transient upregulation of 
CAST activity was seen here in Braak III tissue, and this could also be a result of 
compensatory mechanisms induced by increased calpain-mediated cleavage of its 
endogenous inhibitor.  
There is growing evidence suggesting that not all Ca2+-related changes in AD are 
harmful to neurons (reviewed by Supnet and Bezprozvanny, 2010), and it is 
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possible that the elevations in CAST and synaptic protein amounts observed here 
in Braak stage II to III AD brain  may indicate cellular compensation mechanisms 
mediated by Ca2+ and calpain that are eventually overcome as disease severity 
increases, conveying the insufficiency of early neuroprotective mechanisms in 
light of widespread neural cell damage.  
 
3.3.4 Limitations of this work 
The use of post mortem brain in this study enabled a valuable analysis of 
biochemical and neuropathological changes associated with the progression of 
AD. However, there are many limitations associated with the use of post mortem 
tissue. First, there is a limited tissue availability, which limited the sample size of 
each group (n = 3 - 6). Early Braak stage tissue is especially hard to source since 
clinical diagnosis is more difficult at these stages. Since human brain is 
notoriously heterogeneous, it is possible that the results presented here are not 
wholly representative. There was frequent observation of significant variation 
within sample groups, which may have been exacerbated during the experimental 
procedures. For this reason, inferences concerning certain proteins of interest 
could not always be made confidently.  
Other considerations include the effects of PMD on sample integrity, and freeze-
thawing steps, conditions in which activate proteases can that degrade their 
cellular substrates. For example, calpain cleavage of GSK3 was found to correlate 
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with PMD in a previous study (Goñi-Oliver et al., 2007). However, variations in 
PMD between Braak stages did not exceed 10 h in this study, with the mean PMD 
(in h) for each group being: CTRL 43.5, II 33.8, III 33.7, IV 39.8, V 36.0, VI 33.9. 
Moreover, PMD did not correlate with calpain-1 or GSK3 activities in this study.  
Control tissue is obtained from individuals with a variety of acute or chronic 
conditions, and it is possible that these co-morbidities could potentially affect 
brain health and therefore results obtained here. For example, calpains and 
caspases are activated during cerebral ischaemia (Pike et al., 2004). Furthermore, 
the controls were age-matched, and it is clear that certain neurodegenerative 
processes, including calpain activation, also occur naturally during ageing (Banay-
Schwartz et al., 1994; Arsene and Ardeleanu, 2010; Rodriguez-Arellano et al., 
2015). Another factor to take into account is the likelihood of secondary or 
compensatory effects during the course of primary disease in control and AD 
subjects, such as medication, smoking and chronic illnesses. It is possible that any 
CNS changes mediated by these factors may underlie some of the observed 
changes in post mortem tissue, and these are difficult to distinguish from 
pathological changes intrinsic to AD. Post mortem analyses of brain obviously 
prevents the possibility of manipulation (e.g. pharmacological or genetic) of the 
tissue, therefore any data is merely descriptive or correlational and is insufficient 
for mechanistic inferences. For this reason, further experiments in tractable 
models are required to determine the pathogenic role of protein changes 
observed in AD brain.  
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Finally, following use of the anti-NCX3 antibody in initial experiments (sections 
3.2.3/4), this antibody (and others) then failed to detect NCX3 in subsequent 
Braak II-IV AD studies. The NCX3 antibody was provided by a collaborator with 
limited stocks, and it was not possible to obtain additional reagents to continue 
this work. It would have been useful to examine other changes in NCX3 in these 
tissues since calpain cleavage of NCX3 during early Aβ-induced Ca2+ elevations are 
shown to give rise to hyperfunctional forms of NCX3 that correct Ca2+ 
dyshomeostasis in cell lines (Pannaccione et al., 2012). Identification of this or 
other NCX3 fragments in early Braak brains would have provided further insight 
into the neuroprotective effects of Ca2+ and calpain activities.  
 
3.3.5 Conclusions 
The findings presented in this chapter suggest that calpain-1 overactivation is a 
common feature of neurodegenerative tauopathies that in AD occurs in early 
disease stages, preceding pathological changes in tau and increased production of 
Aβ. The following chapter extends these results by investigating the importance 
of calpain-1 in Aβ-mediated neurotoxicity, Ca2+ dysregulation and tau changes 







Aβ causes elevation of Ca2+ in SH-SY5Y cells and 
induces calpain-dependent signalling and 
neurotoxicity in neurons 
 
4.1 Introduction 
Ca2+ dysregulation is believed by many to play a crucial neurodegenerative role 
in AD and is seen to occur adjacent to amyloid plaques in neurites of APP 
transgenic mice (Pascale and Etcheberrigaray, 1999; Kuchibhotla et al., 2008; Lim 
et al., 2014; Grolla et al., 2013) and in neurons containing abnormal disease-
related tau species (Decker et al., 2015). Multiple studies have shown that 
dysfunction and degeneration of synapses are induced by soluble Aβ oligomers 
through cytotoxic elevations of dendritic Ca2+  (Wu et al. 2010; Selkoe 2002; Ittner 
et al., 2010). These synaptic perturbations correlate with cognitive decline in 
transgenic mice (McLaurin et al., 2006; Cissé et al., 2011), and it is therefore 
proposed that the early cognitive deficits seen in the pre-symptomatic stages of 
AD are caused by early accumulation of soluble Aβ oligomers and synaptotoxicity 
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that is dependent on disruption of neuronal Ca2+ homeostasis (Chakroborty et al., 
2012; Chakroborty, 2012). 
The mechanisms through which Aβ-induced Ca2+ perturbations lead to synaptic 
dysfunction and neuronal degeneration remain to be fully elucidated. In cellular 
models of sporadic AD, application of Aβ has been shown to cause the formation 
of Ca2+-permeable pores in bilayer membranes (Arispe et al., 1993) or thinning of 
membranes resulting in increased ion permeability (Kayed et al., 2004). 
Numerous studies demonstrate that Aβ can also stimulate dysregulated Ca2+ 
influx through interaction with native ion channels and/or receptors, including 
voltage-gated Ca2+ channels (VGCCs), NMDARs and transient receptor potential 
(TRP) channels (Small, 2009), which leads to rapid increases in neuronal Ca2+ 
content. 
As described in the previous chapter, an abundance of evidence implicates the 
Ca2+-sensitive cysteine protease calpain as a central mediator of numerous AD 
processes (Ferreira, 2012). Calpains are activated during conditions of high 
intracellular Ca2+, which can be induced by Aβ in primary neural cell cultures 
(Town et al., 2002; Hanger et al., 2009) and in transgenic mice overexpressing 
mutant human APP (Vaisid et al., 2007a). Post mortem AD brain shows elevated 
calpain-1 activity, with associated increased proteolysis of cytoskeletal and Ca2+-
regulating proteins (Chapter 3; Atherton et al., 2014; Tsuji et al., 1998; Nixon, 
2003). The work described in this thesis has shown that calpain-1 upregulation 
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occurs in the early, asymptomatic stages of AD and is sustained throughout 
disease progression (section 3.2.7). It was therefore important to investigate 
these findings in more detail in a tractable model where protein activities could 
be modulated. Therefore, the effects of Aβ on Ca2+, calpain and associated 
neurodegenerative events were next investigated in rat primary neurons and a 
neuronal cell line.  
The aims of this work were to 1) confirm the importance of calpain activity in 
mediating Aβ-induced neurotoxicity, 2) investigate the mechanistic relationship 
between Aβ, calpain, changes in tau and APP processing and synaptic function, 
and 3) begin to determine the mechanisms underlying Aβ-induced Ca2+ elevations 
in primary cortical cultures.  
 
4.2 Results 
It was necessary to first characterise the composition of the rat primary cortical 
cultures used in these studies. To establish the number and type of neural cells in 
primary cultures, cells were fixed after 10 DIV and labelled with antibodies to 
neurons (MAP2), and astrocytes (GFAP; Fig. 5.1). This laboratory has previously 
demonstrated that cultured prepared as used here contain negligible numbers of 
microglia and oligodendrocytes (Garwood et al., 2011).  Hoechst-33342 nuclear 
stain was used to indicate the total number of cells present. Typical cortical 
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neuronal cultures primarily contained neurons, and 17 ± 1.9 %, (n=6, 












To investigate the contribution of calpain to Aβ neurotoxicity, the synthetic 
calpain inhibitor calpeptin was used to block calpain activity in primary cortical 
cultures treated with soluble oligomers of human Aβ1-42. The effect of calpain 
blockade on mechanisms shown to be induced by Aβ, including changes in APP 
processing, tau kinase activation, tau phosphorylation and synaptic damage 
Fig. 4.1 Rat primary cortical cultures contain ~17 % astrocytes. Cultures were fixed at 
10DIV and immunostained with antibodies against neurons (MAP2), astrocytes 
(GFAP) and cell nuclei (Hoescht-33342). GFAP-positive cells were quantified as a 
proportion of total nuclei. n=8. Scale bar = 75μm.  
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(Buxbaum et al., 1994; Garg et al., 2011b; Town et al., 2002; Hooper et al., 2008) 
were studied using immunoblotting with antibodies against proteins of interest. 
Using fluorescent live imaging, it was then determined whether or not Aβ induces 
elevations in intracellular Ca2+ prior to calpain activation. Finally, to investigate 
the mechanisms that contribute to Aβ-induced Ca2+ changes, neural cells were 
pre-treated with synthetic inhibitors of NMDARs, calpains, caspases and PARP.  
 
4.2.1 Calpeptin dose-dependently inhibits calpain activity 
Calpeptin is cell-permeable calpain-specific inhibitor that has previously been 
used by this laboratory (Atherton et al., 2014) and others (Bano et al., 2005; Yano 
et al., 1993) to abolish calpain activity in vitro. To establish the minimum effective 
calpeptin dose for use in the present study, a dose-response experiment was 
performed using a logarithmic range of calpeptin concentrations (0.1 μM, 1 μM 
and 10 μM).  
Lysates from rat primary cortical cultures treated with different doses of 
calpeptin or vehicle for 3 h were immunoblotted using an antibody specific to the 
cytoskeletal protein α-spectrin, a known substrate of calpain. This antibody 
detected α-spectrin holoprotein at 240 kDa as well as calpain- and caspase-
cleaved (140-150 kDa) and caspase-cleaved (110-125 kDa) fragments (Fig. 4.2A). 
Blots were also probed with an antibody against the housekeeping protein, β-
actin. Amounts of full-length, cleaved and total α-spectrin were separately 
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quantified as a proportion of β-actin content in the same sample. This allowed 
normalisation of protein amounts to account for differences in protein loading 
and/or protein concentration in each sample. Quantitative analysis of band 
densities revealed that there were no significant difference in the amounts of total 
α-spectrin between control and calpeptin-treated cultures (Fig. 4.2B). 
Unexpectedly, amounts of full-length α-spectrin appeared to be reduced by 
calpeptin treatment (Fig. 4.2C) but this reduction was found to be not statistically 
significant from control, possibly reflecting variation within groups. Calpeptin 
treatment reduced amounts of calpain- and caspase-cleaved (140-150kDa) α-
spectrin species in a dose-dependent manner (Fig. 4.2D), with approximately 
50% of calpain-cleaved fragments reduced when 10 μM calpeptin was used (p< 
0.05), as previously found in this and other laboratories (Atherton et al., 2014; 
Bano et al., 2007). Levels of caspase-cleaved α-spectrin were also dose-
dependently reduced by calpeptin (Fig. 4.2E), significantly so at 10 μM 
concentrations (p 0.01), indicating reduced caspase proteolytic activity. This may 
be expected as calpains are shown to directly cleave and activate caspases 
(McCollum et al., 2002; Nakagawa and Yuan, 2000).  
To ensure that calpeptin treatments of cultures were not cytotoxic, a live/dead 
cell assay was performed (section 2.2.5) and these experiments revealed no 
differences in cell death between untreated and calpeptin-treated neurons (Fig. 
4.2F). Therefore, any neurotoxic effects of Aβ on primary culture in further 
experiments were not a result of calpeptin application.  Based on these 
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experiments, 10 μM calpeptin was established as a dose at which calpeptin 
significantly inhibits calpain proteolytic activity without causing toxicity, and this 




Fig. 4.2 Calpeptin dose-dependently inhibits calpain activity in primary cortical 
neurons. (A) Representative immunoblots of lysates from neurons treated with 
vehicle (CTRL) or 0.1, 1, 10 µM calpeptin (CPTN). Blots were probed with an antibody 
against α-spectrin which detects holoprotein at 240 kDa, calpain- and caspase-
cleaved fragments at 140-150 kDa and caspase-cleaved fragments at 110-125 kDa. 
Blots were also probed with an antibody against β-actin (42 kDa), as a loading control. 
Bar graphs show amounts of (B) total α-spectrin, (C) full-length α-spectrin, (D) 
calpain- and caspase-cleaved α-spectrin, and (E) caspase-cleaved α-spectrin, all 
normalised to β-actin. (F) Bar graph shows % cell death in cultures with each 
treatment. n=9. Data is mean ± SEM. *p < 0.05, **p < 0.01. 
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4.2.2 Aβ-induced neurotoxicity is rescued by calpain inhibition 
in vitro  
The amyloid hypothesis proposes that Aβ is directly toxic to neurons through 
mechanisms that may involve excess glutamate-mediated NMDA receptor 
activation and subsequent Ca2+ accumulation (Harkany et al., 2000a; Molnár et al., 
2004; Mattson et al., 2000). Indeed, Aβ-induced cholinergic neurodegeneration 
was recently shown to be reversed by inhibiting calpain activity in rats  (Granic et 
al., 2010). In order to investigate the role of calpain in Aβ-induced neurotoxicity 
in primary cortical cell cultures, it was first vital to determine whether calpain 
inhibition is neuroprotective in primary neurons exposed to a toxic dose of Aβ.  
Synthetic human Aβ1-42 peptide was prepared as previously described by this 
group (Hanger et al., 2009; Garwood et al., 2011; Atherton et al., 2014). This Aβ 
preparation was previously described to consist of  several species of soluble Aβ 
oligomers (Town et al., 2002) and provides physiological (nM) concentrations of 
peptide. This was an important consideration since there is substantial evidence 
that oligomers are likely responsible for Aβ-induced neurotoxicity (Walsh and 
Selkoe, 2007). To examine the Aβ preparation used in this work, recombinant 
peptide was assessed by SDS-PAGE and immunoblotting with an antibody against 
C-terminal APP that detected 3 major Aβ1-42 species: monomers at 4 kDa, dimers 
at 8 kDa and oligomers of greater than 12 kDa (Fig. 4.3A).  
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Primary cortical cultures were treated with 10 μM Aβ1-42, of which 500nM is 
active Aβ oligomers, for 48 h - conditions previously shown to be neurotoxic in 
primary cultures in this laboratory (Garwood et al., 2011; Atherton et al. 2014). A 
live/dead assay revealed that exposure of neurons to Aβ caused more than a 2-
fold increase in cell death when compared to untreated cells (p < 0.05; Fig. 4.3B), 
in line with previous reports (Atherton et al., 2014; Garwood et al., 2011). To 
determine the importance of calpain activity in Aβ-induced neurotoxicity, Aβ-
treated cultures were also pre-treated with 10 μM calpeptin for 3 hr. These 
cultures exhibited a cell death levels nearing those in control cells (p < 0.05; Fig. 
4.3B.), indicating that calpain plays a key role in mediating Aβ neurotoxicity. 
These findings support previous reports by this group (Atherton et al., 2014), and 
provided a basis for the subsequent investigations into downstream calpain 
targets and their role in Aβ-induced cell death in this chapter.  
 
4.2.3 Aβ-induced elevation of calpain proteolytic activity is 
prevented by calpain inhibition 
Cortical Aβ1-42 burden correlates with calpain-1 activity in AD brain (section 
3.2.14). To confirm previous reports that  primary neurons exposed to Aβ show 
increased activation of calpain-1 (Atherton et al. 2014), lysates from primary 
cortical neurons treated with Aβ with and without calpeptin pre-treatment were 




active subunit of calpain-1 (Fig. 4.4A). In these cell lysates, this antibody, and 
several other commercial antibodies against rat calpain-1 that were tested, failed 
to detect the active calpain-1 fragment; however, a calpain fragment of 28 kDa 
was labelled. This band is believed to represent the regulatory calpain-1 subunit 
that is known to heterodimerize with the 80 kDa subunit of calpain-1 in the 
presence of Ca2+ and optimize calpain proteolytic activity (Ravulapalli et al., 
2009).  
Figure 4.3 Aβ-induced neurotoxicity in primary cortical cultures is rescued by 
calpeptin (CPTN). Cultures were exposed to Aβ for 48 hours. (A) Western blot 
showing the Aβ species found in the soluble Aβ preparations used in this study.  5 µg 
Aβ was loaded in each lane of a 20 % polyacrylamide gel, and the resulting blots were 
probed with the 6E10 antibody, which primarily labels low molecular weight Aβ 
oligomers, as well as APP.  The predominant species of Aβ detected were monomeric 
(approximately 4 kDa). nM concentrations of dimers (approximately 8kDa) and 
higher order oligomers of approximately 12 kDa and above were also apparent. (B) 
Bar graph shows % cell death in primary neurons treated with vehicle (CTRL), Aβ, Aβ 




Following standardization of 28 kDa calpain bands to β-actin, quantitative 
analysis revealed a two-fold increase in the amount of the regulatory calpain-1 
fragment in cultures treated with Aβ when compared to control (p < 0.001), 
suggesting that calpain activity is increased following Aβ treatment of primary 
cortical neurons. This suggestion is supported by findings that the presence of this 
calpain fragment was reduced by approximately 60 % when cells were treated 
with calpeptin prior to application of Aβ (p < 0.01; Fig. 4.4B).  
Blots were also probed an antibody specific for α-spectrin, detecting holoprotein 
at 240 kDa, calpain- and caspase-cleaved fragments at 140-150 kDa and caspase-
cleaved fragments at 110-125 kDa. An antibody against β-actin antibody was used 
as a loading control. Aβ treatment of cortical neurons was found to lead to a 4-fold 
increase in amounts of calpain- and caspase-cleaved α-spectrin fragments (p < 
0.001; Fig. 4.4E) relative to control cultures, which were significantly reduced 
when cells were pre-treated with calpeptin (p < 0.05). Aβ treatment of cultures 
also resulted an approximately 4-fold increase in caspase-cleaved α-spectrin 
species (p < 0.05) which was also somewhat reduced by calpeptin pre-treatment 
(Fig. 4.4F). Amounts of total and full-length α-spectrin were not significantly 
altered with any treatment compared to control (Fig. 4.4C, D). Taken together, 
these findings suggest that calpain activity is increased in primary cultured 
neurons following treatment with soluble Aβ oligomers, corroborating previous 







Fig. 4.4 Aβ-induced changes in calpain activity in primary cortical cultures. (A) 
Representative immunoblots of neurons treated with vehicle (CTRL), Aβ, Aβ in 
combination with calpeptin (CPTN), or calpeptin alone. Blots were probed with an 
antibody against active (76 kDa) calpain, which also detects the 28 kDa regulatory 
subunit of calpain that is required for calpain activation. Blots were also probed with 
an antibody against α-spectrin which detects holoprotein at 240 kDa, calpain- and 
caspase-cleaved fragments at 140-150 kDa and caspase-cleaved fragments at 110-
125 kDa. An antibody against β-actin was used as a loading control. Bar graphs show 
amounts of (B) 28 kDa calpain-1, (C) total α-spectrin, (D) full-length α-spectrin, (E) 
calpain- and caspase-cleaved α-spectrin, and (F) caspase-cleaved α-spectrin, all 
following normalisation to β-actin amounts in the same sample n=9. Data is mean ± 
SEM. *p < 0.05, **p < 0.01, ***p < 0.001 
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4.2.4 Non-amyloidogenic APP processing is altered by Aβ and 
calpain 
Calpain has been found to regulate the cell surface distribution and proteolytic 
processing of APP in cells (Mathews et al., 2002; Trinchese et al., 2008), therefore 
it was of interest to determine the effect of Aβ and calpeptin treatment on APP 
amounts in the cell system used here. APP is a type 1 membrane glycoprotein that 
has been widely researched in the context of AD, as it is pathologically cleaved to 
generate neurotoxic and pro-aggregatory species of Aβ (Zhang et al., 2011), and 
mutations in APP and PS1, the latter part of the γ-secretase complex that cleaves 
APP, cause familial forms of AD (Hardy et al., 2014). In addition, N-terminal 
processing of APP was recently found to release a series of small N-terminal 
fragments (NTFs) in the adult human CNS, which display key physiological and 
neurodevelopmental functions in mice (Portelius, Brinkmalm, et al., 2010; 
Hoshino et al., 2003; Vella and Cappai, 2012). In the present study, it was of 
interest to determine whether generation of these physiological NTFs is altered 
by Aβ- and/or calpain-dependent mechanisms.  
Protein extracted from primary cortical cultures treated with Aβ and/or calpeptin 
was immunoblotted with an antibody against N-terminal APP (22c11), which 
detects mature full-length APP at 120 and 130 kDa, and immature 
(unglycosylated) APP at 110 kDa (Fig. 4.5A). Blots were also probed with the 42 
kDa housekeeping protein β-actin for normalisation of data when taking into 
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account potential protein loading variations (Fig. 4.5A). Quantitative analysis of 
the intensity of bands in the resulting blots showed that there were no changes in 
total (Fig 4.5B), mature (Fig. 4.5C, D) or immature (Fig. 4.5E) APP following 
treatment of cells with either Aβ or calpeptin. The above findings suggest that 
neither Aβ nor calpain alter APP maturation or synthesis, at least not in the cell 
cultures used here. In contrast, cultures treated with calpeptin, whether in 
combination with Aβ or not, generated 17 kDa APP NTFs (Fig. 4.5A).  
Recently, 17-28 kDa NTFs were detected in transgenic mouse and post mortem 
AD tissue, as well as SH-SY5Y cells, using the same antibody and these were shown 
to be protein kinase C-regulated and secretase-independent cleavage products of 
APP (Vella and Cappai, 2012). Preferentially expressed in the developing mouse 
brain, these NTFs were suggested by the authors to contribute to synaptogenesis 
and copper homeostasis. Since the NTFs identified here were not generated in 
control or Aβ-treated cultures, where calpain activity may be elevated by Aβ 
(section 4.2.3) or culture stress, but were detected following calpain inhibition, 
this suggests that calpain suppresses physiological N-terminal APP processing 
under basal conditions.  
To further investigate potential effects of Aβ and calpeptin treatment on APP 
processing, blots were also probed with an antibody against the α-secretase 
protein a disintegrin and metalloproteinase domain-containing protein 10 
(ADAM10), which yielded two prominent bands at 75 and 68 kDa, respectively 
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characteristic of the proenzyme and active protease. This band profile was 
expected since this enzyme is constitutively active in primary neurons (Kuhn et 
al., 2010). Treatment of cultures with Aβ significantly reduced levels of active 
(68kDa) ADAM10 compared to control (p < 0.001; Fig. 4.5F). This could either 
signify that 1) Aβ directly shifts the equilibrium from non-amyloidogenic to 
amyloidogenic (α-secretase-independent) APP processing in a positive feedback 
mechanism, or 2) other mechanisms activated by Aβ alter ADAM10 activity and 
APP processing. For example, Aβ-induced oxidative stress was shown to stimulate 
amyloidogenesis in human vascular smooth muscle cells (Coma et al., 2008). 
Surprisingly, treatment of cultures with calpeptin alone also significantly reduced 
levels of ADAM10 (p < 0.005; Fig. 4.5F), which suggests that calpain activity may 
be required for non-amyloidogenic processing that does not yield 17-28 kDa 
NTFs. Indeed, the combination of calpain inhibition and Aβ exposure reduced 
levels of ADAM10 in cultures to a greater extent than either treatment alone (p < 
0.001; Fig. 4.5F).  As pre-treatment of Aβ-treated cultures with calpeptin did not 
recover ADAM10 activity to control levels, it can be deduced that the mechanism 
through which Aβ regulates ADAM10 activity does not involve calpain.   Together, 
these findings suggest that Aβ and calpain independently and differentially 
regulate non-amyloidogenic APP processing, with calpain inhibition 1) promoting 
generation of APP NTFs through an Aβ- and secretase-independent pathway or 2) 
suppressing α-secretase-dependent non-amyloidogenic processing, and Aβ 
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Fig. 4.5 Aβ and calpain differentially suppress non-amyloidogenic APP processing. (A) 
Representative immunoblots of neurons treated with vehicle (CTRL), Aβ, Aβ in 
combination with calpeptin (CPTN), or calpeptin alone. Blots were probed with an 
antibody against N-terminal APP (22c11), detecting bands at 110 to 130 kDa 
representative of mature and immature APP isoforms, and proteolytically generated 
N-terminal fragments (NFTs) at 17 kDa. Blots were also probed with an antibody 
against a disintegrin and metalloproteinase 10 (ADAM10), detecting holoprotein at 
75 kDa and 68 kDa active ADAM10. An antibody against β-actin was used as a loading 
control. Bar graph shows amounts of (B) total APP, (C) 130 kDa mature APP, (D) 120 
kDa mature APP, (E) 110 kDa immature APP and (F) active (68kDa) ADAM10, with all 
bands normalised to β-actin n=9. Data is mean ± SEM. **p < 0.01, ***p < 0.001 
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4.2.5 Exogenous Aβ promotes amyloidogenic APP processing 
and intracellular generation of Aβ  
It was important to also examine the effects of Aβ and calpain inhibition on Aβ 
production through the amyloidogenic pathway since there is emerging evidence 
that 1) extracellular Aβ stimulates further intracellular Aβ synthesis in astrocytes, 
possibly via inflammatory signaling pathways (Dal Pra et al., 2011), and 2) calpain 
inhibition reduces Aβ production in 3xTg-AD mice (Medeiros et al., 2012). The 
contribution of exogenously applied Aβ to neuronal APP processing and Aβ 
production was therefore investigated here.  
Neuronal lysates of cultures treated with Aβ and/or calpeptin were 
immunoblotted with an antibody that labels APP C-terminal fragments (CTFs) 
generated by β- and γ-secretases during amyloidogenic processing in AD (Fig 
4.6A). This antibody recognized a single prominent band around 15 kDa in size, 
representing the membrane-bound C99 fragment (C99), generated by the action 
of β-secretase, and a 4 kDa band characteristic of Aβ monomers.  Blots were also 
probed with antibodies against the beta-site amyloid precursor protein cleaving 
enzyme (BACE-1), which revealed a band at 70 kDa representative of BACE 
holoprotein, and nicastrin, which forms part of the γ-secretase protein complex 
and yields a band at 78 kDa. For standardization purposes, blots were also probed 
with an antibody against the housekeeping protein β-actin. Following 
standardization of the above bands to β-actin, quantitative analysis showed that 
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Aβ treatment did not significantly alter BACE levels in neurons (Fig. 4.6B), 
although small increases in total BACE levels were apparent relative to control 
cells. In accordance with this, Aβ treatment of cells did not significantly alter 
amounts of the C99 fragment (Fig. 4.6C), which is proteolytically generated by 
BACE during the initial step of APP metabolism (Zhang et al., 2011), likely due to 
variations within the treatment group.  Generation of the C99 fragment was 
significantly increased by combined Aβ and calpeptin treatments compared to 
control (p < 0.05; Fig. 4.6C), which was inconsistent with the lack of effect of 
treatment with calpeptin alone on BACE activity or C99 fragment production, 
suggesting that these effects are likely to be mediated by Aβ rather than being 
modulated by inhibition of calpain activity. Furthermore, the measurement of 
BACE protein expression does not reflect activity of the enzyme; thus, it is possible 
that BACE activity is increased in the cultures that show accumulation of C99 
fragment. 
Notably, treatment of cultures with Aβ significantly increased protein amounts of 
nicastrin (p < 0.05), which was recovered to control by calpeptin pre-treatment 
(p < 0.05; Fig 4.6D). This suggest that Aβ promotes γ-secretase activity through 
increased nicastrin expression - as seen in active astrocytes and microglia 
following neuronal insults (Nadler et al., 2008) - and further amyloidogenesis 
through calpain signalling. Indeed, cultures treated with Aβ increased displayed 
Aβ in cell lysates when compared to control cultures (Fig. 4.6A), further 
suggesting a positive feedback loop whereby increased extracellular Aβ promotes 
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further Aβ production, possibly by inhibiting non-amyloidogenic APP cleavage 
(Fig. 4.6A). However, pre-treatment of cultures with calpeptin did not prevent 
accumulation of Aβ in lysates, which is inconsistent with the reduction of nicastrin 
levels in these samples, and perhaps reflects the additional presence of exogenous 
Aβ that has been internalized following treatment - as seen in neurons lacking 
ApoE  (Saavedra et al., 2007).  
Aβ is widely recognised as being notoriously sticky, therefore it was important to 
establish that the Aβ detected in lysates was intracellular and not residual 
synthetic peptide harvested together with the protein. Thus, primary cultures 
treated with Aβ were immunostained with an antibody that recognizes C-terminal 
APP and CTFs (6E10; Fig. 4.7). Cells were also stained with an antibody against 
microtubule-associated protein 2 (MAP2), which labels the neuronal 
cytoskeleton, and the nuclear stain Hoescht-33342. The staining protocol 
included a permeabilization step which ensured that access of the antibody to its 
intracellular protein antigen.  
Neurons exposed to Aβ showed high 6E10 immunoreactivity in addition to many 
degenerating dendrites, in contrast to a lack of 6E10 labelling in control cultures 
(Fig. 4.7). Cultures were also treated with H2O2, which is used to model oxidative 
stress in AD  (Dávila and Torres-Aleman, 2008), as a positive control for neuronal 
damage. These cells exhibited DNA fragmentation consistent with oxidative DNA 


















Fig. 4.6 Aβ promotes amyloidogenic APP processing and intracellular accumulation 
of Aβ. (A) Representative immunoblots of neurons treated with vehicle (CTRL), Aβ, Aβ 
in combination with calpeptin (CPTN), or calpeptin alone. Blots were probed with an 
antibody against C-terminal APP fragments, detecting a single prominent band at 15 
kDa, indicative of the C99 APP fragment. Blots were also probed with antibodies 
against BACE and nicastrin, detecting holoprotein at 70 kDa and 78 kDa, respectively. 
An antibody against β-actin was used as a loading control. Bar graphs show amounts 
of (B) BACE, (C) C99 and (D) nicastrin, with all bands normalised to β-actin. n=6. Data 
is mean ± SEM. *p < 0.05 
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indicates that this antibody recognizes Aβ rather than APP, since APP is 
constitutively expressed on the cell surface of neurons and would not be labelled 
using these methods (Zhang et al., 2011). Furthermore, there was no Aβ 
immunoreactivity in H2O2-treated cultures, indicating that Aβ generation is a 
result of extracellular Aβ-mediated mechanisms and not general  stress responses 
(Paola et al., 2000). High magnification (X63) of labelled cells (Fig. 4.8) showed 
that some Aβ was not associated with cells, and appeared to be simply stuck to 
the glass coverslips, or had accumulated following degeneration of the associated 
neuronal processes. However,  there were also Aβ puncta that co-localized with 
neuronal processes (Fig. 4.8) as previously described by this group (Williamson 
et al., 2008). Together, these findings suggest that the application of exogenous 
Aβ1-42 peptides to rat primary cortical cultures results in inhibition of α-
secretase mediated non-amyloidogenic APP processing, calpain-dependent 
stimulation of γ-secretase, subtle increases in β-secretase cleavage of APP, and 
elevated intracellular production of Aβ in a positive feedback loop. This is in 
agreement with and extends previously published findings (Dal Pra et al., 2011). 
Alternatively, these findings might suggest that exogenous Aβ is taken up by 

















4.2.6 Aβ-induces mild alterations in tau phosphorylation that 
are reduced upon inhibition of calpain 
Calpain is known to promote tau phosphorylation through N-terminal cleavage 
and activation of tau kinases, including cdk5 and GSK3 (Goñi-Oliver et al., 2007; 
Fig. 4.7 Exposure of primary cortical cultures to Aβ causes neuronal damage 
associated with increased Aβ immunoreactivity. Neurons treated with vehicle (CTRL), 
Aβ, or H2O2, which is used to stimulate oxidative stress in culture, were 
immunostained with antibodies against C-terminal APP (6E10), which detects Aβ, 
neuronal microtubule-associated protein 2 (MAP2), and the nuclear stain Hoescht-














Taniguchi et al., 2001; Jin et al., 2015). Calpains and tau kinases are activated by 
Aβ (Town et al., 2002; Zheng et al. 2002; Lloret et al. 2011; Liang et al. 2010); 
therefore, it is hypothesized that tau phosphorylation occurs downstream of Aβ 
and is mediated by calpain activation. 
 
Fig. 4.8 Exposure of primary cortical cultures to Aβ causes neuronal damage 
associated with increased dendritic accumulation of Aβ (white arrows). Neurons 
treated with vehicle (CTRL), Aβ, were immunostained with antibodies against C-
terminal APP (6E10), which detects Aβ, neuronal microtubule-associated protein 2 
(MAP2), and the nuclear stain Hoescht-33342. Cultures were viewed under X63 
magnification to determine co-localization of Aβ puncta with neuronal structures. 
Scale bars are 75µm. n=6 
185 
 
To examine this process, cell lysates from primary cortical cultures treated with 
Aβ and/or calpeptin were probed with antibodies detecting total tau bands, 
independent of phosphorylation state, (DAKO) at approximately 55 kDa, tau 
phosphorylated at the AD-relevant epitopes Ser396/404 (PHF1) and Ser202 
(CP13), and tau dephosphorylated at Ser199/202/Thr205 (tau-1). Blots were 
also probed with an antibody against β-actin for standardization purposes (Fig. 
4.9A). Following standardization of total tau (DAKO) amounts to β-actin, and 
phosphorylated (PHF1 and CP13 immunoreactive) tau to total tau (DAKO) 
amounts, quantitative analysis revealed no changes in total tau amounts (Fig. 
4.9B) or tau phosphorylated at Ser396/404 or Ser202 (Fig. 4.9D, E) following 
treatment with Aβ or calpeptin relative to controls. In contrast, Aβ-treated 
cultures showed significantly reduced amounts of dephosphorylated (Tau-1) tau 
(p < 0.05), an effect reduced upon pre-treatment of cultures with calpeptin (p < 
0.001; Fig. 4. 9C).  
The findings that tau is not phosphorylated at the CP13 and PHF1 epitopes in 
response to Aβ is a somewhat unexpected result since these epitopes have 
previously been shown to be phosphorylated under similar conditions (Garwood 
et al., 2011). However, the cultures used here were of an older developmental 
stage than those reported by Garwood et al. (2011), which may account for some 
of these differences. Nevertheless, these experiments showed that 
phosphorylation of the Tau-1 epitope (Ser199/202/Thr205) is significantly 
elevated following Aβ treatment via a calpain-dependent mechanism. Increased 
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calpain activity upon Aβ treatment of primary cells has also been described to lead 
to the generation of a neurotoxic 17 kDa calpain-cleaved tau fragment (Park and 
Ferreira, 2005). However, this fragment was not observed in Aβ-treated neurons 
in this study (Fig. 4.9A). Furthermore, the relevance of this fragment for Aβ-
induced toxicity remains uncertain (Garg et al., 2011b).  
 
4.2.7 Aβ-induced activation of GSK3 is prevented by calpain 
inhibition  
It was important to examine the mechanisms by which increased calpain activity 
might lead to tau phosphorylation in response to Aβ treatment. GSK3 is a key tau 
kinase that phosphorylates tau at multiple disease-relevant epitopes (Hanger and 
Noble, 2011) and is central to multiple neurodegenerative pathways in AD 
(Hooper et al., 2008). GSK3 can be activated by calpain, which removes the N-
terminal portion of the kinase which contains inhibitory phosphorylation 
epitopesSer21 (GSK3α) and Ser9 (GSK3β). It is therefore possible that GSK3 is 
involved in Aβ-mediated tau phosphorylation and neurotoxicity as a downstream 
effector of calpain.   
Aβ- and/or calpeptin-treated primary neuronal lysates were immunoblotted 
using antibodies against total GSK3 which detected two bands at 51 and 47 kDa 


















Fig. 4.9 Aβ-induced tau phosphorylation at the Tau-1 epitope is attenuated by calpain 
inhibition. (A) Representative immunoblots of neurons treated with vehicle (CTRL), 
Aβ, Aβ in combination with calpeptin (CPTN), or calpeptin alone. Blots were probed 
with antibodies against total tau (DAKO) at approximately 55 kDa, tau phosphorylated 
at Ser396/404 (PHF1) and at Ser202 (CP13), both detecting bands at 50-61 kDa and 
tau dephosphorylated at Ser199/202 (tau1) which detects bands at 17 to 55 kDa. 
Blots were also probed with an antibody against β-actin (42 kDa) as a loading control. 
Bar graphs show amounts of (B) DAKO following normalisation to β-actin amounts in 
each sample, and (C) tau dephosphorylated at tau1 sites, and tau phosphorylated at 
(D) PHF1 and (E) CP13 epitopes, all of which were standardized to total tau (DAKO) 
amounts in each sample. n=9. Data is mean ± SEM. *p < 0.05, ***p < 0.001 
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with an antibody against GSK3 phosphorylated at Ser21/9 (pGSK3), yielding two 
bands at 51 and 47 kDa representing GSK3 phosphorylated at Ser21 and Ser9, 
respectively. An antibody against β-actin was used as a loading control. Following 
standardization of the intensity of protein bands, quantitative analysis revealed 
no change in total protein amounts of GSK3α (Fig. 4.10B) and a significant 
increase in GSK3β amounts in cultures treated with Aβ (p < 0.05; Fig. 4.10C). 
These findings are in support of evidence of upregulated GSK3 expression in post 
mortem AD hippocampal tissue (Blalock et al., 2004) and synaptosomes (Pei et 
al., 1997), and suggest that GSK3 expression is regulated is regulated by Aβ.  
In addition, there was a significant reduction in the amounts of GSK3 
phosphorylated at Ser21/9 in Aβ-treated cultures (p < 0.05), which was reduced 
to control levels by calpeptin pre-treatment (p < 0.01; Fig. 4.10D). These findings 
indicate an increase in the activity of GSK3 in response to Aβ, which was 
attenuated by inhibition of calpain. Aβ has been previously reported to increase 
GSK3β activity through inhibition of PI3-kinase in primary neurons (Takashima 
et al., 1993), the effect of AD pathology on GSK3 activity is still controversial, with 
numerous studies reporting no change in activity  (Pei et al., 1997) or reduced 
activity (Swatton et al., 2004) of GSK3 in AD brain. The findings shown here are, 




















Fig. 4.10 Aβ-induced GSK3 activation is reduced by calpain inhibition. (A) 
Representative immunoblots of neurons treated with vehicle (CTRL), Aβ, Aβ in 
combination with calpeptin (CPTN), or calpeptin alone. Blots were probed with 
antibodies against GSK3, detecting GSK3α and GSK3β at 51 and 47 kDa, respectively, 
and GSK3 phosphorylated at Ser21/9 (pGSK3), yielding two bands at 51 and 47 kDa 
respectively representing GSK3 phosphorylated at Ser21 and Ser9. Blots were also 
probed with an antibody against β-actin (42 kDa) as a loading control.  Bar graphs 
show amounts of (B) total GSK3α and (C) total GSK3 β, both standardized to β-actin 
and (D) total phosphorylated GKS3 (pGSK3), standardized to total GSK3. n=6. Data is 




4.2.8 Aβ increases Cdk5 activity through elevated calpain-
mediated cleavage of p35 to p25 
Cdk5 is a tau kinase that in AD is aberrantly regulated to result in tau 
phosphorylation, tangle formation and early memory deficits (Cruz et al., 2003; 
Giese, 2014).  Cdk5 activity depends on physical association with one of its 
activators, p35, which can be truncated by Ca2+-activated calpain to form p25, 
which is a more potent activator of cdk5 and results in sustained hyperactivity of 
the kinase (Goñi-Oliver et al., 2007). Lysates from primary cortical neurons 
treated with Aβ and/or calpeptin were immunoblotted with antibodies against 
cdk5 holoprotein, detecting a single prominent band at 33 kDa, and the cdk5 
activator p35 which detects a single band at 35 kDa and a calpain-cleaved p25 
fragment at 25 kDa (Fig. 4.11A). Blots were also probed with an anti-β-actin 
antibody for use as a loading control. Quantification revealed that Aβ did not alter 
levels of cdk5 holoprotein or p35 amounts from those detected in control 
conditions (Fig. 4.11B, C); although calpeptin-treated cells unexpectedly showed 
significantly elevated amounts of cdk5 (p < 0.01; Fig. 4.11B).  
Aβ treatment induced an approximately 35 % increase in p25 amounts, when 
quantified as a proportion of cdk5 (p 0.05; Fig. 4.11D), which were notably 
reduced following calpeptin pre-treatment, but this reduction did not reach 
statistical significance. When quantified as a proportion of p35, p25 fragments 
showed a similar pattern of an increased p25/p35 ratio following Aβ treatment, 
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with slight reductions in this ratio following pre-treatment with calpeptin (Fig. 
4.11E). These findings indicate that Aβ stimulates the calpain/p35-p25/cdk5 
signalling pathway, via mechanisms that are likely to at least partially involve 
increased activation of calpain.  
 
4.2.9 Aβ and calpain reduce amounts of PSD95 and synapsin, 
respectively   
Aβ accumulation is implicated in the early synaptic dysfunction and loss seen in 
the early stages of AD in humans and in transgenic mice (Shankar and Walsh, 
2009; Cummings et al., 2015). In recent reports, Aβ oligomers were shown to 
downregulate key pre- and postsynaptic proteins through actions on Ca2+ 
excitotoxicity mediated via NMDARs (Liu et al. 2010; Ittner et al., 2010). It is 
therefore postulated here that calpain is involved in Aβ–induced synapse loss.   
To begin to gain an insight into the effects of Aβ and calpain on synapse health, 
primary neuronal lysates treated with Aβ and/or calpeptin were immunoblotted 
with antibodies against PSD95 and the presynaptic protein synapsin I, yielding 
bands at approximately 95 and 80 kDa, respectively (Fig. 4.12A). Blots were also 
probed with an antibody against β-actin to use as a loading control. 
Standardization to β-actin and quantification revealed that protein amounts of 




















Fig. 4.11 Aβ-induced cdk5 activation is reduced by calpain inhibition. (A) Representative 
immunoblots of neurons treated with vehicle (CTRL), Aβ, Aβ in combination with 
calpeptin (CPTN), or calpeptin alone. Blots were probed with antibodies against cyclin 
dependent kinase 5 (cdk5), detecting holoprotein at 33 kDa, and an antibody against cdk5 
activator p35, detecting a band at 35 kDa, and the calpain-cleaved p25 fragment at 25 kDa. 
Blots were also probed with an antibody against β-actin (42 kDa) as a loading control.  Bar 
graphs show amounts of (B) cdk5 standardized to β-actin, (C) p35 and (D) p25 
standardized to cdk5, and (E) p25 standardized to p35. n=6. Data is mean ± SEM. *p < 0.05, 




inconsistent with previous evidence of reduced PSD95 amounts in conditions of 
high Aβ, but these difference may be attributed to normalization of PSD95 
amounts to β-actin, which is also expressed in astrocytes. 
In contrast, levels of synapsin I were significantly increased in cultures treated 
with calpeptin, either alone or in the presence of Aβ (p < 0.01), while Aβ had no 
effect on the amounts of this presynaptic marker (Fig. 4.12C).   These findings may 
also reflect that the cultures used in these experiments are still relatively 
immature (10 DIV). Although synapses are considered to be relatively mature by 
this time, not all receptors may be fully functional. Unfortunately, attempts to 
culture neurons for longer periods of time were not successful due to issues with 
C02 regulation across the whole Institution. Synapsin I is cleaved by calpain 
during activity-dependent calpain-mediated regulation of presynaptic activity in 
neurons (Murrey et al., 2006a; Khoutorsky and Spira, 2009). Moreover, synapsin 
I is upregulated in concert with elevated calpain activity in early AD brain, in what 
is likely a compensatory response to increased calpain cleavage of synapsin 
(section 3.2.13). The findings here in primary culture indicate that inhibition of 
calpain activity promote expression of synapsin I, thereby supporting the role of 
calpain as a regulator of synaptic activity.  
To further investigate the role of Aβ on the postsynapse, primary neurons 
exposed to Aβ were immunostained with the 6E10 antibody that recognises C-
terminal APP fragments, including Aβ (Fig. 4.13A). Cultures were also stained 
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with an antibody against microtubule-associated protein 2 (MAP2), which is 
predominantly found in neuronal dendrites, and the nuclear stain Hoescht-33342. 
These markers were expressed in both untreated and Aβ-treated cultures; 
however, cultures exposed to Aβ displayed abnormal dendritic morphology and 
cell loss (Fig. 4.13A). Cultures were then assessed under higher magnification so 
as to better visualize individual PSD95 puncta located on dendrites (Fig. 4.13B). 
PSD95 intensities were quantified separately in dendrites and somata as a 
proportion of MAP2 intensity, using the ‘RGB measure’ plugin in ImageJ, 
Quantification of immunostaining revealed that Aβ reduced dendritic PSD95 
signals by more than 50% (p < 0.01), indicating that there is likely synapse loss in 
these cultures (Fig. 4.13C). Aβ also diminished somal PSD95 signals, however this 
reduction was not statistically significant likely due to variation between cells. 
These findings corroborate extensive reports of the synaptotoxic effects of Aβ 
(Lue et al., 1999; Kelly et al., 2005; Lacor et al., 2004; Shankar and Walsh, 2009), 
and in addition, indicate that western blotting is not a sufficiently sensitive 
method with which to examine the amounts of pre- and postsynaptic markers in 

















Fig. 4.12 Synapsin I protein expression is regulated by calpain. (A) Representative 
immunoblots of neurons treated with vehicle (CTRL), Aβ, Aβ in combination with 
calpeptin (CPTN), or calpeptin alone. Blots were probed with antibodies against the 
postsynaptic marker post synaptic density 5 (PSD95), detecting holoprotein at 95 
kDa, and the presynaptic marker synapsin I, which detects two bands around 80 kDa. 
Blots were also probed with an antibody against β-actin (42 kDa) as a loading control.  
Bar graphs show amounts of (B) PSD95 and (C) synapsin I standardized to β-actin. 










Fig. 4.13 Primary cortical cultures exposed to Aβ show reduced dendritic PSD95 
puncta. (A) Neurons treated with Aβ were stained with antibodies against the major 
postsynaptic marker, post synaptic density 95 (PSD95), microtubule associated protein 
2 (MAP2) which selectively labels neurons, and the nuclear stain Hoescht-33342. (B) 
Individual PSD95 puncta (white arrows) were visualized under X65 magnification. (C) 




4.2.10 Naturally secreted human Aβ oligomers do not alter 
calpain activity or tau phosphorylation in primary 
neurons 
Synthetic human Aβ oligomers are commonly used at nM concentrations to model 
the effects of Aβ accumulation observed in AD in vitro, since this allows 
examination of the effects of different human Aβ species. However, it is argued 
that these Aβ preparations are not physiological and therefore may lack relevance 
for the study of human disease. In addition, the reporting of such Aβ preparation 
in the literature is a matter of controversy because of insufficient details 
concerning peptide size, concentration, species and aggregation state.  
A naturally-derived source of Aβ oligomers has been reported to inhibit LTP and 
impair cognition in vivo, and this has been presented as a potential solution to the 
above obstacles associated with synthetic peptide (Walsh et al., 2002b; Cleary et 
al., 2005). Therefore, the well-characterized source of natural human Aβ 
oligomers from Chinese hamster ovary (CHO) cells stably expressing mutant APP 
(7PA2 cells; Walsh et al., 2002b) was also examined in this study. Conditioned 
medium from 7PA2 CHO cells contains secreted oligomeric Aβ that is SDS-stable 
and, importantly, is found at the same concentrations (0.1-2 nM) as detected in 
human cerebrospinal fluid.   
Lysates of primary neurons treated with 7PA2 Aβ for 48 h and/or calpeptin were 
immunoblotted using an antibody against α-spectrin, detecting holoprotein at 
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240 kDa, calpain- and caspase-cleaved α-spectrin species at 140-150 kDa and 
caspase-cleaved α-spectrin species at 110-125 kDa (Fig. 4.14A). Blots were also 
probed with antibodies against total tau (DAKO) which detects multiple bands 
around 55 kDa, tau Ser199/202/Thr205 (tau-1), total GSK3 that detects a doublet 
at 51 and 47 kDa, respectively representing GSK3α and -β, and GSK3 
phosphorylated at Ser21/9 that detects two bands at 51 and 47 kDa, respectively 
indicating GSK3 phosphorylated at Ser21 (GSK3α) and Ser9 (GSK3β) (Fig. 4.15A). 
An antibody specific for β-actin was used as a loading control.  
Quantification of bands revealed no changes in total or full-length α-spectrin (Fig. 
4.14B, C) or calpain- and caspase-cleaved fragments (Fig. 4.14D, E), between 7PA2 
cell medium-treated and wild-type CHO cell-treated (control) cells. These findings 
show that treatment of primary cultures with natural Aβ for the same duration as 
synthetic Aβ does not elevate calpain activity or cause calpain-mediated 
cytoskeletal degradation. Amounts of total tau (Fig. 4.15B) or tau 
Ser199/202/Thr205 (tau-1; Fig. 4.15C) were also unchanged between any 
treatment group and control. In accordance, there was no change in GSK3 
expression or activity in response to natural Aβ and/or calpeptin treatment (Fig. 
4.15D, E). The concentrations of synthetic Aβ oligomers used here exceed those 
of naturally secreted Aβ oligomers by approximately 500-fold. Therefore, it is 
possible that synthetic Aβ is more fast-acting in vitro, and may be preferred for 
short-term studies of Aβ mechanisms in primary cell culture.   The time course of 
naturally-derived Aβ effects, on the other hand, may recapitulate the slow Aβ-
199 
 
mediated toxicity observed over long periods of time in transgenic animal models 















Fig. 4.14 Natural human Aβ oligomers do not alter activity-spectrin cleavage in 
primary cortical cultures (A) Representative immunoblots of lysates from neurons 
treated with vehicle (CTRL), 7PA2 CHO cell conditioned medium, 7PA2 medium with 
calpeptin (CPTN), or calpeptin alone. Blots were probed with an antibody against α-
spectrin which detects holoprotein at 240 kDa, calpain- and caspase-cleaved 
fragments at 140 to 150 kDa and caspase-cleaved fragments at 110 to 125 kDa. Blots 
were also probed with an antibody against β-actin (42 kDa), as a loading control. Bar 
graphs show amounts of (B) total α-spectrin (C) full-length (D) calpain- and caspase-
cleaved α-spectrin, and (E) caspase-cleaved α-spectrin, with all species normalised to 
















Fig. 4.15 Naturally secreted human Aβ oligomers do not alter tau kinase activity or 
tau phosphorylation in primary cortical cultures (A) Representative immunoblots of 
lysates from neurons treated with vehicle (CTRL), Aβ derived from 7PA2 Chinese 
Hamster Ovary cells (7PA2), 7PA2 Aβ with calpeptin (CPTN) or calpeptin alone. Blots 
were probed with an antibody against total tau (DAKO) and tau phosphorylated at 
Ser396/404 (PHF1), both of which detect a single band around 55 kDa.  Blots were 
also probed with antibodies against total glycogen synthase kinase 3 (totGSK3), 
detecting bands at 51 and 47 kDa, representing GSK3α and -β, respectively and GSK3 
phosphorylated at Ser21 and Ser9 (pGSK3), detecting two bands at 51 and 47 kDa, 
respectively. An antibody against β-actin (42 kDa) was sued as a loading control. Bar 
graphs show amounts of (B) DAKO standardized to β-actin, (C) PHF1 as a proportion 




4.2.11 Lithium suppresses calpain activity through inhibition of 
GSK3 
In a recent study, treatment of primary hippocampal neurons with lithium was 
found to reduce calpain activity, tau phosphorylation and excitotoxicity mediated 
by kainic acid (Crespo-Biel et al., 2010). Lithium is a mood-stabilizer that has 
emerged as a promising neuroprotective agent in AD since it inhibits GSK3 
activity, reduces tau phosphorylation and prevents neuronal apoptosis in vitro 
and in vivo (Hong et al., 1997; Song et al., 2002). In the study by Crespo-Biel et al. 
(2010), calpain activity was reduced after 3-5 days of lithium treatment, 
suggesting that calpain is reciprocally regulated by its downstream effector GSK3. 
Since a close correlation between GSK3 and calpain activities has been observed 
in the work presented here, it was deemed important to investigate the effects of 
GSK3 inhibition by lithium on calpain activity. 
To test the effect of acute GSK3 inhibition on calpain activity, primary cortical 
cultures were treated with 5, 10 and 20mM lithium chloride (LiCl) or sodium 
chloride (NaCl) control for 4 h. Cortical lysates were first immunoblotted with 
antibodies against GSK3α and -β, detecting two respective bands at 51 and 47 kDa, 
and GSK3 phosphorylated at Ser21 and Ser9 (pGSK3) which also detects a doublet 
at 51 and 47 kDa, respectively (Fig. 4.16A). Blots were then probed with an 
antibody against the calpain substrate α-spectrin, which labels holoprotein at 240 
kDa, calpain- and caspase-cleaved fragments at 140-150 kDa and caspase-cleaved 
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fragments at 110-125 kDa (Fig. 4.17A). For normalization purposes, an antibody 
against β-actin was used.  
Quantitative analysis of immunodetected band intensities confirmed a dose-
dependent inhibition of GSK3 following LiCl treatment, since there were 
significantly increased amounts of GSK3 phosphorylated at Ser21/9 in cultures 
treated with 10 mM (p < 0.05) and 20 mM (p < 0.01) LiCl (Fig 4.16B). At these 
concentrations, LiCl also significantly reduced the expression of GSK3 (p < 0.05; 
Fig. 4.16C).  Increased GSK3 protein amounts are observed in late stage AD brain 
(section 3.2.12); thus LiCl treatment may potentially counteract the detrimental 
effects of increased GSK3 expression in these stages of disease. LiCl treatment was 
also found to reduce the amounts of total α-spectrin by 50% when used at 20 mM 
(Fig. 4.17B). Treatment also caused significantly increased amounts of α-spectrin 
holoprotein at 20mM concentration (p<0.05) and also when used at 10 mM (p < 
0.001Fig. 4.17C). In accordance with this, the amounts of calpain- and caspase-
cleaved fragments were reduced by more than 50% with 10 mM (p < 0.05) and 
20 mM (p < 0.01) LiCl (Fig. 4.17D), indicating suppression of calpain proteolytic 
activity. The amounts of caspase-cleaved α-spectrin also showed a trend towards 
reduction following lithium treatment of neurons (Fig. 4.17E); however, these 
decreases did not reach significance likely due to the variation within the control 
group. These results therefore support previous reports that calpain inhibition 
can be induced upon treatment with LiCl. As the mechanisms of action of lithium 
on calpain activity are as yet undetermined, it is possible that alterations in 
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calpain activity are not directly mediated by GSK3, but may, for instance, result 
from modulation of Ca2+ entry (as suggested by Crespo-Biel et al., 2010). 
Nevertheless, this data suggests another possible mechanistic link between Ca2+ 
signalling and tau phosphorylation that is mediated by GSK3 and calpain 




Fig. 4.16 Lithium dose-dependently reduces GSK3 expression and activity in primary 
cortical cultures. (A) Representative immunoblots of lysates from neurons treated with 
NaCl vehicle (CTRL), and lithium chloride (LiCl) at 5, 10 and 20 mM doses. Blots were 
probed with antibodies against total glycogen synthase kinase 3 (totGSK3), detecting 
bands at 51 and 47 kDa, representing GSK3α and -β, respectively and GSK3 
phosphorylated at Ser21 and Ser9 (pGSK3), detecting two bands at 51 and 47 kDa, 
respectively. An antibody against β-actin (42 kDa) was used as a loading control. Bar 
graphs show amounts of (B) total GSK3 normalised to β-actin, and (C) pGSK3 normalised 


















Fig. 4.17 Lithium dose-dependently decreases calpain activity in primary cortical 
cultures. (A) Representative immunoblots of lysates from neurons treated with 
vehicle (CTRL), and lithium chloride (LiCl) at 5, 10 and 20 mM doses. Blots were 
probed with antibodies against α-spectrin, which detects holoprotein at 240 kDa, 
calpain- and caspase-cleaved fragments at 140-150 kDa and caspase-cleaved 
fragments at 110-125 kDa. Blots were also probed with an antibody against β-actin 
(42 kDa), as a loading control. Bar graphs show amounts of (B) total α-spectrin (C) 
full-length (D) calpain- and caspase-cleaved α-spectrin, and (E) caspase-cleaved α-




4.2.12 Aβ does not alter neuronal Ca2+ dynamics in primary 
cortical culture  
Aβ is believed to mediate synaptic dysfunction and neuronal loss by causing 
cytotoxic elevations of intracellular Ca2+ (Kuchibhotla et al., 2008; Supnet and 
Bezprozvanny, 2010). Human and rodent primary neurons (10 to 21 DIV) 
undergo rapid increases in intraneuronal Ca2+ within minutes of exposure to Aβ 
(Atherton et al. unpublished; Mattson et al., 1992; De Felice et al., 2007). 
Therefore, it was hypothesized that the AD-relevant protein changes induced by 
calpain in this chapter occur downstream of intraneuronal Ca2+ accumulation in 
response to Aβ. To determine whether Aβ modulates intracellular Ca2+ in primary 
cortical neurons, it was first important to distinguish neurons from other cell 
types, as cultures used here were established as predominantly neuronal but 
containing ~17 % astrocytes and a negligible (0.01 %) proportion of microglia 
(Garwood et al., 2011). Neurons were identified under bright-field based on 
dendritic and axonal morphology and stasis in culture, while astrocytes showed 
stellate morphology and motility over time. As this thesis examines neuronal 
mechanisms of Ca2+ dysregulation, only neurons were selected for live imaging. 
Soluble oligomeric Aβ1-42 was applied to primary cultures incubated in fluo-4 
AM Ca2+ indicator (section 2.1.6) immediately prior to imaging. Standard 
fluorescence live microscopy was used to measure changes in fluo-4 signal 
intensity, thereby indicating changes in cytosolic Ca2+. Images were taken over the 
course of 10 min, at a 1 s interval and were analysed as described in section 2.2.7.  
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Application of Aβ oligomers did not evoke a detectable change in neuronal fluo-4 
signal over 10 min from baseline (Fig. 4.18). Cultures were checked for neuronal 
viability by application of 50 mM KCl, which is known to induce rapid neuronal 
depolarization in healthy neurons (Franklin et al., 1995). The observed  Ca2+ peak 
increase of ΔF/F = 1.6 ± 0.6 (S.E; Fig. 4.18.C) immediately after treatment with KCl 
confirmed the viability of these cultures, signifying that neuronal health was not 
a factor in the absence of a Ca2+ response to Aβ. Although these results are 
inconsistent with previous findings in this group, it is likely that variations in Aβ 
and culture preparations or differential effects of exogenous and intracellular Aβ 
could account for this discrepancy.  
 
4.2.13 Aβ-induced Ca2+ elevations in SH-SY5Y cells are mediated 
by influx of extracellular Ca2+  
Human SH-SY5Y cells commonly replace neuronal culture as an in vitro model for 
neurodegenerative disorders as they are morphologically similar to primary 
neurons, express a number of mature neuronal markers and are immortal 
(Kovalevich and Langford, 2013). Importantly, these cells express Ca2+ channels, 
receptors and pumps known to be dysregulated in AD by Aβ (Kulikov et al., 2007; 
Morton et al., 1992; Magi et al., 2005). Thus, SH-SY5Y cells were used here to 
model Aβ mechanisms of Ca2+ dysregulation in the absence of results in primary 
neurons (section 4.2.12).  
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Aβ was applied to SH-SY5Y cells loaded with fluo-4 Ca2+ dye (section 2.1.6) 





Fig. 4.18 Synthetic human Aβ does not alter intracellular Ca2+ concentration in 
primary cortical cultures. (A) Cultures loaded with fluo-4 Ca2+ dye were imaged at 1 s 
intervals for a period of 10 min immediately after application of Aβ or KCl. (B) 
Representative Ca2+ traces from cultures imaged prior to application of either Aβ 
(purple arrow) or 50 M KCl (blue arrow). Ca2+ signal was calculated as change in fluo-
4 fluorescence as a proportion of original fluorescence (ΔF/F). (C) Bar graph shows 
maximum intracellular Ca2+ in resting cultures (basal) and cultures treated with KCl 
or Aβ. Data is mean ± SEM. **p < 0.01 
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was measured by standard live fluorescence microscopy, with changes in signal 
intensity representing changes in intracellular Ca2+. Images were captured at 1 s 
intervals for a total of 10 min, and were analysed as described in section 2.2.7.  
Fluo-4 signal was measured from multiple cells on each coverslip so as to 
determine the proportion of cells responding to Aβ and derive an average Ca2+ 
trace. Interestingly, while Aβ induced a Ca2+ response in > 90 % (n = 120) of cells, 
there was variability between cells in the patterning of the response. The majority 
of cells displayed large Ca2+ transients, while less than 20 % (n = 24) responded 
with prolonged elevations and minor increases in Ca2+ (Fig. 4.20A). Differences in 
the temporal patterning of Ca2+ signals is likely to indicate execution of different 
Ca2+-sensitive cellular processes under physiological conditions (Berridge et al., 
2000). On the other hand, the differential Ca2+ dynamics evoked here by Aβ may 
possibly indicate intercellular communication or propagation of the Aβ response.  
On average, cells that were exposed to Aβ displayed elevated Ca2+ transients that 
lasted around 60 s and dampened over time, with an initial highest peak increase 
of ΔF/F = 3.3 ± 0.2 (S.E) at 60 s after treatment (Fig 4.19 and 4.20B). These Ca2+ 
transients significantly exceeded the Ca2+ response to depolarization by KCl (p < 
0.05; Fig 20.C), supporting the hypothesis that Aβ destabilizes neuronal Ca2+ 
homeostasis (Mattson et al., 1992). Moreover, the amplitudes of these Ca2+ 
transients were previously reported as characteristic of Aβ oligomer action in SH-






The Ca2+ response to Aβ was abolished when cells were imaged in Ca2+-free 
solution (Fig. 4.19 and 4.20B, C), thereby indicating that Aβ-induced cytosolic Ca2+ 
elevations are mediated by influx of extracellular Ca2+, in line with numerous 
Fig. 4.19 Aβ transiently elevates intracellular Ca2+ concentrations via influx of 
extracellular Ca2+ in SH-SY5Y cells. Cultures loaded with fluo-4 Ca2+ dye were imaged 
at 1 s intervals for a period of 10 min immediately after application of either KCl, Aβ,  
Ca2+ Aβ in free solution or natural Aβ derived from 7PA2 Chinese hamster ovary cells 
(7PA2 Aβ).  
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reports (Supnet and Bezprozvanny, 2010; Bezprozvanny and Mattson, 2008; 







Fig. 4.20 Aβ transiently elevates intracellular Ca2+ concentrations via influx of 
extracellular Ca2+ in SH-SY5Y cells. (A) Representative Ca2+ traces from different cells 
in a single culture treated with Aβ and (B) cultures treated with either KCl, Aβ, Aβ in 
Ca2+-free solution or 7PA2 CHO cell media (7PA2 Aβ). Ca2+ signal was calculated as 
change in fluo-4 fluorescence as a proportion of original fluorescence (ΔF/F). (C) Bar 
graph shows maximum intracellular Ca2+ in resting cultures (basal) and cultures 
treated with KCl, Aβ, Aβ in Ca2+ free solution and 7PA2 Aβ. Data is mean ± SEM. **p < 
0.01, ***p < 0.001 
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However, there was evidence of a small Ca2+ peak occurring immediately after Aβ 
application to cells in Ca2+-free solution (Fig. 4.20C), measuring ΔF/F = 1.28 ± 0.3 
(S.E) above basal, and possibly signifying release of Ca2+ from intracellular stores. 
Pharmacological modulation of ER Ca2+ release has previously been shown to 
significantly reduce the cytosolic Ca2+ increases induced by Aβ (Suen et al., 2003). 
This suggests that Aβ mediates neuronal Ca2+ insults partially through stimulation 
of ER stores, which may account for the Ca2+ response seen here in the absence of 
extracellular Ca2+. However, the small size of this observed Ca2+ peak implies that 
it does not play a major role in the overall Aβ-induced Ca2+ response, and the role 
of ER Ca2+ signalling in Aβ neurotoxicity remains unclear, at least in the model 
used here.  
 
4.2.14 Physiological Aβ does not alter short-term Ca2+ dynamics 
in SH-SY5Y cells 
As described in section 4.2.10, an important aim of this chapter was to compare 
the effects of naturally secreted Aβ oligomers derived from 7PA2 cells to those 
elicited by synthetic Aβ oligomers in primary neurons (section 4.2.12). Since 
7PA2 Aβ did not increase activity of Ca2+-sensitive calpain-1 after 48 h (section 
4.2.10), this suggested that 7PA2 Aβ would also not affect Ca2+ dynamics over the 
same time period. 
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Indeed, when measured by standard fluorescence microscopy in fluo-4-loaded 
SHSY-5Y cells, treatment of cells with 7PA2 cell medium prior to recording did not 
increase cytosolic Ca2+ from baseline over 10 min (Fig. 4.19 and 4.20B, C), in 
contrast to the prolonged Ca2+ elevations observed in response to synthetic Aβ 
(section 4.2.13).  Again, this might reflect the differences in Aβ concentration 
between these two preparations, as discussed above.  
 
4.2.15 Aβ-induced Ca2+ elevations in SH-SY5Y cells are blocked by 
inhibition of calpains, caspases and PARP 
Aβ has shown to dysregulate neuronal Ca2+ by modulating a variety of 
mechanisms that form the Ca2+  signalling toolkit, including activation of NMDARs 
(Molnár et al., 2004) and calpains (Atherton et al., 2014). Accumulating evidence 
also implicates PARP in Aβ-mediated neurotoxicity, since PARP is activated 
during the oxidative stress induced by Aβ (Fonfria et al., 2005), Aβ-induced 
NMDAR activation (De Felice et al., 2007) and elevations in neuronal Ca2+ (Viráģ 
et al., 1999). PARP initiates apoptosis through activation of caspase-3 and calpain-
1 (Chaitanya et al., 2010), which in turn respectively activate and inhibit PARP. 
Therefore, the contribution of calpain, caspase and PARP activities in Aβ-induced 
Ca2+ elevations were next investigated in live neurons.  
213 
 
Prior to Ca2+ imaging, cultures were pre-treated for 3 h with calpain inhibitor 
calpeptin (CPTN), NMDAR antagonist MK-801 (MK), pan-caspase inhibitor VI (CI 
VI) and PARP inhibitor SB750139 (SB). Synthetic Aβ was prepared as described 
in section 2.2.7 and was directly added to fluo-4-loaded SH-SY5Y cells 
immediately prior to imaging using standard live fluorescence microscopy (Fig. 
4.21). Images were captured at 1 s intervals for a duration of 10 min and fluo-4 
signal intensity was used as an arbitrary measure of intracellular Ca2+ 
concentration.   
Treatment of cells with Aβ produced a series of large Ca2+ transients as described 
in section 4.2.13. These transients were suppressed in the presence of all 
compounds, with a marked variation in the patterning of Ca2+ signals depending 
on which compound was used  (Fig. 4.22A, B). Treatment with MK-801 (MK) 
reduced the initial Aβ-evoked Ca2+ peak by approximately 42 % (p < 0.05; Fig. 
4.22B), followed by a steady decline in intracellular Ca2+ concentrations that was 
punctuated by minor oscillations that temporally synchronized with the 
diminishing transients elicited by Aβ alone (Fig. 4.22A). These results are in 
agreement with the literature, indeed the role of NMDARs in Aβ oligomer-induced 
Ca2+ dysregulation in AD is widely supported (Texidó et al., 2011; Alberdi et al., 




Exposure of Aβ-treated cells to SB750139 (SB) reduced the Ca2+ peak evoked by 
Aβ by approximately 25 % (Fig. 4.22B) but this did not reach statistical 
significance, likely due to variation between experiments. However, SB abolished 
the later Ca2+ oscillations seen with Aβ, instead causing a steady decline of Ca2+ to 
basal levels (Fig. 4.22A). These findings imply that PARP signalling may play a key 
secondary role in the Ca2+ response to Aβ, following an initial  Ca2+ influx via 
NMDARs as previously described (Viráģ et al., 1999; Vosler et al., 2009).  
Treatment of cells with a cocktail of Aβ and calpeptin (CPTN) caused an almost 3-
fold reduction of the initial Aβ-induced Ca2+ transient to levels slightly elevated 
from basal (p < 0.001, Fig 4.22), which were only completely recovered after 6 
min of imaging (Fig. 4.22A). These findings suggest that calpain activity plays a 
key role in mediating the prolonged Ca2+ increase induced by Aβ, as proposed in 
this thesis and previous work by this group (Atherton et al., 2014). Calpain cleaves 
and inactivates NCX3 in AD brain, which in primary culture confers neurotoxicity 
(Chapter 3). NCX3 is responsible for clearing excess Ca2+ from cells to protect 
neurons. These findings therefore support the hypothesis that calpain inhibition 
may relieve the toxic effects of Ca2+-mediated calpain-induced NCX3 cleavage and 
inactivation of NCX3 in response to Aβ.  
Imaging of cells treated with Aβ in the presence of pan-caspase inhibitor VI (CI VI) 
revealed a 62 % reduction in the initial Ca2+ spike evoked by Aβ (p < 0.001; Fig. 
4.22B), following which Ca2+ levels were further reduced to basal for the duration 
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of the experiment (Fig. 4.22A). Elevations in intracellular Ca2+ were previously 
shown to upregulate expression and activity of caspases  (Juin et al., 1998; Gong 














Fig. 4.21 Aβ-induced transient elevations of intracellular Ca2+ are modulated by 
inhibition of N-methyl-D-aspartate receptors (NMDAR), calpain, caspase, and 
poly(ADP)ribose polymerase (PARP) activities. Prior to imaging, cultures were pre-
treated for 3 h with calpain inhibitor calpeptin (CPTN), NMDAR antagonist MK-801 
(MK), pan-caspase inhibitor VI (CI VI) and PARP inhibitor SB750139 (SB). Cultures 
were loaded with fluo-4 Ca2+ dye and imaged at 1 s intervals for a period of 10 min 
immediately after application of Aβ.  
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The tight interrelationship between caspases and calpains (Nakagawa and Yuan, 
2000) suggests that caspases could also play a role in calpain-mediated 
mechanisms of Ca2+ overload. Elevated caspase-3 activity has been found to 
mediate synaptic dysfunction in APPSWE mice, suggesting that caspase activity is 
activated by Aβ (Kuwako et al., 2002). However, these authors also showed that 
caspase-3 downregulates glutamatergic transmission, by removing the GluR1 
subunit of AMPARs, and that caspase-3 is not involved in NMDAR signalling. 
Therefore, the degree to which caspases appear to contribute to the Aβ-induced 
Ca2+ response in these experiments was somewhat unexpected, but could simply 
imply activation of caspases other than caspase-3 since the inhibitor used here is 
not specific to caspase-3 alone. 
 
 
Fig. 4.22 Aβ-induced transient elevations of intracellular Ca2+ are abolished by 
inhibition of N-methyl-D-aspartate receptors (NMDAR), calpain, caspase, and 
poly(ADP)ribose polymerase (PARP) activities. (A) Representative Ca2+ traces from 
cultures pre-treated for 3 h with calpain inhibitor calpeptin (CPTN), NMDAR 
antagonist MK-801 (MK), pan-caspase inhibitor VI (CI VI) and PARP inhibitor 
SB750139 (SB). Ca2+ signal was calculated as change in fluo-4 fluorescence as a 
proportion of original fluorescence (ΔF/F). (C) Bar graph shows maximum 
intracellular Ca2+ in cultures treated with Aβ only or with Aβ in combination with 
CPTN, MK, CI VI and SB. Data is mean ± SEM. *p < 0.05, **p < 0.001 
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4.3 Summary and Discussion 
 
The main findings of this chapter are:  
• Aβ induces neuronal death and calpain proteolytic activity in primary 
culture, which is reduced by inhibition of calpain 
• Aβ and calpain have independent and differential effects on non-
amyloidogenic and amyloidogenic processing of APP to influence 
intracellular Aβ production 
• Aβ alters tau phosphorylation via a mechanism at least partly dependent 
on calpain and which likely involves alterations in GSK3 and cdk5 activities 
• Calpain-activated GSK3 reciprocally upregulates calpain activity  
• Aβ and calpain affect synaptic markers suggesting effects on synapse 
health 
• Aβ stimulates intracellular accumulation of Ca2+ through influx of 
extracellular Ca2+ 
• Naturally secreted human Aβ oligomers does not alter Ca2+ homeostasis, 
calpain activity or tau phosphorylation in the cell models used here 
• Aβ-induced elevation of cytosolic Ca2+ is rescued by inhibition of NMDAR, 





4.3.1 Calpain plays a significant role in Aβ mechanisms of 
neurotoxicity  
In this chapter, exposure of primary cortical neurons to Aβ caused a significant 
increase in cell death, which was rescued by pharmacological inhibition of calpain 
(section 4.2.2). These findings were previously observed by this group and others 
(Atherton et al., 2014; Kelly et al., 2005; Kelly and Ferreira, 2006; Nicholson and 
Ferreira, 2009), and suggest a key role for calpain in Aβ-induced neurotoxicity.  
Calpain-1 is predominantly expressed in neurons and regulates a variety of vital 
physiological processes by catalysing proteolytic degradation of more than a 100 
protein substrates (Ferreira, 2012). These include cytoskeletal proteins 
(including α-spectrin and tau), signal transduction proteins, synaptic markers, 
glutamate receptors and transcription factors.  It is thus unsurprising that, under 
physiological conditions, calpain activity is tightly regulated by intracellular Ca2+ 
levels, the endogenous calpain-specific inhibitor calpastatin, and a number of 
protein kinases (Goll et al., 2003; Kiss et al., 2008). Calpains are primarily 
inactivated by homoestatic cytosolic Ca2+ concentrations in the nM range, and are 
activated by discrete elevations of Ca2+ to μM concentrations (in the case of 
calpain-1). It may therefore be expected that prolonged activation of calpain-1 
induced by chronically elevated Ca2+ would result in significant cellular damage 
due to massive proteolytic activity.  
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Indeed, the Aβ-induced neuronal death seen here was associated with increased 
calpain-mediated cleavage of α-spectrin, indicating elevated calpain proteolytic 
activity and cytoskeletal degradation.  This was accompanied by increased 
generation of cleaved (active) caspase species, indicating that Aβ signals 
apoptosis through caspase activity, which is likely calpain-dependent (Warren et 
al., 2007; Nakagawa and Yuan, 2000). Inhibition of calpain activity attenuated 
calpain-mediated breakdown of α-spectrin and was neuroprotective to cultures. 
Therefore, these findings support previous evidence that Aβ mediates neuronal 
death through calpain-dependent cellular damage.  
Aβ-induced neuronal death in primary culture is accompanied by synaptic 
damage (Shankar and Walsh, 2009; Sivanesan et al., 2013). Depletion of dendritic 
spines by Aβ oligomers is mediated by elevations of spine Ca2+ and occurs prior 
to localized activation of tau kinases and tau phosphorylation (Zempel et al., 
2010).  Calpain-1 is enriched between synaptic vesicles, where it regulates 
vesicular trafficking and neurotransmitter release (Khoutorsky and Spira, 2009; 
Murrey et al., 2006b); therefore, it is likely that Aβ-induced synaptic loss involves 
local calpain dysregulation mediated by local Ca2+ elevations. In this study, Aβ-
induced neurotoxicity and calpain upregulation was associated with loss of 
synaptic markers, particularly significantly reduced PSD95 immunoreactivity in 
neuronal dendrites (section 4.2.9). However, inhibition of calpain did not recover 
PSD95 protein expression, which is inconsistent with previous reports (Lu et al., 
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2000) and does not add further support for a role of calpain in synaptic loss, at 
least in the culture model used here.  
 
4.3.2 Aβ and calpain differentially promote amyloidogenic APP 
processing and Aβ production 
Although many consider Aβ as the initial pathogenic trigger in AD, there is 
growing evidence that Ca2+ dyshomeostasis occurs upstream of and contributes 
to aberrant APP processing and Aβ production (Buxbaum et al., 1994; Hoey et al., 
2009). Mutations in the Ca2+ channel CALHM1 in patients with sporadic AD lead 
to Aβ overproduction (Dreses-Werringloer et al., 2008), and PS mutations in 
animal models of familial AD increase Aβ generation through dysregulated ER 
Ca2+ signalling (Green et al., 2008).  
The observations here of Aβ accumulation in neurons exposed to synthetic Aβ 
(section 4.2.5) was somewhat surprising since 1) Aβ is classically secreted 
extracellularly following proteolytic cleavage of plasma membrane APP (Zhang et 
al., 2011), and 2) current literature lacks evidence on the role of Aβ in modulating 
APP processing. However, a number of studies have demonstrated that 
intracellular pools of Aβ are generated from APP located within intraneuronal 
compartments in transgenic animals and AD brain (LaFerla et al., 2007; Vetrivel 
and Thinakaran, 2006; Tomita et al., 1998), and intracellular Aβ1-42 was shown 
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to be synthesized de novo in normal human cerebral astrocytes exposed to Aβ25-
35 - a surrogate of Aβ1-42  (Dal Pra et al., 2011). Axonal and dendritic Aβ has been 
shown to disrupt synaptic plasticity and reduces dendritic spine numbers (Wei et 
al., 2010), which causes cognitive and memory impairment (Lacor et al., 2004). 
When taken together, these findings suggest that Aβ may mediate memory loss 
and neuronal death in AD through synaptotoxic mechanisms that involve further 
overproduction of Aβ and intracellular accumulation of the peptide.  
Several lines of evidence suggest that Ca2+ mediates changes in APP processing 
through calpain activation and signalling. Calpain activation increases BACE 
expression, amyloidogenesis and plaque formation in mice expressing mutant 
APP either alone or together with mutant PS1 (Liang et al., 2010). Moreover, BACE 
is shown to be elevated in brain tissue and CSF from patients with early AD (Evin 
et al., 2010). On the other hand, inhibition of calpain by calpeptin in murine L cells 
has shown to dose-dependently increase Aβ1-42 secretion (Mathews et al., 2002). 
Thus, the role of calpain in APP processing remains controversial. The calpain-
mediated modulation of physiological APP processing observed in the current 
study (section 4.2.4) suggests that calpain shifts APP homeostasis towards 
amyloidogenesis; however calpain inhibition had no effect on BACE expression, 
or Aβ production (section 4.2.5). Therefore, it is possible that Aβ and calpain 
promote aberrant APP processing via separate mechanisms, independent of each 
other. On the other hand, the marked increase in the BACE-cleaved C99 fragment 
in cultures treated with calpeptin may signify increased BACE proteolytic activity 
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(which was not directly measured in this study). As these cultures also showed 
increases in Aβ peptide, which requires both β- and γ-secretase proteolytic 
activity, it is therefore possible that calpain inhibition increased BACE activity, 
without altering BACE expression, in primary neurons.  
Importantly, the finding of increased Aβ accumulation in lysates from cultures 
exposed to exogenous Aβ was accompanied by increased expression of nicastrin 
in these samples. Nicastrin is essential for secretase activity, and CHO cells 
overexpressing nicastrin display increased γ-secretase proteolytic activity and Aβ 
production (Marlow et al., 2003). Therefore, the increase in nicastrin expression 
in Aβ-treated primary neurons implies that the Aβ detected in these lysates is 
indeed intracellularly generated as a result of increased APP proteolysis. The 
increase in nicastrin expression was recovered by calpeptin treatment, 
supporting previous evidence by Liang et al. (2010) that calpain stimulates Aβ 
production. However, the amounts of Aβ peptide found in lysates were unaltered 
by calpeptin, which may suggest the additional presence of exogenously applied 
Aβ in these samples.  
Table 4.1 illustrates the differential effects of Aβ and calpain on the secretases and 





Protein CTRL Aβ 
Aβ + 
CPTN CPTN 
ADAM10 - ↓ ↓ ↓ 
BACE - - - - 
nicastrin - ↑ ↓ - 
FL APP  - - - - 
N-APP (17 kDa) - - ↑ ↑ 
C-APP (C99) - ↑ ↑ - 






The alteration of APP processing by calpain shown in this study supports the 
upstream role of Ca2+ signalling in regulating APP homeostasis, and suggests an 
enhancing effect of calpain on Aβ production. Furthermore, as calpain is shown 
here to be activated by Aβ (section 4.2.3), this study may support emerging 
evidence of a bidirectional relationship between Ca2+ signalling pathways and Aβ 
production, where Aβ-induced cytotoxic Ca2+ elevations lead to further 
generation of Aβ in a vicious cycle (Kyratzi and Efthimiopoulos, 2014).  
Table 4.1 Aβ and calpain differentially affect amyloidogenic and non-amyloidogenic 
APP processing in primary cortical neurons. Cultures were treated with vehicle 
(CTRL), Aβ, Aβ together with the calpain inhibitor calpeptin (CPTN), or calpeptin 
alone. The effect of treatments on APP processing was assessed by examining changes 
in protein amounts of ADAM10, BACE and nicastrin, indicating activities of α, β, and 
γ-secretases, respectively. Changes in protein amounts of full-length (FL) APP, N-
terminally cleaved (N-APP) and C-terminally cleaved (C-APP) species, including Aβ 
were also assessed. ‘-‘ indicates no effect; ↑ indicates increased protein amounts and 
↓ indicates decreased protein amounts.  
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4.3.3 Calpain mediates Aβ-induced tau phosphorylation 
It is shown here that calpain plays a role in Aβ-induced tau phosphorylation, as 
Aβ treatment caused reduced amounts of dephosphorylated tau in primary 
neurons, an effect reduced by calpain inhibition (section 4.2.6).   
Substantial evidence implicates Aβ as an upstream trigger of tau pathology seen 
in AD (reviewed by Stancu et al., 2014).  Aβ phosphorylates tau in degenerating 
cholinergic neurons in vitro and in APP and tau mutant rodents (Zheng et al., 
2002; Zempel et al., 2010; Huang and Jiang, 2009; Götz et al., 2001; Lewis et al., 
2001). Tau processing is also subject to modification by Ca2+, and this has been 
strongly implicated in neurodegeneration. In cultured neurons, Ca2+ influx 
stimulated by membrane depolarization leads to transient phosphorylation of tau 
by GSK3 and cdk5 (Pierrot et al., 2006).  Similarly, in SH-SY5Y cells, prolonged 
Ca2+ influx stimulated by treatment of cells with a Ca2+ ionophore increased levels 
of phosphorylated tau, which was reversed upon inhibition of Ca2+-dependent 
kinases (Shea and Ekinci, 1999).   
Since Aβ increases concentrations of neuronal Ca2+ it is highly plausible that Aβ 
may induce pathological changes in tau through aberrant Ca2+ signalling. In 
support of this, marked calpain immunoreactivity in dystrophic neurites 
associated with NFTs and amyloid plaques are observed in patient AD 
hippocampal tissue (Adamec et al., 2002). Indeed, Aβ is known to phosphorylate 
tau through activation of calpain and mitogen-activated protein kinase, both of 
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which differentially stimulate tau kinases, as well as downregulation of 
calcineurin-dependent tau dephosphorylation (Zheng et al., 2002; Lloret et al., 
2011). Therefore, the attenuation of Aβ-induced tau phosphorylation by calpain 
inhibition seen here supports the hypothesis that Aβ influences tau 
phosphorylation through Ca2+-dependent calpain activity and downstream tau 
kinase activation.  
It may have been expected that Aβ would increase tau phosphorylation at PHF1 
and CP13 epitopes, which are implicated in AD (Hanger et al., 2009) and are sites 
phosphorylated by GSK3 in vivo (Noble et al., 2005). However, phosphorylation at 
these sites was unaltered by Aβ in the present study, perhaps indicating that these 
sites are only involved upon aggregation of tau into PHF in progressed stages of 
AD, as seen in animal models. Alternatively,  activation of calpain by glutamate in 
hippocampal neurons was shown to decrease tau phosphorylation due to 
concomitant activation of the Ca2+ -dependent phosphatase, calcineurin 
(Kerokoski et al., 2002), and it is possible that these opposing effects would 
counteract each other to result in no overall effect of Aβ on tau phosphorylation 
in the experiments shown here.  
In addition to phosphorylation, tau is pathologically truncated by calpains and 
caspases to generate 17-50kDa species, argued by some to be neurotoxic and 
trigger NFT formation (de Calignon et al., 2010; Liu et al., 2011; Park and Ferreira, 
2005). Aβ was shown here to activate both proteases (section 4.2.3), and it was 
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expected that generation of caspase- and/or calpain-cleaved tau species might be 
detected in Aβ treated neurons.  However, these tau fragments were not observed 
in Aβ-treated cultures, despite being described to be induced by Aβ in 
hippocampal neurons (Park and Ferreira, 2005). This discrepancy may be 
explained by the use of different Aβ preparations of different concentrations, and 
a difference in neuronal type and age between previously reported studies and 
the current work.  
 
4.3.4 Aβ elevates neural Ca2+ through activation of NMDARs, 
calpains, caspases and PARP  
In this chapter, primary neurons did not show any response to synthetic Aβ 
treatment, which likely reflected ongoing problems with primary neuron health 
in the host institution. As an alternative model, SH-SY5Y cells were used, and 
when exposed to Aβ these displayed rapid increases in cytosolic Ca2+ in the form 
of prolonged Ca2+ transients or sustained elevations. The Ca2+ responses to Aβ 
were abolished by removal of Ca2+ from extracellular solution and were reduced 
in the presence of inhibitors of NMDARs, calpains, caspases and PARP. Together, 
these findings show that Aβ elevates neural Ca2+ through a mechanism that 
involves influx of extracellular Ca2+, followed by dysregulated activation of 
signalling cascades that lead to sustained intracellular Ca2+ overload. These Ca2+ 
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events occur prior to the changes in APP, tau phosphorylation and neurotoxicity 
seen in primary cultures.  
Multiple studies have shown that Aβ-induced synaptic and neuronal loss is 
mediated by excitotoxic increases in Ca2+ (Harkany et al., 2000a; Boehm, 2013; 
Liu et al., 2008). Excitotoxicity in primary culture is dependent on overactivation 
of NMDARs either by glutamate or Aβ, and occurs in three steps (Brustovetsky et 
al., 2010a). There is an initial Ca2+ spike triggered by NMDARs, followed by a 
transient decrease to levels above resting Ca2+. After some delay, this is followed 
by a large and sustained Ca2+ increase, termed ‘delayed calcium deregulation’ 
(DCD), which is required to induce neurotoxicity (Nicholls and Budd, 1998).  The 
varied Ca2+ responses to Aβ in the current study did not fit the described pattern 
(section 4.2.13) and may be specific to SH-SY5Y cells, which may be less 
vulnerable to Aβ toxicity and may not share an identical Ca2+ toolkit with neurons.  
Nevertheless, the Aβ-induced Ca2+ elevations were NMDAR-dependent, and 
exceeded physiological increases both in amplitude and duration, indicating Ca2+ 
dysregulation. The mechanisms underlying DCD remain unclear due to conflicting 
evidence. In striatal neurons, excitotoxic cell death depends on calpain activation 
and cleavage of NCX3 (Bano et al., 2005), which is also observed in post mortem 
brain from end stages of AD (section 3.2.3) where increases in neuronal Ca2+  
reach excitotoxic levels (Berridge, 2014).  It was therefore postulated that calpain 
is vital for Aβ-induced Ca2+ dysregulation. Indeed, the transient Ca2+ elevations 
elicited here by Aβ were immediately abolished by calpain inhibition (section 
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4.2.15). This suggests that calpain is activated during the initial NMDAR-
dependent Ca2+ rise in Aβ excitotoxicity, and contributes to DCD via mechanisms 
that may include NCX3 inactivation (illustrated in Fig 4.23).   
Aβ-induced oxidative stress in primary neurons causes Ca2+ accumulation 
through aberrant PARP signalling (Halliwell, 2006). PARP is a nuclear enzyme 
that catalyzes production of ADPR during its primary function of DNA repair. 
ADPR activates plasmalemmal TRPM2 - a heat-sensitive subtype of Ca2+-
permeable TRP channels. Earlier reports in this laboratory, and others (Fonfria et 
al., 2005; Miller, 2004; Xie et al., 2010), have shown that PARP-mediated TRPM2 
activation is important in mediating neuronal Ca2+ overload in AD. The findings 
shown here are in support of this hypothesis, as blockade of TRPM2-gated Ca2+ 
entry by inhibition of PARP attenuated the Aβ-induced Ca2+ response (section 
4.2.15). However, the initial Ca2+ rise was not significantly reduced by PARP 
blockade, suggesting that PARP-TRPM2 signalling occurs secondary to NMDAR 
and calpain activation. Therefore, it is possible that TRPM2-mediated entry could 
play a role in DCD, in response to intracellular mechanisms stimulated by the 
initial Ca2+ influx (Fig 4.23). To support this idea, Aβ-induced Ca2+ elevations were 
completely abolished by inhibiting caspases, which are activated downstream of 
calpains (Nakagawa and Yuan, 2000) and are known to cleave PARP in NMDAR-
induced excitotoxicity and apoptosis (Chaitanya et al., 2010).  The role of the 

















4.3.5 Physiological Aβ oligomers do not recapitulate disease 
processes in vitro  
As described above, the source of Aβ used in cell culture studies is a subject of 
great debate in the field. Therefore, in addition to synthetic Aβ, conditioned media 
from 7PA2 cells was used as a well-characterized natural source of human Aβ 
Fig. 4.23 A hypothetical model of the mechanisms underlying Aβ-induced excitotoxic 
elevations in neural Ca2+ based on the findings described in this chapter. Aβ mediates 
excitotoxicity in neurons through initial activation of N-methyl-D-aspartate receptors 
(NMDAR) and other native Ca2+ channels (Harkany et al., 2000b). The resulting Ca2+ 
elevations are shown to occur in two phases (Brustovetsky et al., 2010a). Phase 1 is 
characterized by small increases in Ca2+, which stimulate the Ca2+-sensitive protease 
calpain-1.  This is followed by a fall in to levels elevated from basal, during which 
calpain and caspase signalling may lead to cleavage of the sodium calcium exchanger 
3 (NCX3) and activation of poly(ADP)ribose polymerase (PARP), respectively. After a 
delay, these events may contribute to the sustained and irreversible Ca2+ elevations 
seen during excitotoxicity prior to neuronal demise. 
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oligomers. Exposure of primary neurons to physiological (2-500nM) 
concentrations of 7PA2 Aβ did not differentially alter calpain activity, tau kinase 
activities or tau phosphorylation in primary neurons or SHSY5Y cells. Moreover, 
these Aβ oligomers had no effect on short-term neural Ca2+ dynamics.  
The worsening of cognitive symptoms in AD have been linked with a gradual and 
progressive rise in intracellular Ca2+ over the time-course of the disease (Berridge, 
2014). Hypothesized to be stimulated by early Aβ deposition, these Ca2+ 
elevations start during the early pre-clinical stages of AD and only reach 
concentrations that impair synaptic function and plasticity years later, when the 
first cognitive  and memory symptoms appear (section 1.2). Furthermore, 
excitotoxic intracellular Ca2+ levels above 300 nM  are only reached in terminal 
stages of AD, at which point this contributes to global neuronal atrophy (Berridge, 
2014).  
Aβ oligomers found in 7PA2 cell medium are highly similar in molecular mass and 
amounts to SDS-stable oligomers derived from human AD cortex. In adult rats, 
7PA2 Aβ blocked LTP 3 hours after stimulation (Walsh et al., 2002a), and 
disrupted cognitive function 3 days after microinjection (Cleary et al., 2005). In 
this study, 7PA2 Aβ was applied to primary culture and neural cells for 10 min to 
48 h. Therefore, use of cell models and relatively short incubation periods may 
have prevented 7PA2 Aβ from exerting the pathological effects seen in vivo in 
human AD brain.  This suggests that cell-derived natural Aβ oligomers may not be 
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suitable for modelling mechanisms of Aβ neurotoxicity in vitro. However, 
treatment of hippocampal neurons with 7PA2 for 5 days previously triggered 
spine and synapse loss (Shankar et al., 2007). Thus, longer treatments with 7PA2 
may have to be carried out before conclusions can be made about its ability to 
alter AD-relevant proteins in vitro.  
 
4.3.6 Limitations of this work 
There are several limitations to the experiments performed in this chapter. As the 
chapter focuses on the role of calpain in Aβ mechanisms, it was first important to 
establish the effect of Aβ on calpain activity by means of immunoblotting with an 
antibody that labels the 76-78 kDa active calpain fragment. Multiple anti-calpain-
1 antibodies were tested, none of which detected this fragment. However, these 
antibodies consistently revealed a 28 kDa band (section 4.2.2), which represents 
the regulatory subunit of calpains (Cong et al., 1993). This 28 kDa subunit is 
required for autolysis and, hence, proteolytic activation of the 80 kDa catalytic 
subunit of calpain. Therefore, the increase in the presence of the 28 kDa calpain 
subunit observed here after Aβ treatment likely signify increased calpain-1 
proteolytic activity, although this cannot be stated with certainty. Increased 
calpain activity was confirmed by the increased generation of calpain-cleaved 
fragments of α-spectrin. Immunoblotting for detection of cleaved α-spectrin was 
previously used in multiple studies to indirectly assess calpain and caspase 
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activities in the absence of calpain blots  (Warren et al., 2007; Axelsson et al., 
2006; Trinchese, Liu, et al., 2008). However, a direct and more accurate 
measurement of calpain activity would require detection of the 76-78 kDa active 
calpain subunit or a calpain activity assay.  
In the current study, Aβ application to neurons did not alter Ca2+ homeostasis over 
10 min. The effects of soluble Aβ oligomers on neuronal Ca2+ dynamics have been 
extensively researched, yet are inconsistent. There are numerous reports of Aβ 
inducing Ca2+ overload in primary neurons prior to their demise (Bezprozvanny 
and Mattson, 2008; Ramsden et al., 2002; Price et al., 1998). However, Aβ has also 
shown to decrease intraneuronal Ca2+, selectively alter astrocytic Ca2+ or have no 
effect at all (Abramov et al., 2004; Chin et al., 2006). Since the effects of Aβ on 
calpain activity, APP processing, tau phosphorylation and synaptic health were 
studied here in primary neurons, it was important to show that Aβ aberrantly 
alters these processes through dysregulated Ca2+ signalling in the same cell model. 
Earlier findings in this group and others suggest that excitotoxic Ca2+ elevations 
in primary neurons induced by glutamate and Aβ are seen after 20 min to 1 h 
(Bano et al. 2005; Brustovetsky et al. 2010; Atherton et al., unpublished). 
Furthermore, Aβ induced neurotoxic calpain activity in primary neurons after 48 
h, but had no effect on calpain activity or cell death after shorter treatments. 
Therefore, longer imaging experiments and Aβ incubations may have been 
required to see aberrant Ca2+ changes. However, exposure of fluo-4-labelled 
neurons to fluorescent light for longer than 10 min caused photobleaching, during 
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which Ca2+ spikes evoked by KCl depolarization were not detected by the 
software. This limitation is likely specific to the dye used, and may have been 
avoided by using a ratiometric dye, such as fura-2, which minimizes the effects of 
photobleaching.  
Aβ transiently elevated cytosolic free Ca2+ in SH-SY5Y cells to levels that were 
higher than those detected under basal conditions or induced by KCl (section 
4.2.13). The discrepancy between these findings and earlier results in primary 
neurons may be accounted for by phenotypic differences between the two cell 
types. It is suggested that enrichment of tau in primary neurons regulates 
dendritic Ca2+, whereas SH-SY5Y cells contain smaller amounts of tau and may, 
therefore, respond more readily to Aβ (Eva-Maria Mandelkow, personal 
communication). Excitotoxic increases in Ca2+ that are associated with NMDAR 
overactivation are characterized by prolonged, irreversible elevations in Ca2+. 
However, the Ca2+ elevations in SH-SY5Y cells did not follow this pattern, instead 
showing a series of diminishing transients not previously characterized in this cell 
type, that suggest processes which may follow from or protect against acute Ca2+ 
dysregulation. Further studies would be required to uncover these mechanisms 
and could, for example, investigate receptor internalization and recycling in 
excitotoxic conditions (Waxman et al., 2007). Furthermore, as calpain proteolytic 
activity has shown to cause cytoskeletal degradation in response to Aβ here 
(section 4.2.3), it may have been worth determining whether the cytoskeletal 
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structures degraded by calpain included membrane portions containing Ca2+-
permeable receptors or channels.  
Finally, the findings reported in section 4.2.15 and earlier work performed in this 
group suggest that TRPM2 Ca2+ gating is important in shaping the dysregulated 
Ca2+ response to Aβ. This could be further investigated either by overexpression 
of functional TRMP2 channels in primary neurons or transfecting them with a C-
terminally truncated isoform of TRPM2 which inhibits Ca2+ influx and 
excitotoxicity  (Zhang et al., 2003). Equally, genetically manipulating NCX3 
expression in neurons would confirm whether calpain-mediated cleavage and 
loss of NCX3 function (described in Chapter 3) mediates the calpain-dependent 
Ca2+ accumulation induced by Aβ in section 4.2.15.  
 
4.3.7 Conclusions 
The findings presented in this chapter suggest that Aβ neurotoxicity in primary 
neurons involves calpain-mediated degradation of the cell cytoskeleton, synaptic 
degeneration, increased activation of tau kinases and tau phosphorylation, 
apoptotic caspase signalling and Aβ accumulation. In SH-SY5Y cells, Aβ may 










The limited efficacy of NMDAR antagonists, such as memantine, in preventing 
excitotoxic neurodegeneration in AD patients (Lipton, 2004) and clinical stroke 
models (Ikonomidou and Turski, 2002) suggests the involvement of additional 
Ca2+ influx pathways. Oxidative stress occurs early in AD, alongside alterations in 
intraneuronal Ca2+, and is acknowledged to contribute to neuronal death during 
AD progression (Halliwell, 2006). Studies show that soluble Aβ oligomers cause 
neuronal insults by directly binding intraneuronal metal ions and lipoproteins, 
leading to generation of ROS, energy depletion, mitochondrial dysfunction and 
apoptosis (Su et al., 2008). This process results in increased expression of BACE1 
and PS1, which sequentially metabolise APP to yield Aβ, thereby promoting 
further Aβ production and neurotoxicity (Mouton-Liger et al., 2012; Oda et al., 
2010). Of interest for this research, experiments in primary neurons have shown 
that oxidative stress-induced DNA damage triggers activation of nuclear PARP-1, 
which belongs to a family of 17 enzymes that play multiple roles in cytoskeletal 
regulation, cell division and cell viability (Luo and Lee Kraus, 2012). PARP-1 is the 
major enzyme in this family that determines cell fate, depending on stress 
stimulus, by catalyzing repair of single and double stranded DNA breaks or 
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signalling apoptosis. PARP-1 uses nicotinamide adenine dinucleotide (NAD+) as a 
substrate to synthesize PAR, which are added to nuclear and cytoplasmic proteins 
during PARP signalling (Schreiber et al., 2006).  
Substantial evidence suggests that PARP activity is aberrantly increased in AD, 
and that it signals apoptosis in response to Aβ-induced oxidative stress (Love et 
al., 1999; Abeti et al., 2011; Strosznajder et al., 2000; Wang et al., 2010). For 
example, exposure of aged rat hippocampus to Aβ oligomers upregulates PARP 
activity by 80 %, causing depletion of NAD+, mitochondrial respiratory stress and 
release of apoptosis inducing factor (AIF) from mitochondrial pores inserted by 
PAR (Strosznajder et al., 2000). PAR has also been shown to be directly 
neurotoxic, and to contribute to NMDAR-dependent excitotoxicity in cortical 
neurons (Andrabi et al., 2006). In addition, aging of APP and PS1 mutant mice is 
associated with accumulation of PAR (Abeti et al., 2011), and both PAR and PARP 
immunoreactivity is increased in post mortem AD cortex (Love et al., 1999). In the 
experiments described here in section 4.2.15, pharmacological inhibition of PARP 
was found to attenuate neural Ca2+ elevations that are elicited by oligomeric Aβ. 
This data further suggests that oxidative stress induced by Aβ may trigger 
downstream Ca2+ dyshomeostasis through PARP upregulation.  
Recently, a new non-selective Ca2+-permeable channel, TRPM2, was found to 
mediate neuronal death in response to oxidative stress (McNulty and Fonfria, 
2005a; Perraud et al., 2003). TRPM2 belongs to family of heat-sensitive TRP 
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channels that are widely expressed in the CNS, in both neurons and glia. The 
primary physiological activator of TRPM2 is ADPR, which is proteolytically 
cleaved from PAR by PARG, leading to PAR accumulation in the cytoplasm (Blenn 
et al., 2011). ADPR binds to the Nudix hydrolase moiety of TRPM2, causing 
opening of the channel pore and entry of Ca2+ along an electrochemical gradient 
(Naziroǧlu, 2011). TRPM2 is also gated by intracellular Ca2+, which accumulates 
following Aβ activation of NMDARs (section 4.2.15) and ADPR-stimulated Ca2+ 
release from the ER (Naziroǧlu, 2011). Therefore, PARP-induced activation of 
TRPM2 channels may play a role in Aβ-induced Ca2+ dysregulation and 
neurotoxicity in AD. Indeed, TRPM2 is reported to contribute to Aβ-induced 
oxidative stress induced in striatal neurons (Fonfria et al. 2005), and suppressing 
TRPM2 function prevented Aβ-induced increases in neuronal Ca2+ and rescued 
cell death (Fonfria et al., 2005). TRPM2 activation has also been shown to activate 
caspases and induce translocation of mitochondrial AIF to the nucleus in response 
to PARP-1, thereby triggering apoptosis (Blenn et al., 2011). Despite efforts to 
establish the importance of the PARP-TRPM2 pathway in AD, there is as yet no 
evidence of TRPM2 alterations in AD brain and further studies are required to 
determine the relationship between PARP-TRPM2 signalling and other 
degenerative mechanisms in AD.  
The aims of the current chapter were to determine if 1) There are alterations in 
PARP or TRPM2 protein expression during the progression of AD, 2) Aβ-induced 
neurotoxicity is mediated by PARP hyperactivity, 3) TRPM2 expression is altered 
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in response to PARP upregulation or Aβ treatment and 4) PARP mediates Aβ-
induced changes in tau phosphorylation.  
 
5.2 Results 
Post mortem tissue from control and AD brain was first used to examine changes 
in PARP and TRPM2 expression at different stages of AD. To investigate the 
contribution of PARP-TRPM2 signalling to Aβ neurotoxicity, the synthetic PARP 
inhibitor SB750139 was used to block PARP activity in primary cortical cultures 
treated with soluble oligomers of human Aβ1-42. The effect of PARP inhibition on 
mechanisms shown to be induced by Aβ, including calpain activation, PAR 
synthesis and tau phosphorylation, were studied using immunocytochemistry 
and immunoblotting with antibodies against proteins of interest. The effect of 
PARP inhibition on Aβ-induced neurotoxicity was determined using a cell death 
assay.  
 
5.2.1 PARP cleavage is increased in moderate and late stages of 
AD  
PARP-1 is known to orchestrate different types of cell death, including apoptosis, 
necrosis and parthanatos, during which it is differentially cleaved by suicide 
proteases such as caspases and calpains (Chaitanya et al., 2010). Cleavage of 
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PARP-1 by these proteases generates characteristic fragments, which serve as 
signatures of different modes of cell death, and can also provide insight into 
signalling cascades activated during neurodegeneration (Chaitanya et al., 2010; 
O’Brien et al., 2001). Animal and cell models of AD feature activation of both 
apoptotic and necrotic pathways prior to neuronal loss (Behl, 2000), and PARP-1 
activity has previously been shown by immunohistochemistry to be increased in 
AD brain (Love et al., 1999). It was therefore of interest to characterize PARP-1 
amounts and cleavage at different stages of AD. Importantly, this would also 
provide an insight into the cell death mechanisms involved in the development of 
AD.  
Post mortem brain homogenates from control brains and those from different AD 
Braak stages (II-VI) were immunoblotted with an antibody against PARP-1, which 
detects intact PARP-1 at 116 kDa and an 89 kDa caspase- and cathepsin-cleaved 
fragment, which is generated during apoptosis (Fig. 5.1A). These PARP species 
were detected here, along with additional bands at 75 kDa, characteristic of PARP-
1 cleavage by cathepsins during necrosis, and 100 kDa, which has not been 
characterized in literature and may indicate non-specific binding of the antibody. 
Blots were also probed with an antibody against NSE, which was used to control 
for protein amounts in each sample. Since the levels of the75 kDa PARP-1 
fragment were not sufficiently intense to allow quantification, this fragment was 
excluded from quantitative analysis. Full-length PAPR-1 (116 kDa) and the 
apoptosis-related PARP-1 fragment (89 kDa) were separately quantified as a 
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proportion of NSE. This quantification revealed no significant difference in the 
amounts of full-length PARP-1 in any AD stage compared to control (Fig. 5.1B). 
The 89 kDa PARP-1 fragment was not detected in control or early (Braak II-III) 
AD brain (Fig. 5.1A, C). In contrast, amounts of the 89 kDa PARP-1 fragment were 
significantly increased in moderate stage (Braak IV; p < 0.01), and further 
increased in end stage disease AD brain homogenates (Braak V-VI; p < 0.001) 
when compared to control samples (Fig. 5.1C).  
These findings of increased cleaved PARP in moderate to late stages of AD but not 
in early disease, suggest that caspase-dependent apoptotic cell death is induced 
in later AD stages. These findings may be related to the accumulation of Aβ1-42 
that was also found to accumulate in moderate to late stages of AD (section 3.2.6). 
The 89 kDa C-terminal catalytic subunit of PARP-1 generated by caspase cleavage, 
shown here to be increased during AD progression, has previously been found to 
inhibit PARP-1 activity and PAR synthesis in multiple studies (D’Amours et al., 
2001; Boulares et al., 1999; Chaitanya et al., 2010; Cohen, 1997). Thus, these 
findings are inconsistent with evidence of increased PARP activity in AD brain 
(Love et al., 1999) and in rat striatal neurons undergoing apoptosis in response to 
Aβ (Fonfria et al., 2005). Thus, the role of PARP-1 in AD appears to be complex 

















5.2.2 TRPM2 expression is unaltered in AD brain  
 
TRPM2 is a non-selective Ca2+-permeable channel that is activated in response to 
PARP-1 and that confers susceptibility to cell death in models of AD (McNulty and 
Fonfria, 2005a; Fonfria et al., 2005; Miller, 2004). TRPM2 channels are widely 
Fig. 5.1 PARP-1 is progressively cleaved throughout AD development by caspases 
and cathepsins.  (A) Representative immunoblots of post mortem homogenates from 
control and Braak II-VI AD brains. Blots were probed with an antibody against 
poly(ADP)ribose polymerase (PARP-1), detecting holoprotein at 116 kDa, caspase- 
and cathepsin- cleaved PARP-1 at 89 kDa, and  cathepsin- and calpain-cleaved PARP-
1 at 75 kDa. Blots were also probed with an antibody against NSE to control for 
protein loading. Bar graph shows amounts of (B) PARP-1 holoprotein and (C) 
caspase- and cathepsin- cleaved (89 kDa) PARP-1, with all bands normalised to NSE. 
CTRL: control (n = 7), Braak II: early AD (n = 4), Braak III: early AD (n = 3), Braak IV: 
moderate AD (n = 4), Braak V: advanced AD (n = 3), Braak VI: severe AD (n = 4). Data 




expressed in the CNS, although their expression pattern and function are poorly 
understood. It is also, so far, unknown whether TRPM2 expression is altered in 
response to or triggers neurodegenerative processes in AD. Studies in human 
bone marrow, monocytes and other immune cells have identified a naturally 
occurring short TRPM2 splice variant (TRPM2-S) which lacks the entire C 
terminus of the channel, including the channel pore (Zhang et al., 2003, 2006). 
This TRPM2-S variant is non-functional and exerts a dominant-negative effect on 
Ca2+ gating by functional long TRPM2 variants (TRPM2-L) in vitro. The relative 
expression levels of the two TRPM2 variants, as well as the function of TRPM2-S, 
in neurodegenerative disease have yet to be investigated. Therefore, protein 
expression of both TRPM2-L and TRPM2-S was compared here in control and AD 
post mortem brain, including early Braak stages of AD.  
Post mortem lysates from control and end-stage (Braak stage VI) AD frontal 
cortex were immunoblotted with an antibody against functional TRPM2 (TRPM2-
L), which label the N-terminus of TRPM2 at 171 kDa, and also detects the short 
TRPM2 isoform (TRPM2-S) at 95 kDa (Fig. 5.2A). The antibody specific to TRPM2-
L also revealed multiple bands from 35 to 40 kDa in size, which may represent 
TRPM2 cleaved fragments. Blots were also probed with an antibody against NSE, 
for standardisation of protein amounts in each sample. Normalisation of the 
density of bands of each TRPM2 variant to NSE in the same sample and 
quantification of these results revealed no differences in protein amounts of 
TRPM2-L and TRPM2-S between control and end-stage (Braak stage VI) AD brain 
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(Fig. 5.2B). However, there was a visible increase in bands measuring 35 to 40 
kDa in AD samples when compared to control (Fig. 5.2A). TRPM2 fragments of 
this size have not been described in literature and were not shown in previous 
studies using these and other TRPM2 antibodies. Since these bands were 
consistently absent in control tissue, it is likely that they represent cleaved species 
of TRPM2 rather than non-specific binding of the antibody. There are no reports 
of TRPM2 cleavage; however, a related TRP channel, TRPML1, is known to 
undergo cathepsin-mediated cleavage in lysosomes under physiological 
conditions (Kiselyov et al., 2005). As TRPM2 is also localized to lysosomes 
(Sumoza-Toledo and Penner, 2011), it may also be subject to proteolysis by 
lysosomal enzymes. Moreover, elevated calpain activity in AD brain (shown here 
in Chapter 3) is thought to lead to lysosomal membrane rupture and dysfunction, 
which may involve cleavage of TRP channels, including TRPM2 (McBrayer and 
Nixon, 2013).However, although potentially interesting, it is not possible to 
determine if there is any functional relevance of these cleaved TRPM2 species and 
these bands were excluded from analysis. Since there were no apparent changes 
in the amounts of TRMP2-L or TRPM2-S in late stage AD brain, the amounts of 














5.2.3 Increased PARP-1 activity in primary neurons undergoing 
oxidative stress does not alter TRPM2 expression 
To gain some insight into potential roles of PARP and TRPM2 in AD, additional 
experiments were performed in cell cultures. Oxidative stress-induced DNA 
damage has been shown to upregulate activity of nuclear PARP-1 prior to cell 
death in a variety of disease models, including AD (Luo and Lee Kraus, 2012; 
Boesten et al., 2013; Love et al., 1999). Therefore, it was first important to confirm 
that PARP activity is increased in response to oxidative stress in rat primary 
Fig. 5.2 TRPM2 expression is not altered in end-stage AD brain compared to control. 
(A) Representative immunoblots of post mortem homogenates from control and end-
stage (Braak stage VI) AD brain. Blots were probed with an antibody against the N-
terminal portion of TRPM2, which detects both functional TRPM2-L holoprotein at 
171 kDa and non-functional TRPM2-S holoprotein at 95 kDa. The antibody also 
detected bands at 37-50kDa which may represent cleaved species of TRPM2. Blots 
were also probed with an antibody against NSE to control for protein loading. Bar 
graphs shows amounts of (B) TRPM2-L and TRPM2-S, with all bands normalised to 
NSE CTRL: control (n = 7), Braak II: early AD (n = 4), Braak III: early AD (n = 3), Braak 
IV: moderate AD (n = 4), Braak V: advanced AD (n = 3), Braak VI: severe AD (n = 7). 
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cortical neurons. It was also of interest to investigate whether expression of 
TRPM2, an effector of PARP-1, is altered in response to oxidative stress and 
elevated PARP-1 activity.  
Rat primary cortical cultures were briefly treated with H2O2, which is used to 
induce oxidative stress reminiscent of that which occurs in AD (Dávila and Torres-
Aleman, 2008) and cause deterioration of neuron health in primary cultures 
(Whittemore et al., 1995; Haraguchi et al., 2012). To confirm this, a cell death 
assay revealed significantly increased cell death in cultures exposed to 1mM H2O2 
for 1 h compared to vehicle-treated cells (p < 0.05; Fig. 5.4A). It was important to 
observe oxidative stress under neurotoxic conditions, as the role of PARP in Aβ 
neurotoxicity, which involves induction of oxidative stress, will be investigated in 
this chapter. Cultures were pre-treated for 3 h with the PARP inhibitor SB750139 
(SB), which was shown to abolish TRPM2-mediated Ca2+ influx in section 4.2.15. 
Following treatment, cells were washed, fixed and immunostained with 
antibodies specific for PAR and the N-terminal region of TRPM2, which recognizes 
both TRPM2-L and TRPM2-S variants (Fig.5.2A). Cells were also stained with the 
nuclear marker, Hoescht-33342. The staining protocol included a 
permeabilization step which ensured access of the antibody to its intracellular 









Fig. 5.3 Exposure of primary cortical cultures to H2O2 causes oxidative DNA damage and 
increased nuclear PAR immunoreactivity, which are reversed by PARP inhibition. (A) 
Neurons treated with vehicle (CTRL), 1 mM H2O2 for 1 h, which is used to stimulate 
oxidative stress in culture, and/or 1 µM of the PARP inhibitor SB750139 (SB) for 3 h 
were immunostained with antibodies against poly(ADP)ribose (PAR), the N-terminal 
portion of TRPM2 channels, and the nuclear stain Hoescht-33342. (B) X63 
magnification of Hoescht-positive nuclei was used to visualize nuclear fragmentation 
(white arrow). Scale bars are 75µm. n=8 
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Neurons exposed to H2O2 exhibited nuclear condensation and fragmentation (Fig. 
5.3B), indicative of reduced cell viability and cell death and consistent with 
previous observations in neurons during oxidative stress (Higgins et al., 2009). In 
addition, H2O2-treated neurons displayed significantly increased PAR 
immunoreactivity compared to control (p < 0.001), as measured by numbers of 
PAR-positive cells, indicating increased PARP-1 activation in response to 
oxidative stress. Pre-treatment of neurons with SB markedly reduced PAR 
accumulation, as expected (p < 0.001; Fig. 5.4B), and oxidative DNA damage-
associated nuclear fragmentation induced by H2O2 (Fig. 3.B). Interestingly, when 
applied on its own, SB visibly reduced PAR immunoreactivity compared to control 
(Fig. 5.4B), implying that PARP inhibition may be neuroprotective, even under 
basal conditions. Quantification of TRPM2 immunoreactivity using the ‘Measure 
RGB’ plugin in ImageJ revealed no alterations in TPPM2 expression with either 
H2O2 or SB treatment (Fig. 5.4C).  
These findings show that nuclear PARP-1 activity is upregulated during oxidative 
stress induced by H2O2, as evidenced by increased nuclear accumulation of PARP-
synthesized PAR. This findings is in agreement with previous reports (Luo and 
Lee Kraus, 2012; Szenczi et al., 2005). Reduction of nuclear PAR immunoreactivity 
by pre-treatment of cultures with SB indicates suppression of PARP activity by 
this compound, in line with previous evidence (Fonfria et al., 2005). TRPM2 
immunoreactivity in rat primary cortical neurons was found to be localized to 
neuronal somata and processes, as previously shown (Lee et al., 2013; Bai and 
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Fig. 5.4 Exposure of primary cortical cultures to a neurotoxic dose of H2O2 causes 
increased nuclear PAR immunoreactivity, which is reversed by PARP inhibition. 
Neurons treated with vehicle (CTRL), 1mM H2O2 for 1 h, which is used to stimulate 
oxidative stress in culture, and/or 1uM of the PARP inhibitor SB750139 (SB) for 3 h, 
were immunostained with antibodies against poly(ADP)ribose (PAR), the N-terminal 
portion of TRPM2 channels, and the nuclear stain Hoescht-33342. Bar graphs show (A) 
% cell death in cultures treated with vehicle or H2O2, and immunoreactivity of (B) PAR 
and (C) TRPM2 in cultures treated with control H2O2 and/or SB. Data is mean ± SEM. 
***p < 0.001. n=8 
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5.2.4 Increased PARP activity mediates Aβ-induced 
neurotoxicity in primary cultures without altering TRPM2 
expression 
It was important to next determine the effects of Aβ on PARP-1 activity and 
TRPM2 channel amounts and localisation. The data shown in this thesis has 
demonstrated that the PARP inhibitor SB suppresses Aβ-induced intraneuronal 
Ca2+ elevations (section 4.2.15), supporting the hypothesis that PARP-1 activates 
Ca2+-permeable TRPM2 channels through production of its primary physiological 
activator, ADPR (Blenn et al., 2011; Fonfria et al., 2005). In addition, TRPM2 
channels have been implicated in the pathways leading to  cell death in neurons 
undergoing oxidative stress (Kaneko et al., 2006) and following exposure to Aβ 
(Fonfria et al., 2005), which implies a vital role for PARP/TRPM2 channel 
signalling in AD. Therefore, PARP activity and its contribution to Aβ neurotoxicity 
in the cell model used here was investigated.  
Rat primary cortical cultures treated with Aβ +/- SB as described above were 
washed, fixed and immunostained with antibodies specific for PAR and the N-
terminal region of TRPM2, which recognizes both TRPM2-L and TRPM2-S 
variants (Fig. 5.5). Cells were also stained with the nuclear marker, Hoescht-
33342. The staining protocol included a permeabilization step which allowed 
access of antibodies to their intracellular protein antigen. Neurons treated with 
10 µM Aβ for 3 h showed higher numbers of fragmented nuclei, indicating 
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deterioration of culture health consistent with previous reports of Aβ-induced 
neurotoxicity in primary neuron cultures (Garwood et al., 2011, and observed in 
section 5.2.3). In addition, measurement of PAR-positive cells revealed that Aβ 
treatment significantly increased nuclear PAR immunoreactivity when compared 
to control cultures (Fig. 5,6A; p < 0.01). Aβ-induced elevations in PAR 
immunoreactivity were significantly reduced upon pre-treatment of cultures with 
1 µM SB for 3 h (p < 0.05; Fig. 5.6A). These findings indicate that Aβ upregulates 
PARP activity, as indicated by the accumulation of nuclear PAR, and that these 
effects are effectively reduced upon PARP-1 inhibition with the PARP inhibitor SB.  
In contrast, TRPM2 immunoreactivity was not altered by treatment with Aβ or SB 
when compared to control (Fig. 5.6B). Moreover, colocalization analysis using the 
Intensity Correlation Quotient plugin in ImageJ revealed no significant spatial 
correlation of PAR and TRPM2 signals (Fig. 5.6C), indicating that Aβ-induced 
upregulation of PAR signal does not alter TRPM2 expression in the same neurons. 
Cultures treated with SB showed decreased co-localization of PAR with TRPM2; 
however, this is due to a decrease of PAR signal intensity upon SB treatment of 
neurons, conditions where TRPM2 expression remained unaltered. SB appeared 
to protect from Aβ-induced neurotoxicity and to exert a neuroprotective effect on 
neuronal health under basal conditions when compared to control cultures (Fig. 
5.6A), consistent with the findings in section 4.2.3. Therefore, it was next of 
interest to determine if Aβ neurotoxicity could be rescued by PARP inhibition. A 
cell death assay, of cultures treated with Aβ +/- SB, using a fluorescent stain that 
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incorporates into dead cells,  revealed an almost 3-fold increase in neuronal death 
induced by Aβ (p < 0.05) was recovered by SB treatment to control levels (p <0.05; 
Fig. 5.6D). Treatment of cultures with SB alone reduced levels of death below 






Fig. 5.5 Exposure of primary cortical cultures to Aβ causes neuronal damage and 
increases nuclear PAR immunoreactivity, which is reversed by PARP inhibition. Neurons 
treated with vehicle (CTRL), 10 µM Aβ for 48 h, and/or 1 µM of the PARP inhibitor 
SB750139 (SB) for 3 h, were immunostained with antibodies against poly(ADP)ribose 
(PAR), the N-terminal portion of TRPM2 channels, and the nuclear stain Hoescht-33342. 

















The data presented above showing that increased PARP activity is found in 
cultures exposed to Aβ confirm that Aβ is a pro-oxidant and causes DNA damage. 
To support this, previous studies have shown that the induction of oxidative 
stress requires Aβ peptide oligomerization and a high (μM) concentration 
Fig. 5.6 Exposure of primary cortical cultures to Aβ causes increased nuclear PAR 
immunoreactivity and neurotoxicity, which are reversed by PARP inhibition. Neurons 
treated with vehicle (CTRL), 10 µM Aβ for 48 h and/or 1 µM of the PARP inhibitor 
SB750139 (SB) for 3 h, were immunostained with antibodies against poly(ADP)ribose 
(PAR), the N-terminal portion of TRPM2 channels, and the nuclear stain Hoescht-
33342. Bar graphs show (A) Intensity of PAR immunoreactivity, (B) Intensity of TRPM2 
immunoreactivity, (C) spatial correlation of PAR and TRPM2 and (D) Cell death, as 
assessed by live/dead assay, in cultures treated with Aβ and/or SB. Data are expressed 




(Iversen et al., 1995; Kontush, 2001), in line with the Aβ preparation and 
treatment protocol used here and previously reported by this group (Garwood et 
al., 2011; Atherton et al., 2014). The increase in PARP activity in response to Aβ 
observed here has been previously shown by this group and others (Fonfria et al., 
2005; McNulty and Fonfria, 2005b; Love et al., 1999), and supports a pathogenic 
role for PARP in AD. Moreover, the work presented in this thesis shows that 
inhibition of PARP activity with SB prevents Aβ-induced intraneuronal Ca2+ 
elevations in neural cells (section 4.2.15) and protects from Aβ neurotoxicity in 
primary neurons (Fig. 5.6D), in line with previous evidence (Abeti et al., 2011).  
Together, these findings suggest that PARP-mediated activation of TRPM2 
channels is likely a mechanism that contributes to neuronal death induced by Aβ.  
TRPM2 expression was not altered in response to Aβ-induced neurotoxicity, 
consistent with observations in neurons undergoing oxidative stress induced by 
H2O2. This suggests that TRPM2 expression is not altered in models of AD, and 
specifically that upregulation of TRPM2 may not be a mechanism that  contributes 
to increased TRPM2 channel activity, Ca2+ accumulation and toxicity seen in 
models of AD, as previously suggested by Xie et al. (2010).  
 
5.2.5 Aβ induces PARP activation in neurons and not astrocytes 
In AD post mortem cortex, PARP immunoreactivity and accumulation of PAR is 
predominantly localized to  neurons, although a small proportion of astrocytes 
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also show some immunoreactivity (Love et al., 1999). However, PARP is also 
reported to be upregulated in astrocytes in response to Aβ, causing mitochondrial 
metabolic failure which plays a key role in Aβ-induced neuronal death (Abeti et 
al., 2011; Tang et al., 2010). This suggests that mechanisms of Aβ neurotoxicity 
may involve induction of oxidative stress in astrocytes and resultant astrocytic 
PARP hyperactivity. Therefore, it was important to investigate astrocytic PARP 
activity in these cultures in response to Aβ.  
Primary cultures treated with vehicle or 10 µM Aβ for 3 h were immunostained 
with antibodies against the astrocyte-specific marker glial fibrillary acidic protein 
(GFAP), PAR and were labelled with the nuclear stain Hoescht-33342 (Fig. 5.7A). 
Cultures treated with Aβ showed PAR immunoreactivity, consistent with results 
in sections 5.2.3 and 5.2.4, while control cultures did not exhibit any signal above 
background, as previously reported (Abeti et al., 2011).  High magnification (X63) 
of labelled cells showed that PAR-positive nuclei do not colocalize with astrocytic 
nuclei (Fig. 5.7B), indicating that Aβ causes PAR accumulation in neurons and not 
astrocytes. These findings are inconsistent with previous evidence of astrocytic 
PAR accumulation in cortical astrocytes co-cultured with hippocampal neurons 
which were exposed to lower concentrations of  Aβ (Abeti et al., 2011), although 
the PAR immunoreactivity detected in these experiments was predominantly 
cytoplasmic. In addition, astrocytes show higher PAR immunoreactivity than 
neurons in post mortem spinal cord tissue from patients with amyotrophic lateral 
sclerosis - a related neurodegenerative disorder (Kim et al., 2003).  However, 
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these findings are consistent with many other reports of nuclear PAR 
accumulation in neurons in primary culture.  
 
Fig. 5.7 PAR immunoreactivity in primary cortical cultures exposed to Aβ is localized 
to neurons. (A) Neurons treated with vehicle (CTRL), or 10 µM Aβ for 48 h were 
immunostained with antibodies against poly(ADP)ribose (PAR), astrocytic glial acidic 
fibrillary protein (GFAP), and the nuclear stain Hoescht-33342. (B) Higher 
magnification (X63) of neurons was used to visualize co-localization between PAR-




In addition, the neural cell localisation of TRPM2 was examined following 
immunohistochemical labelling of control cultures with antibodies specific to 
astrocytes (GFAP), neurons (MAP2) and TRPM2 (Fig 5.8). These preliminary 
experiments suggest that TRPM2 is predominantly localized to neurons in 
primary culture, since TRPM2 was detected in cells also labelled with MAP2 more 
readily than those labelled with GFAP (Fig. 5.8) which suggests that PARP-
mediated TRPM2 signalling is more dominant in neurons, at least in the age of rat 
primary cortical cultures (10 DIV) used for these experiments. It is likely that 
variations in model systems, Aβ preparations, age of neurons and treatment times 
could account for the contradictory results obtained in the current study and 
others (for instance, treatments with 5 µM Aβ25-35 by Abeti and colleagues 
(2011) for 1 h as opposed to 10 µM Aβ1-42 for 3 h here.  
 
5.2.6 PARP does not mediate Aβ-induced tau phosphorylation 
Aberrant activation of TRPM2 by upon increased activity of PARP-1 has been 
suggested to contribute to Aβ neurotoxicity in animal and cell models of AD (Abeti 
et al., 2011; Fonfria et al., 2005; Xie et al., 2010). However, the downstream effects 
of PARP-TRPM2 signalling remain to be fully understood. In the model systems 
used here, Aβ-induced Ca2+ elevations were dependent on PARP-mediated 
neuronal Ca2+ influx (section 4.2.15), which is likely to lead to activation of 
calpain-1 (section 4.2.3), which could promote neurotoxic tau phosphorylation. 
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Tau is a requirement for Aβ-mediated toxicity in cultured neurons (Rapoport et 
al., 2002) and tau hyperphosphorylation and/or caspase cleavage of tau is well 
established to be important in neurodegeneration in AD (Noble et al., 2013). It 
was therefore of interest to determine the calcium-activated signalling pathways 






Fig. 5.8 TRPM2 channels are primarily localized to neurons in the current cell system. 
Control cortical cultures were immunostained with antibodies against astrocytic 
astrocytic glial acidic fibrillary protein (GFAP), neuronal microtubule-associated 
protein 2 (MAP2) and TRPM2. High magnification (X63) of cultures was used to 
visualize co-localization of TRPM2 with MAP2-positive neurons (white arrows) and 
GFAP-positive astrocytes (yellow arrows). Scale bar = 75 μm. n=4  
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Lysates from primary neurons treated with Aβ +/- SB were next immunoblotted 
with antibodies detecting total tau, independent of phosphorylation state (DAKO), 
which detects bands at approximately 55 kDa, tau phosphorylated at the AD-
relevant epitope Ser396/404 (PHF1) and which labels bands at 55-61 kDa, and 
tau dephosphorylated at Ser199/202/Thr205 (tau-1) which labels species of tau 
at approximately 55 kDa (Fig. 5. 9A). Blots were also probed with an antibody 
against β-actin for standardization purposes. Following standardization of total 
tau (DAKO) amounts to β-actin in the same sample, and the amounts of tau 
phosphorylated at PHF1 to total tau (DAKO) amounts, quantitative analysis 
revealed no changes in total tau amounts (Fig. 5.9B) or tau phosphorylated at 
PHF1 (Fig. 5.9C) following treatment with Aβ and/or SB relative to controls. In 
contrast, Aβ-treated cultures showed significantly reduced amounts of 
dephosphorylated (Tau-1) tau (p < 0.05), indicating tau phosphorylation at these 
sites in response to Aβ treatment. However, Aβ-induced phosphorylation at 
Ser199/202/Thr205 was not reduced upon pre-treatment of cultures with SB 
(Fig. 5. 9D). These results suggest that the capacity of SB to reduce Aβ-induced tau 
phosphorylation is limited. Recently, a calpain-cleaved 17kDa N-terminal tau 
fragment has been reported to be generated after Aβ treatments in neurons (Park 
et al., 2005; Nicholson and Ferreira, 2009; Ferreira and Bigio, 2011). This 
fragment may be toxic to cells (Nicholson and Ferreira, 2009), although its 





















Fig. 5.9 PARP does not influence tau phosphorylation in cultures treated with Aβ. (A) 
Representative immunoblots of lysates from neurons treated with vehicle (CTRL), 
10µM Aβ for 48 hours, 1µM of the PARP inhibitor SB750139 (SB) for 3 hours, or SB 
alone. Blots were probed with antibodies against total tau, independent of 
phosphorylation state (DAKO), which yields bands around 55 kDa in size, tau 
phosphorylated at the AD-relevant epitope Ser396/404 (PHF1), which yields bands 
from 55 to 61 kDa, and tau dephosphorylated at Ser199/202/Thr205 (tau-1), which 




labels tau dephosphorylated at Ser202/205 has previously been found by this 
laboratory to detect calpain-cleaved tau under certain conditions. However, 
scanning of tau-1 immunolabelled membranes at high intensity did not detect this 
fragment in the lysates of the cells treated here. Therefore, it can be concluded 
that the protective effects of PARP-1 inhibition that were found in the 
experiments described in this chapter are likely not related to tau-associated 
neurodegeneration in response to elevated Aβ concentrations. The mechanisms 
of PARP-1/TRPM2-mediated neuronal toxicity in Aβ treated cultures requires 
further investigation since it may represent a novel target for developing new AD 
therapeutics that have the capacity to modify disease course. 
 
5.3 Summary and Discussion 
 
The main findings of this chapter are: 
• Caspase-dependent PARP cleavage occurs in moderate to late AD brain  
• TRPM2 expression is not altered in severe AD brain when compared to 
control, however, TRPM2 is likely to be degraded in moderate to late-stage 
AD brain  
• PARP activity is upregulated in neurons undergoing H2O2-induced 
oxidative stress and following Aβ treatment 
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• Inhibition of PARP activity protects from H2O2-  and Aβ-induced neuron 
death 
• Aβ-induced PARP activation is localized to neurons and not astrocytes 
• PARP-TRPM2 signalling does not influence Aβ-induced tau 
phosphorylation in primary neurons 
 
5.3.1 Aβ-induced neurotoxicity involves upregulation of PARP-
TRPM2 signalling 
 
In this chapter, exposure of primary neurons to Aβ resulted in neuronal death, 
confirming previous experiments (Chapter 4). Here, the data show that Aβ-
induced neurotoxicity is associated with an upregulation of PARP activity 
neuronal, as evidenced by accumulation of nuclear PAR in neurons (section 5.2.6). 
Inhibition of PARP activity by treatment of neurons with SB-750139 rescued 
neurons from Aβ-induced neurotoxicity (section 5.2.6), which is associated with 
decreased calpain activation (section 5.2.6) and attenuation of Aβ-induced 
TRPM2 channel mediated Ca2+ elevations in neural cells (section 4.2.15). These 
cell culture-based findings suggest that PARP-1/TRPM2 may play an important 
role in Aβ-induced degenerative pathways and these data were complemented by 
observation of increasing PARP-1 cleavage by apoptotic caspases in moderate to 
late stage AD brain (section 5.2.1). Expression of functional (TRPM2-L) and non-
functional (TRPM2-S) TRPM2 isoforms were unaltered in AD brain (section 5.2.2) 
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and in neurons undergoing oxidative stress induced by H202 or following Aβ 
treatment (sections 5.2.3 and 5.2.4). 
Plentiful evidence supports a role for PARP in Ca2+ signalling and AD. PARP 
activity and PARylation (attachment of PAR polymers onto target proteins) are 
required for long-term memory (Cohen-Armon et al., 2004; Wang et al., 2012), 
which is known to be governed by Ca2+ dynamics in dendritic spines (Berridge, 
2014). In addition, a deficiency in PARP-1 is associated with aging (Piskunova et 
al., 2008), which is also characterized by altered Ca2+ homeostasis in numerous 
models (Thibault et al., 2007; Oh et al., 2013; Nikoletopoulou and Tavernarakis, 
2012). Furthermore, PARP-1 is known to regulate many transcription factors that 
are involved in modulating the function of Ca2+  handling proteins and Ca2+ pumps 
in myocardial cells (Szenczi et al., 2005), and PARP-1 is activated under 
excitotoxic conditions in a type of PARP-mediated cell death, termed parthanatos 
(Wang et al., 2010).  
Of particular relevance for this work, PARP-1 activity is increased as a result of 
oxidative stress, which is promoted in aging (Boesten et al., 2013) and is triggered 
by Aβ in AD (Su et al., 2008; De Felice et al., 2007). In primary neurons exposed to 
Aβ, oxidative stress-induced DNA damage activates PARP-1 and activates 
downstream TRPM2 channels to cause dysregulated Ca2+ accumulation (Fonfria 
et al., 2005). Importantly, TRPM2 signalling occurs prior to, and is shown to be 
required for, neurodegeneration in multiple studies (Zhang et al., 2003; McNulty 
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and Fonfria, 2005b; Kaneko et al., 2006; Fonfria et al., 2005). Together, these 
findings support the current work, which shows that PARP-1 is upregulated by Aβ 
and mediates Aβ neurotoxicity in primary neurons. Moreover, the attenuation of 
Aβ-induced Ca2+ increases by treatment of cells with SB (section 4.2.15) suggests 
that PARP mediates neuronal death through TRPM2-mediated Ca2+ influx. Indeed, 
TRPM2 also appears to be required for increased NMDAR signalling induced by 
H2O2 in guinea pig midbrain slices (Lee et al., 2013). This implies a key role for 
TPRPM2 in oxidative stress and excitotoxicity, both of which occur in AD and 
feature TRPM2 activation (Takahashi et al., 2011; Xie et al., 2010). Therefore, the 
upregulation of PARP-1 observed here in response to H2O2 and Aβ is likely to be 
indicative of TRPM2 activation in these conditions. 
The above findings are supported by observations of increased caspase-3-
mediated PARP cleavage products in post mortem brain tissue from individuals 
with different stages of AD. Caspase-3 activation and proteolytic cleavage of PARP 
is a hallmark feature of apoptosis (Chaitanya et al., 2010), and therefore could 
indicate progressive brain atrophy at these stages, although this cannot be stated 
with any certainty due to the limited area of tissue examined in this work. The 
increased caspase-mediated proteolysis of PARP-1 was found to occur in parallel 
with the accumulation of toxic and pro-aggregatory Aβ1-42 into neuritic plaques 
in these samples (section 3.2.6), and supports the much discussed hypothesis that 
Aβ triggers neurodegenerative processes in AD (Hardy and Higgins, 1992).  
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PARP cleavage by caspases is featured as an important step in the apoptotic 
cascade, and is preceded by activation of PARP, which itself signals caspase 
activation and release of mitochondrial AIF. Therefore, caspase-mediated PARP 
cleavage in moderate to late AD tissue serves as indirect evidence of PARP 
activation at these stages. While TRPM2 protein expression was not altered in AD 
brain compared to control, caspase cleavage of PARP may also indicate increased 
TRPM2 signalling, as TRPM2 channels are shown to activate caspases prior to 
apoptosis in endothelial cells (Sun et al., 2012).  
 
5.3.2 Aβ selectively upregulates neuronal PARP activity in 
primary neurons 
 
In this chapter, H202 and Aβ treatment of primary cortical cultures resulted in 
accumulation of PAR in nuclei, indicating that these treatments cause activation 
of PARP-1. PAR immunoreactivity in Aβ-treated primary cortical cultures was 
localized to neuronal nuclei, and was not present in astrocytic nuclei. This was 
associated with significantly increased cell death, and both nuclear PAR 
accumulation and cell death were rescued by pre-treatment of cells with the 
PARP-1 inhibitor, SB-750139. These findings suggest that Aβ neurotoxicity is, at 




There is a discrepancy between the current findings and some previous 
observations in AD brain and cell models of AD. In AD cortical sections, PARP and 
PAR immunoreactivity was mostly detected in small pyramidal neurons in 
laminae 3 and 5 (Love et al., 1999). However, the authors also reported occasional 
PAR-labelling of GFAP-positive astrocytes, although the exact proportion of 
astrocytes expressing PAR was not given. Moreover, astrocytes and microglia 
surrounding plaques show high inducible nitric oxide synthase, which is 
indicative of oxidative activation (Akama and Van Eldik, 2000), and Aβ triggers 
oxidative stress in both types of glia via production of ROS (García-Matas et al., 
2010; Schilling and Eder, 2011). In a study by Abeti et al. (2011), Aβ1-42 and 
Aβ25-35 treatment of hippocampal neurons co-cultured with cortical astrocytes 
resulted in predominantly neuronal death, which was associated with 
upregulation of PARP-1 in astrocytes. The increase in astrocytic PARP-1 activity 
was triggered by oxidative stress resulting from Aβ-induced depletion of 
astrocytic nicotinamide adenine dinucleotide phosphate oxidase (a mitochondrial 
substrate) and subsequent loss of mitochondrial membrane potential. This was 
accompanied by rises in astrocytic Ca2+, which might imply PARP-mediated 
activation of TRPM2 channels in astrocytes, although this is not examined by 
these authors. Whether TRPM2 is expressed in astrocytes is disputed, and the 
neural cell localisation of TRPM2 has been shown to vary between brain regions 
(Xie et al., 2010). Nevertheless, TRPM2 activation was found to confer necrosis 
and swelling of primary astrocytes induced by ammonium toxicity in a recent 
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study (Sai et al. 2013). When taken together, evidence of TRPM2 expression in 
astrocytes, Aβ-induced upregulation of astrocytic PARP and resultant Ca2+ 
elevations in astrocytes suggests that an astrocytic PARP-TRPM2 pathway may 
also play a role in Aβ neurotoxicity. On the other hand, expression of TRPM2 was 
previously shown to be predominantly found in  neurons here (Section 5.2.5) and 
by others (Bai & Lipski 2010).  
The lack of astrocytic PAR signal in Aβ-treated primary cultures in the current 
study, which is in disagreement with some previous reports, may be explained by 
experimental inconsistencies between laboratories, such as different Aβ 
incubation periods. Abeti et al. (2011) observed an increase in cytoplasmic 
astrocytic PAR immunoreactivity approximately 8 h post Aβ treatment, whereas 
here cultures were examined for PAR signal after 3 h, and the PAR signal was 
predominantly nuclear. It is possible that astrocytic responses to Aβ occur prior 
to neurons; for instance, preliminary experiments in this group have shown that 
Aβ elevates astrocytic Ca2+ prior to large elevations in neuronal Ca2+ (Atherton et 
al. unpublished). This was also seen in early experiments in rat forebrain cultures, 
where stimulation of astrocytes caused an elevation of Ca2+ that propagated from 
astrocyte to astrocyte, and triggered increases in cytosolic Ca2+ in neighbouring 
neurons (Nedergaard, 1994). Indeed, astrocytic Ca2+ signalling was later shown to 
induce Ca2+ responses in neurons, either through propagation of signal through 
gap junctions or release of transmitters such as glutamate (Verkhratsky and 
Kettenmann, 1996). Furthermore, exocytotic release of glutamate from astrocytes 
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requires elevation of astrocytic Ca2+, and is in turn required for stimulation of 
neuronal NMDARs, which raise neuronal Ca2+ (Parpura et al., 2011).  It is also 
possible that differences in model systems between studies could account for the 
contradictory observations here and in the literature. For instance, astrocytes 
only comprise approximately 17 % of total cells in the current model, whereas 
previous studies show PARP activation in cultured astrocytes (Abeti et al., 2011) 
and AD brain (Love et al., 1999), where the phenotype of the astrocyte population 
is likely considerably different. Indeed, astrocytes in the hippocampus and 
entorhinal cortex display different Ca2+ responses to Aβ, which may in turn 
differentially affect PARP (as proposed in section 4.3.4).  
 
5.3.3 Limitations to this work 
 
There are several limitations to the work carried out in the current chapter that 
are worth mentioning. First, it would have been interesting to compare PARP and 
PAR immunoreactivity in post mortem brain sections from control and Braak II-
VI AD brains, so as to further previous studies by Love et al. (1999) and investigate 
any changes in PARP activity and expression during the progression of AD 
(similar to the studies in Chapter 3). Second, aside from PARP, PARG also plays a 
role in TRPM2-mediated Ca2+ influx as it catalyzes hydrolysis of PAR into ADPR 
monomers prior to their translocation to the nucleus and activation of TRPM2 
channels (Blenn et al., 2011; Andrabi et al., 2006). Immunoblotting of post 
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mortem control and AD tissue or primary cortical cultures with an antibody 
specific to PARG would have provided further insight into the role of PARG in AD 
progression and Aβ-induced neurotoxicity. These analyses were attempted; 
however, the commercial antibodies purchased against PAR, PARP-1 and PARG 
showed limited detection of proteins in post mortem homogenates or rat cortical 
lysates. Another way of determining the contribution of PARG activity to Aβ 
neurotoxicity and TRPM2-mediated Ca2+ signalling would have been to treat 
primary neurons with a PARG inhibitor and observe changes in PAR synthesis, 
Ca2+ dynamics and cell death. For instance, Andrabi et al. (2006) showed that 
knockdown of PARG in neurons made them more sensitive to NMDAR-mediated 
excitotoxicity compared to wild-type cultures, and mice overexpressing PARG 
showed reduced infarcts following focal ischaemia.  
Emerging evidence suggests a role for neuroinflammation in PARP-TRPM2 
signalling, and vice versa, in AD. PARP-1 activity is shown to activate 
inflammation-related genes, including inflammatory cytokine 1 (IL-1) and 
tumour necrosis factor α (TNFα; Ba and Garg, 2011). These pro-inflammatory 
factors were shown to stimulate neuronal PARP and TRPM2 activities and 
subsequent Ca2+ elevations in response to Aβ in preliminary experiments in this 
group (Atherton et al., unpublished) and others (Fonfria et al., 2006; Zhang et al., 
2003). Furthermore, these neuronal effects were preceded by increases in 
astrocytic Ca2+ and changes in astrocytic morphology. It is, therefore, important 
to consider the role of neuroinflammatory processes in Aβ-induced PARP-TRPM2 
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signalling and neurotoxicity. Future work could determine whether soluble 
inflammatory factors released from astrocytes contribute to alterations in AD-
related mechanisms in neurons (e.g. calpain activation and tau phosphorylation) 
through elevations of TRPM2-mediated Ca2+ in neurons.  
The inhibition of PARP by SB was found to prevent Aβ-induced Ca2+ elevations in 
neural cells (section 4.2.15), suggesting an important contribution of TRPM2 
channels in shaping cellular responses to Aβ. This could be confirmed by direct 
pharmacological inhibition of TRPM2 using commercially available TRPM2 
antagonists, such as flufenamic acid and clotrimazole (CLA). However, these 
agents are not specific to TRPM2 and show cell-specific efficacy; for example, CLA 
does not block ADPR-activated TRPM2 in rat hippocampal neurons (Naziroǧlu, 
2011). Furthermore, these agents are difficult to utilize as they are lipophilic and 
irreversible. The use of TRPM2-L and TRPM2-S clones to modulate TRPM2 
function in transfected cells is another approach to directly determine the role of 
TRPM2 in neuronal Ca2+ signalling. In addition, electrophysiological studies have 
shown that PARP inhibition does not prevent TRPM2 activation by ADPR, as ADPR 
is also produced by mitochondria (Naziroǧlu, 2011), and this is worth further 
exploration. Finally, further studies could investigate the role of TRPM7, a close 
relative of TRPM2 channels, in Aβ-induced neurotoxicity and Ca2+ elevations as 
this channel has higher Ca2+ permeability than TRPM2 and is also involved in 
apoptosis induced by oxidative stress (Yamamoto et al., 2007). Unfortunately, 
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time restrictions meant that it was not possible to complete these additional 




In summary, the results presented in this chapter describe a pathway by which 
Aβ induces PARP-1 activity, resulting in cell death through a pathway not 
involving aberrant phosphorylation or cleavage of tau. Further experiments may 
identify the precise mechanisms of cell death involved in these events, and may 
find further evidence in support of PARP-1 inhibitors as novel neuroprotective 
agents for the treatment of AD. Since PARP-1 inhibitors are currently in clinical 
trials for some types of cancer, a successful outcome of these trials would mean 
that they are suitable for drug repositioning which may lead to an accelerated 













The main aims of this thesis were to investigate: 1) the association between Ca2+-
dependent pathways and neurodegenerative processes during the progression of 
AD, and 2) novel mechanisms contributing to Ca2+ dyshomeostasis in AD.   
The studies presented here corroborate the hypothesis that aberrant increases in 
Ca2+ occur early during the development of AD, features that can be replicated in 
cells. Moreover, the findings of this work suggest the involvement of novel 
signalling pathways that contribute to Ca2+ dysregulation and neurodegeneration 
in AD. In particular, increased activity of the Ca2+-activated cysteine protease 
calpain-1 was found to be a common feature of post-mortem AD and other 
neurodegenerative brain, and was associated with calpain-mediated cleavage and 
inactivation of NCX3 in end-stage (Braak VI) disease. The reduction of functional 
NCX3 by knockdown of NCX3 with antisense oligonucleotides was found to 
sensitize primary neurons to subtoxic concentrations of Aβ. Together, these 
findings suggest that aberrant activation of calpain and calpain-mediated 
degradation of functional NCX3 may be a mechanism that contributes to the toxic 
accumulation of intraneuronal Ca2+ in neurons in affected regions of AD brain.  
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An important finding was the presence of elevated active calpain-1 amounts in 
early (Braak II) AD brain, increases that were sustained throughout disease 
progression. The early increases in calpain-1 activity were associated with 
upregulation of the endogenous calpain inhibitor, calpastatin, and preceded 
activation of the prominent tau kinases cdk5 and GSK3, elevated tau 
phosphorylation and loss of synaptic markers. Moreover, the progressive 
increases in calpain-1 activity correlated with increased Aβ1-42 production and 
proteolysis of the cytoskeletal protein α-spectrin. Many of these events had 
previously been shown in isolation in cell or animal model studies, but this is the 
first direct evidence in support of this neurodegenerative cascade in human AD 
brain.  
In cell studies, increased calpain-1 activity resulted from prolonged Ca2+ 
elevations that were induced by oligomeric species of Aβ1-42, and neurotoxicity 
under these conditions was closely associated with activation of tau kinases, tau 
phosphorylation, loss of synaptic markers and altered APP processing. Increased 
PARP signalling and activation of TRPM2 channels was found to contribute to Aβ-
induced Ca2+ elevations and neurotoxicity, and this was supported by  evidence 
for altered PARP processing and signalling in AD brain. Again, there has been 
some previous evidence for PARP-1 involvement in AD, but to the best of our 
knowledge, this thesis provides the first evidence to link altered PARP signalling 
and Ca2 influx through TRPM2 channels in response to AD, with alterations in tau 
and neurotoxicity.  
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To summarise, the primary findings of this thesis are: 
• Calpain-1 activity is increased in early stages of AD and this is 
sustained throughout disease progression. Increases in active calpain-
1 protein amounts are associated with increased calpain-mediated 
proteolysis of α-spectrin and Aβ1-42 accumulation 
• Increased calpain-1 activity precedes increased tau kinase activity, 
tau phosphorylation and synaptic loss in AD. Aβ-induced neurotoxicity 
is dependent on calpain activation, tau phosphorylation and synaptic 
degeneration in primary neurons 
• Calpain-mediated NCX3 cleavage is a feature of end-stage AD brain 
and confers Aβ neurotoxicity. Calpain cleavage of NCX3 was a 
prominent feature of AD brain, but was not apparent in brain from a group 
of related neurodegenerative disorders. Knockdown of NCX3 causes 
neurotoxicity in primary neurons exposed to normally subtoxic 
concentrations of Aβ.  
• PARP hyperactivity mediates Aβ-induced neurotoxicity. Aβ induces 
abnormal Ca2increases in neural cells, which are abolished by blockade of 
Ca2 influx through TRPM2 ion channels using specific PARP inhibitors. The 
physiological relevance of this process is supported by evidence for 
altered PARP signalling in moderate to late AD brain, suggesting a 
neurodegenerative role for PARP/TRPM2 signalling in AD.  
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6.1 Ca2+ and calpain dyshomeostasis in AD 
6.1.1 Increased calpain signalling in AD 
Abnormal calpain activation occurs during conditions of prolonged intracellular 
Ca2+elevation, such as during excitotoxicity and Wallerian degeneration following 
neuronal injury (Nixon et al., 1994). In AD brain, increased calpain-1 and calpain-
2 activities are a consistent and prominent feature of diseased brain, and is 
associated with increased calpain-mediated proteolysis of key signalling and 
cytoskeletal proteins (Nixon et al., 1994; Nixon, 2003; Saito et al., 1993; Grynspan 
et al., 1997; Rao et al., 2008; Atherton et al., 2014). Interestingly, increased levels 
of active calpains were recently observed in CSF from AD patients, and positively 
correlated with Aβ1-42 levels and cognitive impairment in these patients (Laske 
et al., 2015). Increased proteolytic activity of calpain-1 and calpain-2 are also 
observed in double mutant APP and APP/PS1 mutant mice, which overproduce 
Aβ (Vaisid et al., 2007a; Trinchese, Liu, et al., 2008). This work supports these 
previous findings from post-mortem AD brain and transgenic mouse models of 
AD by demonstrating 1) elevated amounts of active calpain-1 and associated 
calpain-mediated cleavage of several calpain substrates in AD brain compared to 
controls, 2) a strong positive correlation between Aβ1-42 burden and calpain-1 
activity in AD brain, and 3) increased calpain-1 activity in Aβ-treated primary 
cortical neurons. Together, these results indicate a close association between Aβ 
production and elevated calpain activity.  
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However, elevated active calpain-1 amounts were also observed here in several 
other neurodegenerative tauopathies, which are not characterized by a 
prominent Aβ phenotype (Boeve, 2012; Wadia and Lang, 2007; Lee et al., 2001). 
Upregulation of calpain-1 in many of these disorders was previously reported 
(Adamec et al., 2002; Vosler et al., 2008), and is thought to either suggest the 
involvement of other mechanisms besides Aβ overproduction in 
neurodegenerative calpain signalling, or that calpain activation occurs 
independently from/upstream of Aβ accumulation. The results in this work 
favour the latter hypothesis, and extend previous studies by demonstrating that 
calpain-1 activity progressively increases from an early stage in AD development, 
prior to significant Aβ burden. Since calpain-1 is a Ca2+-activated protease, and is 
considered to be a good indicator of pathologically elevated intracellular Ca2+ 
levels, this finding suggests that changes in Ca2+ occur prior to early alterations in 
APP processing and Aβ accumulation in AD, as previously suggested by others 
(Buxbaum et al., 1994; Siman et al., 1990; Kyratzi and Efthimiopoulos, 2014). 
However, it is also possible that some Aβ species are present in early AD brain, 
and these were not detected by the methods used here. For instance, certain AD 
mouse models exhibit disruptions in Ca2+ homeostasis months before 
extracellular Aβ pathology is detected (LaFerla, 2002).  Moreover, AD brain shows 
a higher increase in calpain-1 activity than other neurodegenerative conditions 
studied here and in previous reports (Nixon, 2003; Atherton et al., 2014; Adamec 
et al., 2002), which suggests that some form of Aβ species may lie upstream of 
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calpain activation. Indeed, moderate and late stages of AD, which are 
characterized by Aβ1-42 overproduction, also show higher calpain-1 activity 
compared to earlier stages where tissue Aβ levels do not differ from controls. 
Moreover, in the cell systems used here, oligomeric Aβ peptides induce abnormal 
increases in neural Ca2+ and subsequent calpain-1 activation, in line with previous 
reports suggesting that calpain activation is downstream of Aβ in AD (Demuro et 
al., 2011; De Felice et al., 2007; Park and Ferreira, 2005).  
When considering the effects of Aβ production, it is important to also think about 
APP processing. The complex relationship between Ca2+ signalling and APP 
metabolism includes conflicting evidence on the role of calpain in Aβ production. 
Overproduction of Aβ in APP/PS1 mutant mice was shown to be associated with 
increased BACE-1 and calpain activities (Liang et al., 2010).  Liang et al. (2010) 
showed that treatment of primary neurons with Aβ, or overexpression of calpain 
in neurons, acted to increase BACE expression, enhanced APP cleavage and 
promoted Aβ secretion. This was prevented in APP/PS1 mice by overexpression 
of the endogenous calpain inhibitor, calpastatin, which led to a reduced Aβ plaque 
load. These findings suggest that Aβ begets further Aβ production in a positive 
feedback loop, via mechanisms that may involve activation of calpain-1 and 
increased BACE-mediated APP cleavage.  
In a cell-based study, primary neurons treated with Aβ demonstrated increased 
production and intracellular accumulation of endogenous Aβ (Dal Pra et al., 
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2011), again supports the hypothesis of a positive feedback loop of Aβ production. 
However, the role of calpain and APP secretases in this cell system was unclear, 
as expression of BACE was unaltered by calpain or Aβ, and the inhibitory effect of 
Aβ on α-secretase-mediated non-amyloidogenic APP processing was shown to be 
independent of calpain activity. Interestingly, Aβ treatment of cells was found to 
induce a calpain-dependent increase in expression of the γ-secretase component, 
nicastrin. Furthermore, suppressing calpain activity promoted non-
amyloidogenic processing of APP, although independently of Aβ treatment (Dal 
Pra, 2011). In another study, suppressing calpain activity in murine L cells 
increased C-terminal APP proteolysis and Aβ1-42 production, thereby indicating 
an inhibitory role for calpain in amyloidogenic APP processing (Mathews et al., 
2002). Taken together, these findings suggest that Aβ and calpain may 
differentially regulate APP processing, either in concert or independently of each 
other, and the precise effects may be dependent upon the particular model system 
used in additional to other experimental parameters. Further studies in 
transgenic animals or AD brain are required to determine the mechanisms of APP 
regulation at different stages of disease. Interestingly, amounts of APP 
holoprotein are observed to be elevated in early Braak stage AD brain in this 
work, which suggests that the activation of calpain-1 in these stages may act to 
inhibit C-terminal APP metabolism and Aβ production.  
Calpains are also implicated in the generation of pathological tau species, 
including abnormally phosphorylated and truncated tau, in multiple models of AD 
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(Ferreira, 2012; Jin, Yin, Yu, et al., 2015; Taniguchi et al., 2001). Active calpain-2 
is localized to ‘pre-tangle’ tau aggregates in AD brain (Grynspan et al., 1997), and 
activation of calpain-1 and -2 in APP/PS1 mutant mice is associated with tau 
phosphorylation and cognitive deficits (Liang et al., 2010).  Tau 
hyperphosphorylation in AD is causally linked to increased activity of several tau 
kinases, including GSK3, cdk5, mitogen-activated protein kinase (MAPK), DYRK1 
and extracellular signal-regulated kinases (ERK1/-2), which are activated either 
directly or indirectly by calpain (Goñi-Oliver et al., 2007; Taniguchi et al., 2001; 
Veeranna et al., 2004; Qian et al., 2013; Jin, Yin, Gu, et al., 2015). In the work 
presented here, activation of calpain-1 was required for cdk5 and GSK3 activation 
and increased tau phosphorylation induced by Aβ in cultured cells, in agreement 
with previous reports (Hung et al., 2005; Jin et al., 2015; Huang and Jiang, 2009). 
Furthermore, calpain-1 activation occurred prior to increased tau 
phosphorylation at an AD-relevant epitope (pSer396/404, PHF1) and the 
appearance of mature NFTs in AD brain (Chapter 3). Moreover, the increase in 
calpain-1 activity showed a strong positive correlation with activities of GSK3 and 
cdk5 in AD brain, as assessed by measurement of the inhibitory phosphorylation 
sites (Ser21/9) on GSK-3 α/β and the amounts of the neuronal cdk5 activators 
p35 and p25, relative to cdk5 levels. These findings support data from cell and 
animal model studies by suggesting that elevations in calpain activity in the early 
stages of AD progression mediate downstream tau phosphorylation through 
increasing the activity of important tau kinases, in agreement with previous 
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findings (Jin et al., 2015; Hung et al., 2005). Therefore, this work supports a causal 
link between early Ca2+ dysregulation, calpain activation and pathological changes 
in tau.  
Interestingly, despite both being activated by calpain-1, there were differences in 
the stage of disease at which increases in GSK3 and cdk5 activities were observed 
in AD brain. Activity of cdk5 was found to progressively increase in parallel with 
increasing calpain-1 activity, from an early (Braak III) stage in AD. In contrast, 
GSK3 activity was found only to be significantly increased in late (Braak V-VI) AD 
brain. The Cdk5 activator p25 was previously found to preferentially bind GSK3β 
in mouse neurons overexpressing GSK3, altering GSK3β substrate specificity to 
result in increased tau phosphorylation (Chow et al., 2014), independently of 
alterations in Ser21/9 phosphorylation. It is therefore possible, that the GSK3 
contributed to tau phosphorylation from an earlier stage of disease development, 
but this was not apparent through analysis of inhibitory GSK3 phosphorylation, 
as examined here. Conversely, mice overexpressing p25 show increased cdk5 
activity at a young age which is associated with a reduction in active GSK3 species, 
this effect resulting from increased phosphorylation of the inhibitory (Ser9) 
residue of GSK3β via the ErbB and downstream phosphatidylinositol 3-
kinase/Akt pathways (Wen et al., 2008). Notably, these p25 overexpressing mice 
exhibited reduced tau phosphorylation and increased Aβ production at young 
ages. Therefore, the late activation of GSK3 seen here in AD brain could be a result 
of negative regulation of GSK3 by cdk5 in earlier disease stages. This may also 
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explain why accumulation of Aβ in AD brain corresponds to cdk5 activation, 
whereas tau phosphorylation occurs alongside increased GSK3 activity in end-
stage AD brain. Since the cdk5 and GSK3 hypotheses of AD have mostly been 
studied in isolation, it has only been recently that evidence of a complex 
interrelationship between these two kinases has emerged (Engmann and Giese, 
2009). Furthermore, aside from GSK3 and cdk5 influencing each other’s activity, 
GSK3 is reported to reciprocally promote calpain activity in excitotoxic neurons 
(Crespo-Biel et al., 2010). This is also shown here in primary neurons, and 
indicates that the relative contribution of tau kinases and calpain to AD 
neurodegenerative pathways is very complex and not fully understood.   
Other tau abnormalities are linked with calpain activity in neurodegeneration. 
Tau aggregates are reported to contain N- and C-terminally truncated tau species, 
generated as a result of abnormal activation of calpain and other proteases 
(García-Sierra et al. 2008). Moreover, APP mutant mice known to exhibit cognitive 
and behavioural deficits are shown to contain physiologically acetylated, 
ubiquitinated and lysine methylated tau species (Morris et al., 2015). There is 
substantial evidence that these post-translationally modified tau species 
accelerate tau polymerization, induce neurotoxicity and positively correlate with 
severity of dementia in AD (Gamblin et al., 2003; Amadoro et al., 2004; Morris et 
al., 2015). Indeed, Aβ-induced activation of calpain-1 results in the generation of 
17 kDa tau species which leads to degeneration of neurites in hippocampal cells 
(Park and Ferreira, 2005). These 17 kDa tau fragments were also observed in AD 
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brain (Ferreira and Bigio, 2011), indicating that accumulation of calpain-cleaved 
tau species may be a neurodegenerative process induced by Aβ in AD. In another 
study, rat cortical neurons undergoing excitotoxicity displayed accumulation of 
35 kDa tau fragments that were also generated upon cleavage of tau by calpain 
(Liu et al., 2011). Interestingly, neither 17 kDa nor 35 kDa calpain-cleaved tau 
species were observed in AD brain or cultures exposed to Aβ in the current study. 
It is possible that the 17 kDa tau species reported by Park and Ferreira (2005) 
and Ferreiro and Bigio (2011) may actually be much smaller (as demonstrated by 
Garg et al., 2011a), for which reason they may have not been detected here. As 
Garg et al. (2011) also questioned the pathological relevance of these species by 
showing that they do not mediate Aβ toxicity in neural cells, this may suggest that 
calpain-cleaved truncated tau fragments of that size may not be a consistent 
feature of AD. Moreover, as similar tau species have been identified in other 
neurodegenerative conditions, such as CBD and FTD (Ferreira and Bigio, 2011), 
they are likely to represent a common neurodegenerative feature that is not 









6.1.2 CAST, synapses and neuroprotection in AD 
Calpain activity is endogenously regulated via its Ca2+-dependent tripartite 
binding by the native specific calpain inhibitor, CAST, which is closely associated 
with calpain intracellularly (Goll et al., 2003). In turn, CAST is subject to 
Fig. 6.1 The calpain hypothesis of AD. Prolonged elevations in intracellular Ca2+ 
concentrations, triggered by Aβ-mediated channel opening, receptor activation or 
membrane pore formation, lead to dysregulated activation of calpains. This in turn 
causes massive proteolytic cleavage of calpain substrates, including tau. Cleavage of 
tau kinases and pro-caspases leads to tau kinase and caspase activation, resulting in 
tau phosphorylation and truncation of tau into C-terminal toxic fragments, 
respectively. Both of these events are considered to promote tau aggregation, which 
leads to neuronal death. This is contributed to by caspase-dependent apoptotic 
signalling (Wray and Noble, 2009).  
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proteolytic inactivation by calpain and other calpain-activated proteases, 
including caspase-1 and -3. The ratio of functional CAST to calpain is an important 
factor in the control of calpain activity and this has been shown to be 
pathologically altered in various conditions, including AD (Vaisid et al., 2007). 
APP mutant mice exhibit diminished CAST and increased calpain-1 activity, and 
show increased calpain-dependent proteolysis in affected regions of AD brain 
such as the hippocampus and cortex (Vaisid et al., 2007). As CAST expression is 
physiologically lower in these areas compared to other brain regions such as the 
cerebellum (Vaisid et al., 2007), it is likely that calpain is therefore activated more 
readily by modest intracellular Ca2+ increases in these areas, where its aberrant 
activity contributes to AD neuropathology. Indeed, genetic deficiency of CAST or 
overexpression of calpain-1 were shown to augment Aβ production, tau 
phosphorylation, cognitive impairment and mortality in vivo, all of which was 
rescued by overexpression of CAST (Higuchi et al., 2012; Liang et al., 2010).  
The work presented here demonstrates that there is depletion of active CAST in 
the cortex of AD brain when compared to controls. The inactivation of CAST is 
closely associated with increased calpain-1 activity and severity of Aβ and tau 
pathology in these tissues. Similar findings have previous been reported in end-
stage AD brain (Nilsson et al., 1990; Rao et al., 2008). However, it was shown here 
that reduced CAST activity is also observed in other neurodegenerative 
conditions which lack Aβ pathology such as PSP and CBD. Therefore, such 
reductions of CAST activity are not always downstream of Aβ, but might result 
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from overactivation of calpain-1 via poorly understood mechanisms, and calpain-
mediated cleavage CAST. This would result in a reduction in the ratio of active 
CAST to calpain, further exacerbating calpain activity in neurodegenerative 
disease brain.  
The work presented here also investigated the regulation of CAST activity at 
different AD stages. The data revealed an initial increase in CAST activity in 
association with elevated calpain-1 activity in early-mid stage AD brain compared 
to control. The increase in CAST activity was temporary (limited to Braak stage 
III), and was followed by a progressive decline in active CAST amounts in brain 
from later stages of disease. Therefore, these early increases in CAST activity may 
represent a neuroprotective mechanism initiated in response to neural cell 
damage as a result of the pathological activation of calpain-1 in early AD, which is, 
in time, overcome as calpain-1 activity and calpain-mediated degradation of CAST 
increase above a certain threshold in later disease stages. In support of this idea, 
subtle alterations in neuronal Ca2+ regulation are observed early in transgenic 
models of AD, and these are hypothesized to be neuroprotective responses to 
early pathogenic changes in the brain, such as Aβ accumulation or increased 
neuronal excitability (Supnet and Bezprozvanny, 2010). For instance, 3xTg-AD 
mice show increases RyR-mediated ER release in the pre-symptomatic stages of 
disease at which time they exhibit normal synaptic activity (Chakroborty et al., 
2009). In addition, many animal models of AD exhibit neuronal hyperexcitability 
(e.g. Busche et al., 2008), and it has been proposed that early alterations in ER Ca2+ 
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handling may act to prevent excitotoxicity in these animals by depressing 
membrane excitability (Chakroborty et al., 2009). However, these early protective 
responses by cells fail to halt disease progression and the animals go on to develop 
cognitive dysfunction and AD-like neuropathology (Chakroborty et al., 2009). 
Therefore, it is possible that the upregulation of CAST seen in the work presented 
here in early-mid stage AD brain represents a compensatory response to 
abnormal calpain-1 activation by early - possibly neuroprotective - elevations in 
neuronal Ca2+. On the other hand, as CAST is normally activated during high 
cytosolic Ca2+, the increase in CAST activity in early AD brain may be a 
physiological response, which is independent of changes in calpain activity.  
It is also postulated that early compensatory changes in Ca2+ concentrations in AD 
neurons are only effective in protecting from cell death in the early stages of 
disease, and that these same responses may contribute to neurodegenerative 
cascades when they are sustained over the duration of AD progression (Supnet 
and Bezprozvanny, 2010; Maltsev et al., 2014). With this in mind, it is possible 
that the early increase in CAST activity observed here may have only been 
effective at protecting the CNS while levels of active calpain-1 were low enough to 
balance out CAST inhibitory activity. However, sustained increases in 
intraneuronal Ca2+ concentrations likely increased the ratio of active calpain to 
CAST, thereby increasing calpain-mediated proteolytic inactivation of CAST and 
stimulating further calpain activation in a vicious cycle. Indeed, brain from the 
terminal stages of AD features a more than 3-fold increase in calpain-1 activity, in 
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line with previous reports (Nixon et al., 1994). It is clear that further investigation 
into active CAST-calpain dynamics and downstream signalling events are 
required to determine their relative neurodegenerative roles throughout the 
development of AD. For instance, while calpains are shown to be co-localized with 
CAST and widely distributed in quiescent human 103H cells, stimulation of cells 
with Ca2+ ionophore causes redistribution of calpains to predominately plasma 
membranes, without affecting CAST localization (Goll et al., 2003). This suggests 
that calpain-1 overactivation may be at least in part due to the inability of CAST 
to directly interact with and inhibit calpains, which may explain the limited 
effectiveness of CAST upregulation in early AD brain.  
Increased protein expression of pre- and post-synaptic markers was observed 
here in early AD brain, and this may serve as further evidence that a 
compensatory response occurs in response to increased calpain-1 activity in the 
early stages of disease. Synaptic dysfunction is argued by many to occur during 
the prodromal stages of AD (Arendt, 2009), where it is thought to be promoted by 
early alterations in Ca2+ signalling and synaptic excitotoxicity  (Chakroborty, 
2012). Ca2+ influx can cause long-term changes in synaptic efficacy and plasticity, 
with abnormal increases in synaptic Ca2+ - for instance, as a result of insertion of 
Aβ pores - leading to diminished spine density, aberrant dendritic sprouting and 
synaptic dysfunction (Koffie et al., 2009). In addition, abnormal Ca2+ overload in 
neurites and deficits in synaptic integration observed in APP transgenic mice 
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were shown to be dependent on the presence of amyloid plaques (Kuchibhotla et 
al., 2008). 
However, aberrant Ca2+ regulation is also seen to occur prior to the development 
of substantial Aβ pathology in other transgenic mouse models of AD. For example, 
young 3xTg-AD mice display reduced hippocampal plasticity due to altered RyR-
mediated ER Ca2+ release (Parent et al., 1999). Several lines of evidence 
demonstrate that abnormal calpain activity could contribute to early Ca2+ 
dysregulation and synaptic dysfunction in AD. In AD brain, increased calpain-1 
activity causes increased degradation of protein kinase A, which is a positive 
regulator of cAMP-response element binding protein (CREB) - an important 
transcription factor in synaptic plasticity and memory (Liang et al., 2007). In 
hippocampal slices prepared from transgenic mice overexpressing mutant human 
APP and PS1, and in Aβ-treated hippocampal cultures, pharmacological inhibition 
of calpain activity rescued synaptic dysfunction and cognitive and memory 
deficits by preventing calpain cleavage of CREB (Trinchese, Liu, et al., 2008). 
These findings suggest that Ca2+-dependent synaptic abnormalities in AD may 
involve alterations in calpain activity and calpain-mediated degradation of key 
synaptic proteins. Several calpain substrates that are relevant for this process 
have been identified, including synapsin I (Khoutorsky and Spira, 2009) and 
NR2B (Simpkins et al., 2003), both of which are modulated by calpain to regulate 
synaptic activity. The calpain-dependent degradation of NR2B subunits of 
NMDARs is controlled by PSD95 in cortical neurons (Yuen et al., 2008).  
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Furthermore, Trinchese et al. (2008) have shown that immunoreactive clusters of 
synapsin-I, PSD95 and α-spectrin are increased during normal synaptic function 
and plasticity. Therefore, it is possible that the upregulation of synaptic proteins 
seen in this study in early-mid stage AD brain signifies accelerated protein 
synthesis and reduced turnover to compensate for 1) increased calpain-1 activity 
and degradation of these proteins and/or 2) Ca2+-dependent disruption of 
synaptic plasticity. In summary, it is possible that the transient upregulation of 
CAST and synaptic proteins that occur in parallel to increases in calpain-1 activity 
in early to mid-stage AD brain represent compensatory responses to dysregulated 
calpain proteolysis of key cellular proteins. These findings may also serve as an 
indication of early synaptic dysfunction at these disease stages, thereby 
corroborating the hypothesis that aberrant Ca2+ homeostasis and synaptic 
dysfunction occur in the prodromal stages of AD, prior to the development of 
substantial Aβ and tau pathology in AD (Chakroborty and Stutzmann, 2011; 
Selkoe, 2002). It is also important to consider that changes in calpain activity are 
triggered by pre-fibrillar or soluble species of tau or Aβ which are not routinely 
examined in AD brain. Soluble oligomeric species of both Aβ and tau are closely 
linked with synaptic and neuronal loss in models of AD (Welzel et al., 2014; 
Castillo-Carranza et al., 2015). In this work, loss of synaptic markers, in particular 
PSD95, is observed in late Braak stage AD brain, which also shows increased Aβ1-
42 burden, soluble tau and tau phosphorylated at PHF1. Therefore, these findings 
support previous studies by suggesting a link between Aβ, tau and synaptic loss. 
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The loss of synaptic markers did not significantly correlate with amounts of Aβ1-
42, total tau and phosphorylated tau in this study; however, this is likely due to 
the increase in synaptic protein numbers in early Braak stages.  
 
6.1.3 Calpain perturbs NCX3 function in AD 
The native NCX pumps - NCX1, NCX2 and NCX3 - are widely expressed in the brain, 
where they are predominantly localized to the cell surface and mitochondrial 
membranes of neurons, glia and endothelial cells (Gobbi et al., 2007). During 
conditions of abnormally high cytosolic Ca2+, such as during excitotoxicity, 
ischaemia or multiple sclerosis (Bano et al., 2005; Brustovetsky et al., 2010b; 
Kurnellas et al., 2007), NCXs clear excess Ca2+ by providing the major route of Ca2+ 
extrusion out of the cell, (1 Ca2+ in exchange for 3 Na+), and by sequestering Ca2+ 
into mitochondria stores (Wood-Kaczmar et al., 2013). Thus, the so-called 
‘forward’ mode of NCX ion exchange plays a critical role in maintaining neuronal 
and glial Ca2+ homeostasis and function (Parpura and Verkhratsky, 2012; 
Gleichmann and Mattson, 2011). During neuronal depolarization or conditions of 
high intracellular Na+, NCXs switch to ‘reverse’ mode to allow Ca2+ entry into the 
cell; this is also important for astrocytic release of glutamate and its utilization by 
neuronal synapses (Reyes et al., 2012). NCX3 undergoes proteolytic cleavage by 
calpains and caspases, which prevents binding of Ca2+ to the NCX Ca2+ regulatory 
domain and inactivates the exchanger (Bano et al., 2005, 2007).  In striatal and 
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hippocampal cell models of ischemia, calpain cleavage and inactivation of NCX3 
mediated glutamate-induced excitotoxicity and neuronal death (Bano et al., 2005; 
Brustovetsky et al., 2010a). In striatal cultures, cell death was rescued by 
overexpression of CAST or calpain-resistant NCX2; moreover, downregulation of 
NCX3 using NCX3 siRNA sensitized neurons to non-excitotoxic glutamate 
concentrations, resulting in lethal Ca2+  overload (Bano et al., 2005). Together, 
these findings indicate that abnormal calpain-mediated cleavage of NCX3 plays a 
pivotal role in excitotoxic neurodegeneration.  
As discussed above, calpains are overactive in post-mortem AD brain and in the 
brain of relevant AD models, where they are associated with the proteolytic 
degradation of multiple substrates. In a recent study, loss of NCX3 holoprotein 
was observed in AD parietal cortex compared to controls, suggesting that NCX3 
function is impaired in AD (Sokolow et al., 2011). Moreover, NCX3 knockout mice 
exhibit AD-like deficits in learning and memory, while primary cortical cultures 
obtained from these mice show reduced LTP, elevated neuronal Ca2+ 
concentrations and reduced Ca2+ clearance from neurons (Molinaro et al., 2011, 
2013). It was therefore hypothesized here that increased calpain cleavage and 
disruption of NCX3 function could contribute to neuronal Ca2+ overload and death 
in AD. In support of this hypothesis, increased generation of cleaved NCX3 
fragments was observed here in end-stage AD brain compared to control. These 
NCX3 fragments were characteristic of calpain and caspase cleavage, indicating 
that NCX3 degradation in AD results from direct calpain proteolysis, and likely 
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calpain-induced activation of proteolytic caspases (Nakagawa and Yuan, 2000). 
Interestingly, calpain cleavage of NCX3 was not increased in other 
neurodegenerative conditions such as PSP, CBD and FTD (Chapter 3), suggesting 
that calpain-mediated cleavage and inactivation of NCX3 exchangers is somehow 
selective to AD and may be casually linked to Aβ overproduction. Moreover, NCX1 
and NCX2 amounts were found to be unaltered in AD brain, suggesting that other 
Ca2+ transporters are not upregulated to compensate for loss of functional NCX3 
in AD.  
In addition, the generation of calpain-cleaved NCX3 species was found here to 
show a strong positive correlation with Aβ burden in AD brain, suggesting that 
NCX3 cleavage may mediate Aβ neurotoxicity or vice versa. Indeed, NCX3 
knockdown in neurons led to their susceptibility to normally subtoxic 
concentrations of Aβ, resulting in cell death. This was associated with prolonged 
neuronal Ca2+ elevations elicited by Aβ that were abolished in the presence of the 
calpain inhibitor calpeptin. These findings indicate that calpain-cleavage of Ca2+-
regulating proteins, such as NCX3, may contribute to neuronal Ca2+ responses to 
increased Aβ concentrations. When taken together, these findings suggest that 
calpain cleavage of NCX3 may occur downstream of Aβ and contribute to Ca2+ 
overload in AD. Since calpain is initially activated by high intracellular Ca2+, 
calpain cleavage of NCX3 could represent an additional step in the vicious cycle of 
Ca2+ dysregulation that occurs in AD whereby reduced clearance and therefore 
accumulation of excess cytosolic Ca2+ stimulates further calpain activation, 
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cleavage of NCX3 and sustains cellular Ca2+ overload.  Indeed, NCX3 function is 
reduced during aging (Michaelis et al., 1984), which together with progressive 
increases in neuronal Ca2+ with aging (Berridge, 2014), could mean that reduced 
Ca2+ clearance mechanisms increase neuronal susceptibility to excitotoxicity and 
neurodegeneration, particularly in the elderly. Perturbations in glial and neuronal 
Ca2+ are well documented in AD (Lim et al., 2014; Smith et al., 2005); therefore, 
the results of this work suggest that Aβ-induced calpain activation and cleavage 
of NCX3 is a novel mechanism that contributes to Ca2+ dyshomeostasis in AD.   
It is worth mentioning that NCXs may also be disrupted in AD by mechanisms 
other than increased proteolytic degradation. For instance, NCX3 protein 
amounts were shown to be reduced in AD parietal cortex, without evidence of 
increased proteolytic cleavage of NCX3 (Sokolow et al., 2011). The same authors 
demonstrated that NCX1, NCX2 and NCX3 co-localized with Aβ in synaptic 
terminals of AD tissue, suggesting a close association between NCXs and Aβ. 
Indeed, Aβ was found to directly interact with the extracellular hydrophobic loops 
of NCXs, and resulted in reduced forward mode NCX-mediated Ca2+ transport (Wu 
and Colvin, 1994). Furthermore, NCX3 expression is shown to be subject to 
specific downregulation via Ca2+-dependent binding of the transcriptional 
repressor DREAM (also known as calsenilin and KChIP3) to the NCX3 promoter 
(Naranjo and Mellström, 2012). Physiologically, DREAM corrects intracellular 
Ca2+ levels by inhibiting or promoting Ca2+ entry via L-VGCCs or NCX3. 
Overexpression of DREAM mRNA is a feature of AD brain, the cortex of APP 
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transgenic mice (APPSWE) and Aβ-treated primary neurons (Jo et al., 2004). The 
overexpression of DREAM has been shown to lead to apoptosis in cerebellar 
neurons, at least in part through suppression of NCX3 expression and 
perturbation of Ca2+ homeostasis (Gomez-Villafuertes et al., 2005). These findings 
suggest that DREAM overexpression in AD brain may account for reductions in 
NCX3 amounts, and therefore reduced NCX3 function, in AD brain.  
There is also some evidence that alterations in NCX function may be 
neuroprotective in AD. The observation of increased NCX1-3 isoforms by Sokolow 
et al. (2011) in Aβ-laden synaptosomal preparations of AD tissue, and increased 
NCX currents in plasma membrane vesicles extracted from AD cortex by Colvin et 
al. (1994), could signify compensatory responses to Aβ-induced inactivation of 
NCX-mediated Ca2+ transport in diseased brain. In a recent study using PC-12 
cells, early Ca2+ fluxes induced by Aβ1-42 led to calpain activation and cleavage of 
NCX3, generating a hyperfunctional form of the antiporter and increased reverse 
mode NCX currents (Pannaccione et al., 2012). This was paralleled by an 
increased Ca2+ content in the ER, and was suggested to protect cells from the 
detrimental effects of prolonged Aβ exposure, including depletion of ER Ca2+, ER 
stress and activation of apoptotic caspases. This adds further support to the 
hypothesis that rapid and early changes in intracellular Ca2+ concentrations and 
signalling in AD are neuroprotective. Since calpain-1 activity is shown here to be 
elevated in early stage AD brain, it is possible that these stages also feature 
cleavage of NCX3 into fragments that either 1) inactivate NCX-mediated Ca2+ 
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clearance or 2) generate neuroprotective NCX currents. Due to the experimental 
limitations of this study (section 6.2.5), the latter could not be further 
investigated.  
 
6.1.4 Therapeutic targeting of calpains and NCXs for AD 
The findings described in sections 6.1 and 6.2 suggest that modification of 
calpains and NCX activities, in particular calpain-1 and NCX3, could have 
therapeutic benefit for the treatment of AD - a possibility which is already avidly 
discussed in the literature (Rao et al., 2014; Annunziato et al., 2004; Getz, 2012; 
Noble and Herchuelz, 2007a). Multiple studies, including this work, have 
demonstrated that inhibiting calpain in cell models of AD rescues Aβ toxicity, 
through attenuation of several Aβ-induced mechanisms including prevention of 
protein degradation, excitotoxicity, tau phosphorylation, Aβ production and pro-
apoptotic caspase activation (Atherton et al., 2014; Liang et al., 2010; Park and 
Ferreira, 2005; Hung et al., 2005; Jin et al., 2015; Bano et al., 2007). Moreover, 
calpain ablation prevents similar neurodegenerative events in mouse models of 
AD including the 3xTg-AD line and strains of APP mutant mice that all have a well-
established AD-like phenotype (Trinchese, Fa et al., 2008; Liang et al., 2010; Getz, 
2012). As a result of genetic or pharmacological reduction of calpain activation, 
these mice display reduced Aβ secretion and plaque load, attenuation of 
neuroinflammation, and amelioration of synaptic and cognitive deficits. This 
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indicates that new neuroprotective strategies for the treatment of AD could 
involve targeting mechanisms upstream of calpain activation in AD (e.g. NMDAR 
activity, Aβ), calpains directly and/or signalling cascades activated downstream 
of calpain activation (e.g. caspase activation; Yildiz-Unal et al., 2015). The results 
of this work also support the hypothesis that calpain activation occurs early in AD, 
even prior to the deposition of Aβ in plaques and the induction of recognised 
neurodegenerative cascades. Therefore, detecting and targeting calpain activity 
during these early disease stages may also have potential as a biomarker for AD 
diagnosis or for tracking the effectiveness of preventative therapies. However, 
despite numerous attempts to develop effective calpain inhibitors, none have so 
far been approved for clinical use (Yuan, 2009). This is likely due to the lack of 
specificity of existing synthetic calpain inhibitors among other proteolytic 
enzymes which may not be involved in AD pathogenesis. Moreover, effective 
calpain therapy would require modification of calpain inhibitors to allow their 
passage through the blood brain barrier and, most importantly, the specific 
targeting of brain calpains (Saez et al., 2006). Furthermore, since calpains play 
numerous vital physiological roles in the CNS and periphery, such as synaptic 
regulation and cardiac and skeletal muscle function (Sorimachi and Ono, 2012; 
Wu and Lynch, 2006; Goll et al., 2003), efficacious calpain inhibitors may have 
serious on-target toxicity leading to many unwanted side-effects. A similar 
situation arose when trying to develop GKS3 inhibitors as AD therapies (Noble et 
al., 2013). Furthermore, several studies report increased Aβ production 
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(Mathews et al., 2002) and depressed synaptic activity (Khoutorsky and Spira, 
2009) in response to calpain inhibition, which would also be highly undesirable.  
Targeting NCXs for AD therapy may be even less feasible as any potential 
protective effects from their modulation will depend on the mode of operation 
(forward or reverse) that predominates. NCX mode is electrochemically driven by 
relative intracellular Ca2+ and Na+ concentrations, both of which are altered 
during normal physiological responses and in neurodegenerative diseases 
(LaFerla, 2002; Vitvitsky et al., 2012). However, the findings presented in this 
work, as well as in previous studies (Bi et al., 2012; Iwamoto and Kita, 2006; 
Brustovetsky et al., 2010a; Brittain et al., 2012), suggest that pharmacologically 
targeting NCXs may be of therapeutic benefit to AD and, therefore, warrant 
further investigation. The results demonstrated here in Chapter 3, and previous 
work by this group (Atherton et al., 2014; Sokolow et al., 2011), indicate that 
inactivation of forward mode NCX3 exchange by overactive calpain-mediated 
NCX3 proteolysis may, in part, contribute to Aβ-induced Ca2+ dysregulation in AD. 
In support of this, NCX3 knockout mice show AD-like cognitive and memory 
phenotypes, as well as disrupted regulation of neuronal Ca2+ homeostasis 
(Molinaro et al., 2011). These findings suggest that restoring forward mode NCX3 
function may be neuroprotective in AD. However, inhibition of upstream calpain 
activity to prevent NCX3 degradation may be more feasible than directly 
modulating NCX3 protein expression. Furthermore, as NCX3 transcription is 
regulated by the pro-apoptotic transcriptional repressor DREAM - which is 
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overexpressed in AD and downregulates NCX3 expression (Jo et al., 2004; Gomez-
Villafuertes et al., 2005) - another strategy for restoring normal NCX3 function in 
AD may be to block DREAM transcriptional repressor activity.  
Increased reverse mode NCX activity has been documented to pathologically 
increase intracellular Ca2+ in models of cardiac and neuronal ischaemia, multiple 
sclerosis and other excitotoxic conditions (Araújo et al., 2007; Gomez-Villafuertes 
et al., 2005; Noble and Herchuelz, 2007b). NCXs are known to switch to reverse 
mode in response to membrane depolarization and accumulation of high 
intracellular Na+, leading to Ca2+ entry into the cell. Neuronal hyperexcitability 
and abnormalities in Na+ regulation have been described in AD brain and animal 
models of disease (Supnet and Bezprozvanny, 2010; Vitvitsky et al., 2012).  
Therefore, it is possible that increased reverse mode NCX-mediated Ca2+ entry 
could be a pathogenic feature of AD and could therefore represent a potential 
therapeutic target. However, effective therapy would have to ensure high 
selectivity for a specific mode of NCXs, which may be possible by designing 
antibodies or biologics to specific conformations of the receptor. However, the 
vital physiological functions of NCXs would have to be maintained. While NCX1 is 
more common in cardiac and kidney cells, it is also implicated in AD 
neuropathology and increased LOAD risk (Sokolow et al., 2011; Bi et al., 2012). 
NCX2 and NCX3 are highly expressed in the CNS and could therefore be selectively 
targeted for AD treatment. In summary, the role, and hence therapeutic potential 
of targeting NCX isoforms in AD appears to be too complex to be seriously 
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considered. Any treatment would require a precise balance of effect against 
forward and reverse mode NCX activities so as to prevent serious detrimental 
effects.  
 
6.2 PARP and TRPM2 signalling in AD 
6.2.1 Mechanisms of PARP-mediated cell death in AD 
The PARP family comprises 17 nuclear and cytoplasmic enzymes that orchestrate 
a host of vital physiological functions, including DNA repair, genomic stability and 
cell fate (Schreiber et al., 2006). The importance of PARP to normal cell function 
and survival is demonstrated by its deficiency in the brain during aging - a process 
which is characterized by increased susceptibility of neurons and glia to DNA 
damage from oxidative stress, inflammation and metabolic stress (Piskunova et 
al., 2008; Bürkle et al., 2005; Altmeyer and Hottiger, 2009). In adult brain, 
moderate levels of oxidative DNA damage trigger activation of DNA-dependent 
PARP-1, which catalyzes repair of double and single stranded DNA breaks through 
NAD+-dependent addition of PAR polymers onto target nuclear proteins 
(PARylation; Luo and Lee Kraus, 2012). PARP-1 knockout mice exhibit 
hypersensitivity to DNA-damaging stimulants associated with reduced PARP-
mediated protein PARylation in the brain (Altmeyer and Hottiger, 2009), and the 
neuroprotective functions of PARP-1 are compromised in animal models of aging 
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(Bürkle et al., 2005). However, many neuropathological conditions, including 
aging, excitotoxicity, inflammation, ischemia and neurodegeneration, feature 
abnormally increased stimulation of PARP-1 and subsequent induction of cell 
death mechanisms (Boesten et al., 2013; Mandir et al., 2000; Chaitanya et al., 
2010; Ba and Garg, 2011; Strosznajder et al., 2000). The mechanisms by which 
PARP-1 differentially mediate neuronal death depends on the particular stress 
stimulus present as well as the metabolic status of the cell (Boulares et al., 1999; 
Berghe et al., 2010; Chaitanya et al., 2010). Multiple studies, including the work 
presented in this thesis, suggest that PARP-1 plays a critical role in mediating 
neuronal death in AD, through induction of both necrotic and apoptotic cell death 
cascades (Love et al., 1999; Fonfria et al., 2005; Abeti et al., 2011).  
Necrosis is  ‘accidental’ cell death, resulting from cellular damage and metabolic 
failure from oxidative insults (Golstein and Kroemer, 2007), and is observed in 
AD brain and models of AD-associated neurodegeneration (Behl, 2000). 
Immunohistochemical analysis of temporal and hippocampal tissue from 
terminal FAD patients bearing the PS1 E280A mutation shows morphological 
changes characteristic of necrotic cell death (Velez-Pardo et al., 2001), 
accompanied by severe plaque deposition, gliosis and NFTs. Moreover, Aβ is 
shown to induce both PARP activation, as shown here and in previous studies 
(Fonfria et al., 2005; Abeti et al., 2011), and necrotic cell death in PC-12 cells via 
activation of IL-1β converting enzyme (Suzuki, 1997). Therefore, these findings 
suggest that PARP-mediated necrosis can be a downstream effect of Aβ 
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accumulation in AD. Increased PARP-1 activity can also lead to necrosis upon 
depletion of the PARP substrate, NAD+, which requires excess consumption of 
cellular ATP for resynthesis, thereby leading to deficits in the available energy for 
remaining cellular functions (Ha and Snyder, 1999). Necrosis can also be initiated 
by dysregulated activation of cellular proteases, including cytosolic calpains and 
caspases and lysosomal cathepsins (Liu et al., 2004, 2009). Differential cleavage 
of PARP by proteases is reported to be an integral initiating step in necrotic and 
apoptotic cascades, and is therefore used experimentally to differentiate between 
these types of cell death (Table 6.1; Chaitanya et al., 2010).  
In the data presented in this thesis, increased proteolytic cleavage of PARP-1 was 
observed in moderate to late stage AD brain, suggesting a potential role for PARP-
1 in mediating the neuronal loss that occurs as AD progresses. Moreover, the 
fragments generated from full-length PARP-1 were 89 kDa, indicating caspase-3-
/7- and cathepsin-B/-D cleavage, and 75 kDa - characteristic of cathepsin-G and 
calpain-1 cleavage, suggesting that a range of proteolytic enzymes are increased 
in AD brain. In support of this, age-related depletion of lysosomal and autophagic 
activities is link with programmed neuronal necrosis in LOAD, and is shown to be 
driven by calpain-mediated cleavage of lysosomal compartments to release 
proteolytic cathepsins (Yamashima, 2013).  The findings here may therefore 
provide further support to previous publications reporting the activation of 
necrotic cell death pathways in AD (Velez-Pardo et al., 2001; Suzuki, 1997; Behl, 
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2000; Yamashima, 2013), and the involvement of several proteases for protein 
degradation in AD.  
Calpains and caspases are also key mediators of apoptosis – programmed cell 
death that can be triggered by PARP in cases of irreparable oxidative DNA damage 
(Nakagawa and Yuan, 2000; Behl, 2000; Porter and Jänicke, 1999; Scovassi and 
Poirier, 1999; Boulares et al., 1999). Cleavage and inactivation of PARP-1 by 
caspases, and therefore inhibition of DNA repair, is important in preventing cell 
survival, and is considered to be a hallmark of apoptosis in these circumstances 
(Kaufmann et al., 1993). It is possible, therefore, that the increased generation of 
presumed caspase- and calpain-cleaved PARP species observed in this work in 
moderate to late stage AD brains may be indicative of apoptotic cell death in these 
samples. Previous findings have shown that caspase-3 cleavage of PAPR-1 is an 
important regulator of early synaptic dysfunction in AD (D’Amelio et al., 2011). 
However, the activity of caspase-3, as determined by measurement of cleaved 
caspase-3 species, was not globally altered here in any stage of AD brain when 
compared to control. This is in agreement with previous findings that only 
‘exceptional’ neurons label with antibodies against active caspase-3 in AD brain 
(Jellinger and Stadelmann, 2000). Moreover, PARP cleavage products were not 
observed in early stage AD brain, although it is possible that the amounts of these 
cleavage fragments may have been below the detection threshold in these 
samples. Thus, it is possible that an increase in apoptotic cell death seen here 
during progression of AD - as suggested by generation of calpain-cleaved species 
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- may have occurred independently of caspase-3. Indeed, PARP-1 has been widely 
shown to play a pivotal role in a caspase-independent form of apoptosis, termed 
‘parthanatos’ (Wang et al., 2009, 2010).  This involves PAR polymer-mediated 
release of mitochondrial AIF and its translocation to the nucleus, which results in 
DNA fragmentation and neuronal death (Wang et al., 2009). PARP-dependent 
accumulation of nuclear AIF is observed in cerebral slice cultures treated with Aβ, 
suggesting that parthanatos may be important for Aβ neurotoxicity (Adamczyk et 
al., 2005). Although it was not possible to study AIF protein amounts or 
localization here in either AD brain or Aβ-treated neurons due to time restraints, 
Aβ and H2O2 neurotoxicity was found to be associated with DNA fragmentation, 
which suggests that Aβ-induced oxidative DNA damage may have triggered AIF 
and PARP-dependent parthanatos in these cultures.  
Table 6.1 lists the proteolytically generated PARP fragments that are relevant to 
this work. 
 
6.2.2 Mechanisms of Aβ-induced activation of PARP-1 
Aβ has been shown to induce astrocytic and neuronal PARP-1 activation in animal 
and cell models of AD (Fonfria et al., 2005; Abeti et al., 2011; Strosznajder et al., 
2000); however, the mechanisms by which Aβ activates PARP-1 are not fully 
understood.  Multiple studies have demonstrated that Aβ induces oxidative DNA 







and astrocytes (Canevari et al., 2004; De Felice et al., 2007; Fonfria et al., 2005). 
These observations are corroborated by the current study, which shows that Aβ 
neurotoxicity features DNA fragmentation and accumulation of nuclear PAR - a 
marker of increased PARP activity. These effects were also observed here in H2O2-
treated neurons, which could therefore suggest that Aβ-induced increased in 
PARP-1 activity are mediated by induction of oxidative stress responses. Indeed, 
oxidative DNA damage is considered as the primary trigger of PARP activity. 
Consistent with this, the activity of PARP and oxidative stress markers are 
reported to be significantly elevated in APP mutant mice which display 
Table 6.1 Describing the cleavage products of PARP. PARP is subject to differential 
proteolytic cleavage by caspases, calpains and cathepsins during apoptotic and 
necrotic cell death. Generation of 89 and 75 kDa PARP fragments was observed here in 
AD brain, potentially implicating both necrotic and apoptotic mechanisms of cell death 
in AD. It is worth noting that PARP is also subject to cleavage by granzymes and matrix 
metalloproteases; however, characteristic PARP fragments generated by the action of 
these proteases were not observed in AD brain in this work (adapted from Chaitanya 
et al., 2010) 
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substantial Aβ over-production and develop amyloid pathology in old age, and in 
end-stage AD brain (Butterfield et al., 2001, 2010; Abeti et al., 2011; Love et al., 
1999). Moreover, Butterfield et al. (2001) and others (Wang et al., 1999; McLean 
et al., 1999) have demonstrated that oxidative damage to DNA, neuronal lipids, 
and other proteins markers, are directly related to the presence of Aβ plaques, 
and also show strong positive correlations with soluble Aβ amounts. Therefore, 
Aβ-induced oxidative DNA damage is likely to be the primary cause of increased 
PARP-1 activity in AD. 
Aβ-induced oxidative DNA damage and cell stress is proposed to occur through 
activation of neuronal and astrocytic NADPH oxidase, phospholipase A2 (Simonyi 
et al., 2010; Abeti et al., 2011) and nitric oxide synthase (Kim and Koh, 2002), as 
well as redox reactions between Aβ peptides and cellular transition metals, in 
particular Cu2+ (Su et al., 2008). The resultant generation of ROS and H2O2 
disrupts cellular metabolism and causes DNA damage, which in turn triggers the 
activation of PARP-1. Of interest, Cu2+ dyshomeostasis has been widely observed 
in AD models as a correlate of oxidative stress (Eskici and Axelsen, 2012); 
therefore, it could be an important factor in PARP-1 signalling in AD.  
There is substantial evidence to implicate oxidative stress pathways in PARP-1 
mediated cell death. Treatment of mouse embryonic fibroblasts with H2O2 induces 
nuclear translocation of c-Jun-N-terminal kinase 1 (JNK1) and JNK1-mediated 
phosphorylation of PARP-1, followed by activation of parthanatos and cell death 
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(Zhang et al., 2007). Since Aβ neurotoxicity is associated with the activation of tau 
protein kinases such as GSK3 and cdk5 (Chapter 4; Zempel et al. 2010; Town et al. 
2002), it may be interesting to investigate whether these kinases are also involved 
in the activation of PARP-1, which may reveal a novel neurodegenerative cascade 
in AD. In partial support of this idea, GSK3 is reported to phosphorylate and 
activate nuclear tankyrases - a family of PARPs involved in spindle assembly 
during mitosis (Yeh et al., 2006). On the other hand, tau kinases are possibly more 
likely to stimulate PARP-1 activation indirectly; for example, through GSK3-
mediated activation of calpain-1 (Crespo-Biel et al., 2010), or signalling 
downstream respiratory stress and oxidative DNA damage (Brustovetsky et al., 
2010a).  
Importantly, Aβ oxidative DNA damage and subsequent PARP-1 overactivation 
appears to be important for Aβ-induced Ca2+ dyshomeostasis and neurotoxicity, 
since inhibition of PARP-1 by SB750139 here, and in previous studies (Atherton 
et al. unpublished; Fonfria et al., 2005; Vosler et al., 2009; Abeti et al., 2011), 
prevented abnormal Ca2+ elevations and neuronal death. Therefore, targeting Aβ-
dependent mechanisms of PARP-1 activation may represent a promising 




6.2.3 The role of PARP-mediated TRPM2 activation in Aβ 
excitotoxicity  
Oxidative stress has been shown to induce Ca2+ dyshomeostasis through aberrant 
PARP signalling (Aarts and Tymianski, 2005; Uttara et al., 2009; Mattson, 2002). 
Increased PARP activity leads to accumulation of nuclear PAR, which is in turn 
hydrolysed by PARG into free ADPR and translocated to other cellular 
compartments (Blenn et al., 2011). Binding of free ADPR in the cytosol to the C-
terminal cytoplasmic Nudix motif of the neuronally expressed TRPM2 channel 
(Peraud et al., 2001; Fonfria et al., 2004) is believed to be the most potent 
physiological activator of this non-selective and redox-sensitive cation channel 
(Fig. 6.2; Naziroǧlu, 2011; Sumoza-Toledo and Penner, 2011). ADPR-mediated 
prolonged activation of TRPM2 channels then allows dysregulated influx of Ca2+ 
(Xie et al., 2010; Naziroǧlu, 2011). Considerable research has implicated PARP-
TRPM2 signalling in excitotoxic Ca2+ elevations in AD. Fonfria et al. (2005) have 
shown Aβ and H2O2 mediate cell death in rat striatal cultures endogenously 
expressing TRPM2. Transfection of cultures with the dominant negative TRPM2 
isoform, TRPM2-S, which blocks TRPM2 function (Zhang et al., 2003),  prevented 
Aβ-induced increases in intracellular Ca2+  and neurotoxicity in these cultures.  
The same was observed when cultures were transfected with siRNA targeting 
TRPM2, which reduced TRPM2 mRNA levels and uncontrolled Ca2+ fluxes. 
Treatment of striatal neurons with the PARP inhibitor SB750139 also prevented 
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Aβ- and H2O2-induced excitotoxic Ca2+ elevations and cell death in this culture 
model.  Therefore, increased PARP-mediated TRPM2 activation appears to play a 
key role in Ca2+- mediated neuronal death that is triggered by Aβ- and H2O2-









Figure 6.2 PARP-1 mediated TRPM2 channel opening leads to cell death. Aβ 
interaction with intracellular transition metals causes generation of reactive oxygen 
species, such as superoxide radicals (O2-) which reacts with constitutive nitric oxide 
(NO), generating peroxynitrite (PN). PN causes DNA damage, which activates the 
nuclear DNA repair enzyme, PARP-1. PARP-1 utilizes nicotinamide adenine 
dinucleotide (NAD+) to catalyze polymerisation of PAR with nuclear target molecules. 
PAR is in turn hydrolysed by PARG into free ADPR, which in the cytoplasm activates 
plasma membrane TRPM2 channels by binding to the Nudix (Nu) moiety of TRPM2. 
Activation of TPRM2 causes channel opening and entry of Ca2+ into the cell. Prolonged 
activation of PARP and TRPM2 leads to accumulation of cytosolic Ca2+ and activation of 
calpain-1 and caspases, which further disrupt intracellular Ca2+ regulation to result in 
excitotoxicity and cell death(adapted from Park et al., 2014).  
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The work presented in this thesis confirms and extends these previous findings 
by showing that prolonged Ca2+ elevations induced by Aβ in neural cells are 
abolished by pre-treatment of cells with the PARP inhibitor SB750139. 
Interestingly, SB750139 did not appear to affect the initial Aβ-induced Ca2+ 
increase, which occurs within 60 seconds of treatment, but was effective in 
preventing subsequent elevations in Ca2+ that are seen to occur within 10 min of 
Aβ treatment. This profile of Ca2+ flux was not observed when cultured were pre-
treated with inhibitors of NMDARs, calpains and caspases prior to application of 
Aβ - all of these agents significantly reduced the initial Aβ-elicited Ca2+ peak. It is 
therefore plausible that PARP and TRPM2 could be activated downstream of 
NMDAR-mediated induction of calpain and caspases during the initial phase of 
intracellular Ca2+ increases, and that they then contribute to the sustained Ca2+ 
elevations that are recognised to be required for neuronal death (Brustovetsky et 
al., 2010a; Brittain et al., 2012). On the other hand, activation of TRPM2 in human 
monocytes was previously shown to activate caspases and result in cleavage of 
PARP (Zhang et al., 2006). Moreover, increased TRPM2-mediated cytosolic 
accumulation is likely to trigger further calpain-1 activity and downstream 
signalling cascades that would lead to calpain-mediated cleavage of many 
important regulatory proteins (Chapter 4). It is therefore possible that aside from 
increasing Ca2+ influx, TRPM2 may also 1) mediate neuronal death through 
caspase-dependent or caspase-independent apoptotic signalling, 2) further 
increase NMDAR-induced calpain-1 activity or 2) prevent further activation of 
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TRPM2 through caspase-mediated cleavage and inactivation of nuclear PARP in 
AD. The latter may be suggested here by evidence of increased generation of 89 
kDa caspase-cleaved PARP fragments in moderate and severe AD brain. However, 
protein expression of both functional and inactive (TRPM2-S) TRPM2 isoforms 
were unchanged in AD brain compared to control. Therefore, further 
investigation in cell and animal models of AD is required to ascertain the 
mechanisms by which PARP-TRPM2 signalling leads to neurodegeneration in AD.  
Importantly, several studies have shown that activation of PARP and TRPM2 is 
important in glial inflammatory responses in AD. Perturbations of glial Ca2+ 
homeostasis and signalling are widely described in AD (Lim et al., 2014; Grolla et 
al., 2013; Alberdi et al., 2013; Verkhratsky et al., 2010), are shown to be induced 
by Aβ (Atherton et al. unpublished; Grolla et al. 2013; Abramov et al. 2004; 
Kuchibhotla et al., 2009), and involve activation of glial PARP and metabolic 
disruption (Abeti et al., 2011; Kauppinen et al., 2011).  For instance, microglial 
PARP activity was shown to be important for Aβ-mediated microglial activation 
in double transgenic APP mutant/PARP knockout mice and in Aβ-treated mixed 
microglial and neuronal cultures (Kauppinen et al., 2011). This group has also 
shown that Aβ-induced activation of astrocytes leads to neuronal increases in tau 
phosphorylation and neuronal death through the action of astrocyte-secreted 
inflammatory cytokines and chemokines (Garwood et al., 2011). Moreover, Aβ-
induced astrocytic secretion of TNFα was shown to be vital for Aβ toxicity and 
PARP-mediated neuronal Ca2+ overload (Chao and Hu, 1994; Boulares et al., 
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2001). Therefore, the influence of glia in Aβ-induced neurotoxic Ca2+ overload 
cannot be discounted.  
The primary cortical cultures used in this work contain negligible numbers of 
microglia (Chapter 4 and Garwood et al. 2011); therefore, it is unlikely that any 
Aβ mediated effects in neurons were mediated by microglial PARP in this work. 
On the other hand, characterization of primary cultures in this study showed 
approximately 17 % of cultured neural cells were astrocytes. Therefore, it is 
possible that treatment of cultures with Aβ could have triggered activation of 
astrocytic PARP and downstream neuronal damage, as shown by Abeti and 
colleagues (2011). However, Aβ-induced upregulation of PARP appeared to be 
selectively localized to neurons and was lacking in GFAP-positive astrocytes in the 
current study. Accordingly, TRPM2 immunoreactivity was also observed in 
neurons but not in astrocytes. Therefore, to ascertain whether astrocytic PARP 
may mediate Aβ neurotoxicity in this cell system, further work in 
astrocytic/neuronal co-cultures or in neurons treated with inflammatory factors, 
such as TNFα and IL-1β, would be required.  
 
6.2.4 Therapeutic targeting of PARP-1 and TRPM2 in AD 
 
The findings presented here suggest that inhibitors of PARP and TRPM2 may have 
therapeutic potential for the treatment of AD, since the PARP inhibitor SB750139 
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attenuated Aβ-induced DNA damage, intraneuronal Ca2+ elevations and 
neurotoxicity in the cell culture systems used here. Similar findings were also 
previously reported by Fonfria et al. (2005), who first demonstrated the 
importance of PARP-mediated TRPM2 activation for Aβ neurotoxicity. Therapies 
based on inhibiting PARP-1 may be especially relevant since numerous PARP-1 
inhibitors have shown promise as cancer therapies. PARP-1 inhibitors show good 
safety and tolerability profiles, suggesting that the clinical use of such compounds 
is a possibility (Mégnin-Chanet et al., 2010; Davar et al., 2012).  
It is likely that such therapies may be more effective in moderate and severe AD, 
since the pathogenic role of PARP in these stages appeared to be more prominent 
in the later stages of disease as judged by increased markers of PARP-mediated 
apoptotic and necrotic cell death in Braak IV-VI AD tissue compared to control. 
However, the benefits that could be gained from treating later stage disease, when 
much irreparable synaptic and neuron damage has already taken place is likely to 
be limited. Nevertheless, since previous studies have suggested a role for 
astrocytic and microglial PARP signalling in AD (Abeti et al., 2011; Tang et al., 
2010; Kauppinen et al., 2011), PARP inhibition may represent a novel 
mechanisms by which neuroinflammatory processes may be attenuated in AD. 
However, due to evidence of both pathogenic and neuroprotective  roles  for 
neuroinflammatory responses in AD (Verkhratsky et al., 2010; Bélanger and 
Magistretti, 2009; Wyss-Coray, 2006), it is unclear whether targeting these 
responses is a viable strategy. 
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Another important consideration in targeting PARP for AD therapy is whether this 
treatment will be associated with any serious side effects since PARP carries out 
a plethora of important physiological functions including DNA repair, regulation 
of immune responses and suppression of tumorigenesis (Swindall et al., 2013; 
Davar et al., 2012; Bürkle et al., 2005; Chaitanya et al., 2010). However, SB750139, 
used here to inhibit PARP in cell models of AD, is already used for cancer therapy 
(Davar et al., 2012), without evidence of any adverse side effects. Moreover, the 
anti-inflammatory agent minocycline, also a potent inhibitor of PARP is currently 
used as an antibiotic and anti-acne treatment and, despite showing broad 
spectrum effects in the CNS, is not associated with any serious side effects (Plane 
et al., 2010). However, clinical testing of minocycline for neurodegenerative 
conditions, such as Parkinson’s disease, have not yielded promising results (Plane 
et al., 2010). The reason for this could be a complex ‘double-edged sword’ role for 
PARP in conditions associated with neurodegeneration. PARP deficiency is shown 
to accelerate ageing (Piskunova et al., 2008; Bürkle et al., 2005); however, PARP 
is also shown to be hyperactive and accelerate neuronal death in response to 
excess oxidative stress in AD (Love et al., 1999; Abeti et al., 2011; Fonfria et al., 
2005), for which ageing is the most prominent risk factor in sporadic cases. On 
the other hand, chronic oxidative stress and PARP-1 activation are also implicated 
in neuronal death in ageing (Boesten et al., 2013) and PARP is overactive in aged 
animals with endothelial dysfunction (Pacher et al., 2002). It is therefore clear 
that induction of PARP-mediated apoptotic cell death or DNA repair and cell 
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survival depends on multiple factors, such as the strength and type of stress 
stimulus, and therefore fine-tuning of PARP activity may be more beneficial for 
the treatment of AD rather than outright PARP inhibition.    
As an alternative to PARP inhibition, another potential therapeutic strategy may 
be to directly target TRPM2 channels, either by blocking channel opening or 
reducing the levels of functional TPRM2s. Indeed, there is substantial evidence to 
support the role for TPRM2 in neuronal death induced by oxidative stress and Aβ 
in AD and other neurodegenerative disorders (McNulty and Fonfria, 2005a; 
Fonfria et al., 2005; Xie et al., 2010; Lee et al., 2013; Miller, 2004). Moreover, the 
neuroprotective effect of TRPM2 ablation together with the absence of an overt 
phenotype in TRPM2 knockout mice (Yamamoto et al., 2008) serves as evidence 
of the feasibility of anti-TRPM2 therapy in AD. However, none of the currently 
used TRPM2 inhibitors show TRPM2 specificity (Sumoza-Toledo and Penner, 
2011; Naziroǧlu, 2011) as the C-terminal Nudix domain (containing the channel 
activation site) is shared by TRPM2 and other TRP subtypes; thus, they may cause 
adverse side effects associated with inhibition of other TRP channels. Moreover, 
TRPM2 is shown to heterodimerize with other TRP subtypes, such as TRPM7; 
although the role of TRPM7 in AD is gaining interest (Naziroǧlu, 2011).  Therefore, 
development of more specific TRPM2 inhibitors and further investigation into the 
differential roles of different TRP subtypes to neuronal death may yield some 
promising new therapeutic targets.  
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6.2.5 Limitations of this work 
 
Throughout this project, best efforts were taken to ensure that the experimental 
work carried out was well designed, planned and controlled. However, it is 
important to highlight some of the limitations of this work.  
The relationship between Ca2+-associated proteins and pathogenic mechanisms 
in AD was investigated here in post mortem tissue from individuals with different 
stages of AD, related neurodegenerative conditions (CBD, PSP, and FTD) and age-
matched controls. While a relatively large number of end-stage AD cases were 
investigated, there were limited numbers (between 3 and 5) of samples available 
from early and moderate AD cases, CBD, PSP and FTD cases. Due to the high 
variability associated with LOAD pathology and post mortem tissue, analysis of 
larger sample sizes for each condition would yield more accurate results, by 
showing whether there is consistency in subtle protein changes between samples. 
Since less is currently known about the early neurodegenerative mechanisms in 
AD - which may be important for preventative and diagnostic strategies – having 
increased availability of early stage Braak tissue would have been especially 
helpful for this work. Furthermore, although no correlation between protein 
changes and post mortem delay in AD tissue was detected here, it is still possible 
that protein degradation during post mortem delay may have affected protein 
amounts in samples. For example, calpains are shown to be activated post mortem 
(Gandolfi et al., 2011) and amounts of calpain-cleaved cdk5 activator, p25, are 
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considered to be only accurate in tissue with a post mortem delay of less than 25 
h (Engmann et al., 2011). However, although care was chosen to select cases in 
which tissue integrity was believed to be maintained as much as possible, the 
handling of post-mortem brain tissue was ultimately outwith the control of our 
group. 
Western blotting of post-mortem brain and neuronal lysates treated with Aβ 
and/or compounds allowed the quantitative comparison of Ca2+-associated 
protein amounts between different conditions, as well as identification of any 
post-translational modifications to proteins e.g. tau truncation and 
phosphorylation and APP glycosylation. However, this method did not allow for 
the assessment of changes in Ca2+ binding, protein-protein interactions, protein 
function or subcellular localization. For instance, it would be interesting to 
investigate whether the prolonged activation of calpains in AD brain or Aβ-treated 
neurons results from reduced interaction of calpains with CAST and increased 
calpain translocation to cell membranes, as suggested by Goll et al. (2003). 
Furthermore, since animal and cell models of AD feature increased TRPM2 
activity, and hence Ca2+ overload, it would be worth investigating whether this 
alters TRPM2 localization - for instance, leading to compensatory TRPM2 
internalization. TRPM2 and NCX3 currents are proposed to be altered in AD, 
which is indirectly evidenced here by the inhibition of Ca2+ transients in Aβ-
treated neurons by the PARP inhibitor SB750139 and by the increased 
vulnerability of neurons to subtoxic Aβ concentrations following NCX3 
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knockdown. However, a more accurate and direct way of measuring changes in 
TRPM2 and NCX3 Ca2+ conductance in AD would be to perform 
electrophysiological analysis of post mortem AD tissue slices, which are shown to 
remain alive for several weeks in culture (Verwer et al., 2002). This could also be 
done in organotypic brain slices from APP mutant mice or in wild-type slices 
treated with Aβ and calpain inhibitors. Although the techniques required to make 
long-term organotypic slice cultures from transgenic animals (but not post-
mortem AD brain) were available in the laboratory, these is a technically 
demanding and very time consuming technique, and unfortunately constraints 
with time and resources meant that such experiments could not be incorporated 
into this work. 
The Ca2+ imaging experiments performed here provided direct measurement of 
Ca2+ dynamics in response to treatment with Aβ and compounds, including 
inhibitors of PARP, calpains, caspases and NMDARs. However, due to some 
technical difficulties, images could only be recorded for up to 10 min without 
photobleaching of the signal. This was associated with the use of Fluo-4 Ca2+ 
indicators here; use of another type of dye, such as Fura-2, was not possible due 
to issues with the live-imaging equipment with capabilities for ratiometric 
imaging.  Unfortunately, these difficulties were not overcome in time for this 
equipment to be used in this work. If these technical issues had been surpassed, 
it would have been worth conducting longer term imaging experiments, as 
previous studies have reported important changes in Ca2+ concentrations in 
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neurons undergoing Ca2+-mediated excitotoxicity from 15 minutes to 1 hour 
following treatment of cells with glutamate or Aβ (Atherton et al. unpublished; 
Brustovetsky et al., 2010a; Bano et al., 2005). Nevertheless, the data presented in 





In summary, the findings in this thesis yield some interesting insights into the role 
of Ca2+-sensitive pathways during the progression of AD, and they also 
demonstrate a novel mechanism of Ca2+ dysregulation that may contribute to Aβ-
induced neuronal death in AD. Investigation of protein changes in post mortem 
neurodegenerative and control brains confirmed previous reports of increased 
Ca2+-activated calpain-1 activity in end-stage AD and other neurodegenerative 
conditions, such as CBD and FTD, when compared to age-matched control brain. 
These findings were then furthered by the demonstration that calpain-1 activity 
is aberrantly increased in early AD brain and that these elevations are sustained 
throughout the progression of AD. The early increases in calpain-1 activity were 
associated with increased protein amounts of the endogenous calpain inhibitor 
CAST and in major pre- and postsynaptic proteins. These changes may be 
indicative of a possible early neuroprotective response to excess calpain-1 
activity in the very early stages of AD development. However, loss of CAST activity 
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and synaptic markers in end-stage AD brain, along with increased calpain-
mediated degradation of the cytoskeletal protein α-spectrin and the Ca2+ 
extrusion pump NCX3, indicated sustained and prominent effects of calpain-1 
activation and proteolysis of key signalling, structural and Ca2+-regulating 
proteins in these tissues. Notably, calpain-mediated cleavage of NCX3 was only 
observed in AD tissue, in correlation with increased Aβ production, and 
knockdown of NCX3 conferred neuronal vulnerability to normally subtoxic 
concentrations of Aβ in primary cultures. Therefore, Aβ-induced calpain 
activation and cleavage of NCX3 may represent a novel mechanism by which 
elimination of excess cell Ca2+ is perturbed and contributes to neuronal Ca2+ 
dyshomeostasis in AD.  
The early increase in calpain-1 activity in post mortem AD brain was also 
observed to occur prior to Aβ overproduction, activation of the tau kinases GSK3 
and cdk5, increased tau phosphorylation, and synapse loss. Further investigations 
in cell systems, using the synthetic calpain inhibitor, calpeptin, were then carried 
out to show that calpain-1 activity is causally linked to these pathological changes. 
Inhibition of calpain with the chemical inhibitor calpeptin attenuated Aβ-induced 
Ca2+ elevations, GSK3 and cdk5 activation, tau phosphorylation and also altered 
APP processing, Aβ production and synaptic protein expression, independently of 
Aβ. Furthermore, Aβ-induced Ca2+ dysregulation and neurotoxicity were, at least 
in part, attributed to abnormal activation of PARP and TRPM2 signalling. The 
increased involvement of PARP in apoptotic cell death was also seen in moderate 
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and severe AD brain. To conclude, the data presented here add further support to 
the notion that Ca2+ dysregulation is an important early pathogenic event in AD, 
and that targeting key steps in Ca2+-mediated neurodegenerative signalling 
cascades may have potential for the treatment of AD and related 
neurodegenerative diseases. Figure 6.3 summarizes the findings in this work. 
Figure 6.3. Proposed mechanisms of Ca2+-mediated neurotoxicity in AD. Aβ induces 
astrocytic and neuronal DNA damage, which hyperactivates PARPs. In neurons, this 
leads to the production of PAR from NAD+, and subsequently ADPR via PARG 
hydrolysis of PAR. Free ADPR then mediates neuronal Ca2+ overload by excess 
stimulation of TRPM2. This causes prolonged calpain activation, mitochondrial Ca2+ 
overload and pro-apoptotic caspase signalling. Direct cleavage of tau is mediated by 
these proteases, and calpain-mediated AIF cleavage and translocation to the nucleus 
initiates ‘parthanatos’. PARP activation could also result in excessive depletion of 
NAD+, which could mediate necrotic death through metabolic failure. PARP-mediated 
activation of glial cells could also exacerbate neuronal demise through promoting the 
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